Mml的个人主页 - 老虎社区

Mml

Mml

暂无个人介绍

IP属地：未知

458关注

119粉丝

0主题

0勋章

2021-12-21

Yup

MRNA, NVAX, OCGN, PFE, BNTX: What Is Going on With Vaccine Stocks Today?

2021-12-21

Hmmm

AMC Stock: There Are 7 Million Reasons AMC Is on Wall Street’s Big Screen Today

2021-12-19

Hmmm

3 Stocks That Could Be Worth More Than Apple by 2035

2021-12-18

Hmmm

Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows

2021-12-17

Hmmm

5 Stocks To Watch For December 17, 2021

2021-12-17

Informative

Toplines Before US Market Open on Friday

2021-12-16

Informative

10 Biggest Price Target Changes For Thursday

2021-12-16

Hmmmm

抱歉，原内容已删除

2021-12-16

Informative

Shopify rallies after Evercore ISI calls out +25% upside potential

2021-12-16

Informative

抱歉，原内容已删除

2021-12-14

Informative

Tesla Stock Is in a Bear Market Again. What’s Next for Musk’s EV Firm.

2021-12-13

Great

Veru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI

2021-12-11

Hmmm

Sea Ltd stock dropped more than 5% in morning trading

2021-12-09

Good

Rebound Anticipated For Singapore Stock Market

2021-12-08

Hmmm

Pinduoduo shares surged 11% in morning trading

2021-12-07

Good

Intel shares surged more than 7% in after-hours trading

2021-12-06

Hmmm

Singapore Bourse Expected To Remain Rangebound On Monday

2021-12-03

Hmmm

After-Hours Stock Movers 12/02: (SMAR) (TLYS) (JOAN) Higher; (DOCU) (OLLI) (ASAN) Lower (more...)

2021-12-02

Informative

Glaxo says its vaccine retains activity against key Omicron mutations

2021-11-29

Oh

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3584863771682470,"uuid":"3584863771682470","gmtCreate":1622209062843,"gmtModify":1706620618674,"name":"Mml","pinyin":"mml","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":119,"headSize":458,"tweetSize":318,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.79%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.29%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":693793472,"gmtCreate":1640074494388,"gmtModify":1640074495552,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Yup","listText":"Yup","text":"Yup","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/693793472","repostId":"1173202355","repostType":4,"repost":{"id":"1173202355","pubTimestamp":1640053734,"share":"https://www.laohu8.com/m/news/1173202355?lang=&edition=full","pubTime":"2021-12-21 10:28","market":"us","language":"en","title":"MRNA, NVAX, OCGN, PFE, BNTX: What Is Going on With Vaccine Stocks Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=1173202355","media":"InvestorPlace","summary":"As another week kicks off on Wall Street, it’s clear that the ominous coverage of the spreading omic","content":"<p>As another week kicks off on Wall Street, it’s clear that the ominous coverage of the spreading omicron variant is still casting shadows over markets. This week has started off with mixed news surrounding the companies who are working around the clock to get ahead in the vaccine race. This has been making it difficult for the overall sector to gain the type of momentum it needs for all vaccine stocks to start moving upward. While one company has an encouraging update regarding its vaccine’s effectiveness against the variant, most of its peers haven’t been so lucky.</p>\n<p>What’s Going on With Vaccine Stocks?</p>\n<p>For the companies embedded in the race to beat the variant, this week isn’t off to a good start. Indeed, vaccine stocks are facing noticeable turbulence.<b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>) began the day with the announcement that a third dose of its Covid-19 vaccine has been proven to&nbsp;increase antibodies against the new variant. Even with such reassuring news, MRNA stock is down 6.25% today. That said, it did cause shares to surge this morning, putting MRNA stock up almost 10% for the week.</p>\n<p>Meanwhile, most of its peers aren’t fairing much better.<b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>) just received&nbsp;authorization&nbsp;from the European Union to begin distributing its vaccine throughout Europe during the first half of 2022. While this news sent the stock up in premarket trading today, it hasn’t done much since then. NVAX stock is down more than 7% today. Additionally,&nbsp;<b>Ocugen</b>(NASDAQ:<b><u>OCGN</u></b>) is also falling after an initial&nbsp;early day rise&nbsp;driven by superficial catalysts.</p>\n<p>The only vaccine stock in the green this morning is&nbsp;<b>Pfizer</b>(NYSE:<b><u>PFE</u></b>), which is up more than 2% today despite the&nbsp;recent setback&nbsp;the company experienced regarding its vaccine for children five years old and younger. Meanwhile, Pfizer’s vaccine production partner, Germany-based&nbsp;<b>BioNTech</b>(NASDAQ:<b><u>BNTX</u></b>) is down 4.19% so far, despite the&nbsp;recent news&nbsp;that the two companies will be providing more than 200 million additional vaccine doses to the EU in 2022.</p>\n<p>Why It Matters</p>\n<p>While the week is off to a rough start, every company on this list is still up for the week. The only exception is OCGN, which seems more like a meme stock that is losing momentum.</p>\n<p>However, every other name on this list is fair game for a bullish play on vaccine stocks. The new data from Moderna is highly encouraging, in no small part because it likely means that Pfizer won’t be far behind in tailoring its own vaccine to effectively fight the omicron variant. Novavax’s news is also cause for optimism. While it hasn’t helped the stock rise this morning, it does suggest that global vaccine efforts are moving forward. The same could be said for the recent EU news regarding Pfizer and BioNTech. Novavax has been working hard to gain its place among the vaccine producers that helped us beat the pandemic’s earlier waves. And this looks like an opportunity for it to do exactly that.</p>\n<p>What It Means</p>\n<p>Despite today’s downturn, we will likely see another vaccine stock boom in 2022. Indeed, this will come as companies make real strides against the omicron variant.</p>\n<p>Regardless of exactly how that shakes out, world leaders are going to be working hard to speed up global vaccination efforts to ensure that new variants don’t emerge and complicate matters further. Every stock on this list, with the exception of OCGN, is worth watching as the new year takes shape.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MRNA, NVAX, OCGN, PFE, BNTX: What Is Going on With Vaccine Stocks Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMRNA, NVAX, OCGN, PFE, BNTX: What Is Going on With Vaccine Stocks Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 10:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/mrna-nvax-ocgn-pfe-bntx-what-is-going-on-with-vaccine-stocks-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As another week kicks off on Wall Street, it’s clear that the ominous coverage of the spreading omicron variant is still casting shadows over markets. This week has started off with mixed news ...</p>\n\n<a href=\"https://investorplace.com/2021/12/mrna-nvax-ocgn-pfe-bntx-what-is-going-on-with-vaccine-stocks-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","OCGN":"Ocugen","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://investorplace.com/2021/12/mrna-nvax-ocgn-pfe-bntx-what-is-going-on-with-vaccine-stocks-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173202355","content_text":"As another week kicks off on Wall Street, it’s clear that the ominous coverage of the spreading omicron variant is still casting shadows over markets. This week has started off with mixed news surrounding the companies who are working around the clock to get ahead in the vaccine race. This has been making it difficult for the overall sector to gain the type of momentum it needs for all vaccine stocks to start moving upward. While one company has an encouraging update regarding its vaccine’s effectiveness against the variant, most of its peers haven’t been so lucky.\nWhat’s Going on With Vaccine Stocks?\nFor the companies embedded in the race to beat the variant, this week isn’t off to a good start. Indeed, vaccine stocks are facing noticeable turbulence.Moderna(NASDAQ:MRNA) began the day with the announcement that a third dose of its Covid-19 vaccine has been proven to increase antibodies against the new variant. Even with such reassuring news, MRNA stock is down 6.25% today. That said, it did cause shares to surge this morning, putting MRNA stock up almost 10% for the week.\nMeanwhile, most of its peers aren’t fairing much better.Novavax(NASDAQ:NVAX) just received authorization from the European Union to begin distributing its vaccine throughout Europe during the first half of 2022. While this news sent the stock up in premarket trading today, it hasn’t done much since then. NVAX stock is down more than 7% today. Additionally, Ocugen(NASDAQ:OCGN) is also falling after an initial early day rise driven by superficial catalysts.\nThe only vaccine stock in the green this morning is Pfizer(NYSE:PFE), which is up more than 2% today despite the recent setback the company experienced regarding its vaccine for children five years old and younger. Meanwhile, Pfizer’s vaccine production partner, Germany-based BioNTech(NASDAQ:BNTX) is down 4.19% so far, despite the recent news that the two companies will be providing more than 200 million additional vaccine doses to the EU in 2022.\nWhy It Matters\nWhile the week is off to a rough start, every company on this list is still up for the week. The only exception is OCGN, which seems more like a meme stock that is losing momentum.\nHowever, every other name on this list is fair game for a bullish play on vaccine stocks. The new data from Moderna is highly encouraging, in no small part because it likely means that Pfizer won’t be far behind in tailoring its own vaccine to effectively fight the omicron variant. Novavax’s news is also cause for optimism. While it hasn’t helped the stock rise this morning, it does suggest that global vaccine efforts are moving forward. The same could be said for the recent EU news regarding Pfizer and BioNTech. Novavax has been working hard to gain its place among the vaccine producers that helped us beat the pandemic’s earlier waves. And this looks like an opportunity for it to do exactly that.\nWhat It Means\nDespite today’s downturn, we will likely see another vaccine stock boom in 2022. Indeed, this will come as companies make real strides against the omicron variant.\nRegardless of exactly how that shakes out, world leaders are going to be working hard to speed up global vaccination efforts to ensure that new variants don’t emerge and complicate matters further. Every stock on this list, with the exception of OCGN, is worth watching as the new year takes shape.","news_type":1},"isVote":1,"tweetType":1,"viewCount":698,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693793575,"gmtCreate":1640074461030,"gmtModify":1640074462166,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693793575","repostId":"1158137251","repostType":4,"repost":{"id":"1158137251","pubTimestamp":1640054738,"share":"https://www.laohu8.com/m/news/1158137251?lang=&edition=full","pubTime":"2021-12-21 10:45","market":"us","language":"en","title":"AMC Stock: There Are 7 Million Reasons AMC Is on Wall Street’s Big Screen Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1158137251","media":"InvestorPlace","summary":"Movie theater giant and meme-stock darling AMC Entertainment(NYSE:AMC) has an extra spring in its st","content":"<p>Movie theater giant and meme-stock darling&nbsp;<b>AMC Entertainment</b>(NYSE:<b><u>AMC</u></b>) has an extra spring in its step today.<i>Spider-Man: No Way Home</i>crushed box office expectations — and several attendance records. Despite mounting omicron variant concerns, AMC stock is up 1.99% today after Friday’s 20% leap.</p>\n<p>What else do you need to know about AMC’s web-slinging stock surge?</p>\n<p><i>Spider-Man</i>&nbsp;closed its opening weekend with a bang. The film claimed the biggest December opening of all time, even breaking post-quarantine domestic attendance numbers three times since Friday. When all was said and done, AMC sold more than 7 million tickets from Thursday’s midnight premiere through Sunday. More than 5 million tickets were from U.S. theaters alone. This marks the first time AMC sold at least 1 million tickets each day through a premiere since October 2019. International numbers also enjoyed new highs, setting a new single-day attendance record on Saturday.</p>\n<p>Even trifling through screening options, AMC enjoyed across-the-board boosts from the friendly neighborhood spider. Premium large format (PLF), Dolby Cinema and IMAX each saw elevated screenings this weekend, as it was the biggest weekend ever for AMC Prime.</p>\n<p><i>No Way Home</i>isn’t just unique in its sales numbers: It’s a hyper-modern crypto experiment that may have succeeded. AMC surprised consumers after announcing the giveaway of non-fungible tokens (NFTs) for early buyers of the&nbsp;<i>Spider-Man</i>&nbsp;midnight-release showings. There were a number of conditions to be met to receive the NFT, but roughly 86,000 early birds ended up with a digital item.</p>\n<p>Will the Spidey Upswing Shift AMC Stock Perspectives?</p>\n<p>It’s a bit too early to say whether the NFT promotion served as a boost to movie demand —<i>Spider-Man</i>&nbsp;is practically&nbsp;always a box-office success. Additionally, the film received rave reviews from the jump, earning a 94% aggregate score on review site&nbsp;<i>Rotten Tomatoes</i>.<i>CinemaScore</i>even gave the Marvel film&nbsp;a rare A-plus. As such, the NFT offering clearly didn’t stifle interest in Tom Holland’s latest endeavor, despite it being difficult to definitively attach any causation to the giveaway.</p>\n<p>However, will&nbsp;<i>Spider-Man</i>&nbsp;sling the recently stumbling theater industry back into the spotlight? AMC CEO Adam Aron had some uplifting words for the movie business in lieu of the promising numbers.</p>\n<blockquote>\n “Historically, December is one of the biggest months of the year for major blockbuster releases, so to see SPIDER-MAN: NO WAY HOME set a new all-time opening weekend box office record this month is significant not just for AMC, but for the entire theatrical industry. … We commend our friends at Sony Pictures and Marvel on their wonderfully successful movie, which millions of people have already watched at a U.S. AMC theatre in just 4 days.”\n</blockquote>\n<p>The news brings with it a sigh of relief for the recently struggling movie industry. Only time will tell if&nbsp;<i>Spider-Man</i>&nbsp;marks a resurgence for the star-studded business, but prospects are better than ever.</p>\n<p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC Stock: There Are 7 Million Reasons AMC Is on Wall Street’s Big Screen Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC Stock: There Are 7 Million Reasons AMC Is on Wall Street’s Big Screen Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 10:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/amc-stock-there-are-7-million-reasons-amc-is-on-wall-streets-big-screen-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Movie theater giant and meme-stock darling AMC Entertainment(NYSE:AMC) has an extra spring in its step today.Spider-Man: No Way Homecrushed box office expectations — and several attendance records. ...</p>\n\n<a href=\"https://investorplace.com/2021/12/amc-stock-there-are-7-million-reasons-amc-is-on-wall-streets-big-screen-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://investorplace.com/2021/12/amc-stock-there-are-7-million-reasons-amc-is-on-wall-streets-big-screen-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158137251","content_text":"Movie theater giant and meme-stock darling AMC Entertainment(NYSE:AMC) has an extra spring in its step today.Spider-Man: No Way Homecrushed box office expectations — and several attendance records. Despite mounting omicron variant concerns, AMC stock is up 1.99% today after Friday’s 20% leap.\nWhat else do you need to know about AMC’s web-slinging stock surge?\nSpider-Man closed its opening weekend with a bang. The film claimed the biggest December opening of all time, even breaking post-quarantine domestic attendance numbers three times since Friday. When all was said and done, AMC sold more than 7 million tickets from Thursday’s midnight premiere through Sunday. More than 5 million tickets were from U.S. theaters alone. This marks the first time AMC sold at least 1 million tickets each day through a premiere since October 2019. International numbers also enjoyed new highs, setting a new single-day attendance record on Saturday.\nEven trifling through screening options, AMC enjoyed across-the-board boosts from the friendly neighborhood spider. Premium large format (PLF), Dolby Cinema and IMAX each saw elevated screenings this weekend, as it was the biggest weekend ever for AMC Prime.\nNo Way Homeisn’t just unique in its sales numbers: It’s a hyper-modern crypto experiment that may have succeeded. AMC surprised consumers after announcing the giveaway of non-fungible tokens (NFTs) for early buyers of the Spider-Man midnight-release showings. There were a number of conditions to be met to receive the NFT, but roughly 86,000 early birds ended up with a digital item.\nWill the Spidey Upswing Shift AMC Stock Perspectives?\nIt’s a bit too early to say whether the NFT promotion served as a boost to movie demand —Spider-Man is practically always a box-office success. Additionally, the film received rave reviews from the jump, earning a 94% aggregate score on review site Rotten Tomatoes.CinemaScoreeven gave the Marvel film a rare A-plus. As such, the NFT offering clearly didn’t stifle interest in Tom Holland’s latest endeavor, despite it being difficult to definitively attach any causation to the giveaway.\nHowever, will Spider-Man sling the recently stumbling theater industry back into the spotlight? AMC CEO Adam Aron had some uplifting words for the movie business in lieu of the promising numbers.\n\n “Historically, December is one of the biggest months of the year for major blockbuster releases, so to see SPIDER-MAN: NO WAY HOME set a new all-time opening weekend box office record this month is significant not just for AMC, but for the entire theatrical industry. … We commend our friends at Sony Pictures and Marvel on their wonderfully successful movie, which millions of people have already watched at a U.S. AMC theatre in just 4 days.”\n\nThe news brings with it a sigh of relief for the recently struggling movie industry. Only time will tell if Spider-Man marks a resurgence for the star-studded business, but prospects are better than ever.","news_type":1},"isVote":1,"tweetType":1,"viewCount":602,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693093016,"gmtCreate":1639921042860,"gmtModify":1639921044084,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693093016","repostId":"2192035909","repostType":4,"repost":{"id":"2192035909","pubTimestamp":1639886839,"share":"https://www.laohu8.com/m/news/2192035909?lang=&edition=full","pubTime":"2021-12-19 12:07","market":"us","language":"en","title":"3 Stocks That Could Be Worth More Than Apple by 2035","url":"https://stock-news.laohu8.com/highlight/detail?id=2192035909","media":"Motley Fool","summary":"These companies could eclipse the iPhone maker's market cap in the long run.","content":"<p><a href=\"https://laohu8.com/S/AAPL\"><b>Apple</b></a> is currently the world's most valuable&nbsp;company with a market capitalization of $2.82 trillion. That isn't surprising as the tech titan is a dominant player in the smartphone market and has ancillary products and services to drive growth.</p>\n<p>The tech giant generated a whopping $365.8 billion in revenue in fiscal 2021, an increase of 33% over the prior year. The fact that Apple is growing at an eye-popping pace despite being a mega-cap company is impressive, but it's not surprising as its products and services are in great demand. More importantly, Apple isn't resting on its laurels and is looking to push the envelope by seizing emerging tech trends and moving into new markets.</p>\n<p>As such, Apple is pulling several strings to ensure that it remains the world's most valuable company for a long time to come. However, the likes of <a href=\"https://laohu8.com/S/NVDA\"><b>Nvidia</b> </a>, <a href=\"https://laohu8.com/S/ASML\"><b>ASML Holding</b> </a>, and <a href=\"https://laohu8.com/S/AMZN\"><b>Amazon</b> </a> could become more valuable than Apple by 2035, thanks to the fast-growing markets they operate in. Let's see why that may be the case.</p>\n<p>1. <a href=\"https://laohu8.com/S/NVDA\"><b>Nvidia</b> </a></p>\n<p>Nvidia has a market cap&nbsp;of $707 billion. It is worth noting that the graphics card specialist's market cap has grown at a much faster pace than that of Apple's in the past decade.</p>\n<p><img src=\"https://static.tigerbbs.com/014d345dc7df797b4ee5e9f0e2288910\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>NVDA data by YCharts</p>\n<p>Nvidia shares have stepped on the gas since 2016. They have gone supersonic in the past couple of years as it has become clear that its graphics cards play an important role in powering several applications ranging from gaming consoles to personal computers to data centers and autonomous vehicles. The massive demand for Nvidia's graphics cards is evident from the company's recent results.</p>\n<p>The company has generated&nbsp;$19.3 billion in revenue in the first nine months of fiscal 2022, a jump of 65% over the prior-year period. Its adjusted earnings have increased 81% in the first nine months of the year to $3.12 per share. This terrific growth has been driven by two key catalysts -- gaming and data centers.</p>\n<p>Nvidia absolutely dominates these two markets. The company has an 83% share&nbsp;of discrete graphics cards that power gaming PCs, while its share of the booming data center accelerator market reportedly stood at 80.6% a&nbsp;year ago. The good part is that both these markets are expected to add billions of dollars of revenue in the future. The GPU (graphics processing unit) market, for instance, is expected to clock a 33% annual growth rate through 2028 and hit $246 billion in value, according to a third-party estimate.</p>\n<p>The use of GPUs as data-center accelerators is increasing&nbsp;at 42% a year, a pace that's expected to continue through 2027. Throw in budding catalysts such as the omniverse and self-driving cars, and it is easy to see why Nvidia's earnings are expected to increase&nbsp;at an annual pace of close to 40% for the next five years. That's way higher than Apple's projected earnings growth rate&nbsp;of 15% over the same period, which further indicates why Nvidia could be a solid candidate to overtake Apple's market cap in the next 15 years.</p>\n<p>2. <a href=\"https://laohu8.com/S/ASML\"><b>ASML Holding</b> </a></p>\n<p>Apple was unable to make enough iPhones and iPads last quarter due to supply chain constraints arising out of the global chip shortage, and that cost&nbsp;the tech giant $6 billion in revenue. ASML is <a href=\"https://laohu8.com/S/AONE.U\">one</a> company that could help get more chips into the hands of Apple and others that are suffering from a lack of chips on account of the semiconductor shortage.</p>\n<p>This is probably one of the reasons why ASML stock has been a top performer in 2021 and has outpaced Apple's gains by a significant margin this year.</p>\n<p><img src=\"https://static.tigerbbs.com/6aab71d6833e529191334d42cac0289f\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>AAPL data by YCharts</p>\n<p>It won't be surprising to see this trend continue as the demand for ASML's machines that help foundries make chips has gone through the roof. Net bookings for ASML's machines increased&nbsp;to 6.2 billion euros in the third quarter of 2021, more than double as compared to net bookings of 2.87 billion euros in the year-ago period.</p>\n<p>The Dutch giant reported a 32% increase in revenue during the quarter to 5.24 billion euros. The fact that ASML's bookings increased at a faster pace than the actual revenue indicates that it can sustain its impressive top-line growth by fulfilling more of its orders and turning the backlog into actual sales. The company is on track to finish 2021 with 35% revenue growth, and Wall Street's estimates suggest that it can keep growing at such an impressive pace for a long time to come.</p>\n<p>Venture capital firm Air Street Capital estimates that ASML could hit $500 billion in market cap next year, which would be a huge jump over its current market cap of $311 billion. What's more, ASML's earnings are expected&nbsp;to grow at almost 30% a year for the next five years, which is double Apple's projected growth.</p>\n<p>ASML seems to be in a solid position to deliver on Wall Street's forecasts as the semiconductor market is expected to generate&nbsp;$1 trillion in revenue by 2030, a big jump from 2018 levels of $466 billion. Foundries would need to spend more money on equipment to cater to the huge demand, and this could supercharge ASML in the long run as it is the biggest player in the market for photolithography machines.</p>\n<p>3. <a href=\"https://laohu8.com/S/AMZN\"><b>Amazon</b> </a></p>\n<p>Amazon is yet another stock that has easily outpaced Apple's gains in the past decade.</p>\n<p><img src=\"https://static.tigerbbs.com/e823ea95df1ad4c8e9cc5d870dc478b7\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>AAPL data by YCharts</p>\n<p>Amazon's focus on diversifying itself from a vanilla e-commerce company into a leading provider of cloud computing services, video streaming, music streaming, and on dominating the markets it operates in has helped the company grow at an eye-popping pace and hit a market cap&nbsp;of $1.7 trillion. This tech stock is expected to keep up its tremendous growth in the coming years, with earnings expected&nbsp;to increase at a compound annual growth rate of 36%.</p>\n<p>Again, this is much higher than Apple's projected growth rate. That's because Amazon is on track to take advantage of several fast-growing end markets. For instance, the company's Amazon Web Services (AWS) cloud computing division holds&nbsp;a 32% share of the $150 billion cloud infrastructure market. Third-party estimates peg the size of the global cloud computing market&nbsp;at $927 billion by 2027, which should ensure a high pace of growth in the AWS segment.</p>\n<p>Amazon's AWS revenue had jumped&nbsp;39% year over year in the third quarter to $16 billion, outpacing the growth in the e-commerce segments. Meanwhile, Amazon holds 40% of the U.S. e-commerce market that's expected to hit $8 trillion in revenue by 2030. All this indicates that the company's top line could jump big time in the coming years compared to its trailing-12-month revenue&nbsp;of $458 billion.</p>\n<p>As such, Amazon stock could continue to be a better growth pick than Apple in the next decade and beyond. It may eventually eclipse the iPhone maker's market cap in the long run, considering its much faster pace of growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Could Be Worth More Than Apple by 2035</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Could Be Worth More Than Apple by 2035\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-19 12:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/18/stocks-that-could-be-worth-more-than-apple-2035/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple is currently the world's most valuable company with a market capitalization of $2.82 trillion. That isn't surprising as the tech titan is a dominant player in the smartphone market and has ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/18/stocks-that-could-be-worth-more-than-apple-2035/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4505":"高瓴资本持仓","BK4507":"流媒体概念","BK4559":"巴菲特持仓","BK4501":"段永平概念","BK4527":"明星科技股","BK4534":"瑞士信贷持仓","BK4170":"电脑硬件、储存设备及电脑周边","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","AAPL":"苹果","BK4532":"文艺复兴科技持仓","BK4554":"元宇宙及AR概念","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓"},"source_url":"https://www.fool.com/investing/2021/12/18/stocks-that-could-be-worth-more-than-apple-2035/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192035909","content_text":"Apple is currently the world's most valuable company with a market capitalization of $2.82 trillion. That isn't surprising as the tech titan is a dominant player in the smartphone market and has ancillary products and services to drive growth.\nThe tech giant generated a whopping $365.8 billion in revenue in fiscal 2021, an increase of 33% over the prior year. The fact that Apple is growing at an eye-popping pace despite being a mega-cap company is impressive, but it's not surprising as its products and services are in great demand. More importantly, Apple isn't resting on its laurels and is looking to push the envelope by seizing emerging tech trends and moving into new markets.\nAs such, Apple is pulling several strings to ensure that it remains the world's most valuable company for a long time to come. However, the likes of Nvidia , ASML Holding , and Amazon  could become more valuable than Apple by 2035, thanks to the fast-growing markets they operate in. Let's see why that may be the case.\n1. Nvidia \nNvidia has a market cap of $707 billion. It is worth noting that the graphics card specialist's market cap has grown at a much faster pace than that of Apple's in the past decade.\n\nNVDA data by YCharts\nNvidia shares have stepped on the gas since 2016. They have gone supersonic in the past couple of years as it has become clear that its graphics cards play an important role in powering several applications ranging from gaming consoles to personal computers to data centers and autonomous vehicles. The massive demand for Nvidia's graphics cards is evident from the company's recent results.\nThe company has generated $19.3 billion in revenue in the first nine months of fiscal 2022, a jump of 65% over the prior-year period. Its adjusted earnings have increased 81% in the first nine months of the year to $3.12 per share. This terrific growth has been driven by two key catalysts -- gaming and data centers.\nNvidia absolutely dominates these two markets. The company has an 83% share of discrete graphics cards that power gaming PCs, while its share of the booming data center accelerator market reportedly stood at 80.6% a year ago. The good part is that both these markets are expected to add billions of dollars of revenue in the future. The GPU (graphics processing unit) market, for instance, is expected to clock a 33% annual growth rate through 2028 and hit $246 billion in value, according to a third-party estimate.\nThe use of GPUs as data-center accelerators is increasing at 42% a year, a pace that's expected to continue through 2027. Throw in budding catalysts such as the omniverse and self-driving cars, and it is easy to see why Nvidia's earnings are expected to increase at an annual pace of close to 40% for the next five years. That's way higher than Apple's projected earnings growth rate of 15% over the same period, which further indicates why Nvidia could be a solid candidate to overtake Apple's market cap in the next 15 years.\n2. ASML Holding \nApple was unable to make enough iPhones and iPads last quarter due to supply chain constraints arising out of the global chip shortage, and that cost the tech giant $6 billion in revenue. ASML is one company that could help get more chips into the hands of Apple and others that are suffering from a lack of chips on account of the semiconductor shortage.\nThis is probably one of the reasons why ASML stock has been a top performer in 2021 and has outpaced Apple's gains by a significant margin this year.\n\nAAPL data by YCharts\nIt won't be surprising to see this trend continue as the demand for ASML's machines that help foundries make chips has gone through the roof. Net bookings for ASML's machines increased to 6.2 billion euros in the third quarter of 2021, more than double as compared to net bookings of 2.87 billion euros in the year-ago period.\nThe Dutch giant reported a 32% increase in revenue during the quarter to 5.24 billion euros. The fact that ASML's bookings increased at a faster pace than the actual revenue indicates that it can sustain its impressive top-line growth by fulfilling more of its orders and turning the backlog into actual sales. The company is on track to finish 2021 with 35% revenue growth, and Wall Street's estimates suggest that it can keep growing at such an impressive pace for a long time to come.\nVenture capital firm Air Street Capital estimates that ASML could hit $500 billion in market cap next year, which would be a huge jump over its current market cap of $311 billion. What's more, ASML's earnings are expected to grow at almost 30% a year for the next five years, which is double Apple's projected growth.\nASML seems to be in a solid position to deliver on Wall Street's forecasts as the semiconductor market is expected to generate $1 trillion in revenue by 2030, a big jump from 2018 levels of $466 billion. Foundries would need to spend more money on equipment to cater to the huge demand, and this could supercharge ASML in the long run as it is the biggest player in the market for photolithography machines.\n3. Amazon \nAmazon is yet another stock that has easily outpaced Apple's gains in the past decade.\n\nAAPL data by YCharts\nAmazon's focus on diversifying itself from a vanilla e-commerce company into a leading provider of cloud computing services, video streaming, music streaming, and on dominating the markets it operates in has helped the company grow at an eye-popping pace and hit a market cap of $1.7 trillion. This tech stock is expected to keep up its tremendous growth in the coming years, with earnings expected to increase at a compound annual growth rate of 36%.\nAgain, this is much higher than Apple's projected growth rate. That's because Amazon is on track to take advantage of several fast-growing end markets. For instance, the company's Amazon Web Services (AWS) cloud computing division holds a 32% share of the $150 billion cloud infrastructure market. Third-party estimates peg the size of the global cloud computing market at $927 billion by 2027, which should ensure a high pace of growth in the AWS segment.\nAmazon's AWS revenue had jumped 39% year over year in the third quarter to $16 billion, outpacing the growth in the e-commerce segments. Meanwhile, Amazon holds 40% of the U.S. e-commerce market that's expected to hit $8 trillion in revenue by 2030. All this indicates that the company's top line could jump big time in the coming years compared to its trailing-12-month revenue of $458 billion.\nAs such, Amazon stock could continue to be a better growth pick than Apple in the next decade and beyond. It may eventually eclipse the iPhone maker's market cap in the long run, considering its much faster pace of growth.","news_type":1},"isVote":1,"tweetType":1,"viewCount":639,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699244211,"gmtCreate":1639824079138,"gmtModify":1639824080377,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699244211","repostId":"2192754259","repostType":4,"repost":{"id":"2192754259","pubTimestamp":1639811460,"share":"https://www.laohu8.com/m/news/2192754259?lang=&edition=full","pubTime":"2021-12-18 15:11","market":"us","language":"en","title":"Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2192754259","media":"Motley Fool","summary":"Three names you know are trading within 10% of their 52-week lows. They deserve better.","content":"<p>The major market indexes may be near their recent all-time highs, but your portfolio might have missed the memo. There are a lot of stocks struggling outside of the bellwethers that are heavily weighted in the market gauges, and we're not just talking about small and obscure names.</p>\n<p><b>Disney</b>&nbsp;(NYSE:DIS),<b> <a href=\"https://laohu8.com/S/TWTR\">Twitter</a></b>&nbsp;(NYSE:TWTR), and <b>Toast </b>(NYSE:TOST) are all trading within 10% of their 52-week lows. They are market leaders, but investors just aren't feeling the love for the entertainment powerhouse, the social media kingmaker, and the toast of the town in restaurant tech. Let's see why these are three promising ideas for the next $5,000 you want to invest in the market.</p>\n<h4><a href=\"https://laohu8.com/S/DIS\">Disney</a></h4>\n<p>Disney's theme parks call themselves the happiest or merriest places on Earth, but shareholders aren't feeling the same way these days. The media maven's stock is less than 5% away from the 52-week low it hit earlier this month.</p>\n<p>It's pretty surprising to see Disney as a market laggard this year. It's the dominant theme park operator and film studio on the planet, making it a clear beneficiary of the reopening of the economy in 2021. Unfortunately for shareholders, things are never as easy as they seem. Disney+ subscriber growth has slowed recently, and that's problematic since the platform for premium streaming video was the major reason for Disney climbing in 2020.</p>\n<p>Disney near 52-week lows is still a sobering development. The theme parks continue to draw. The top movies this year are largely Disney's handiwork. Even its cruise lines are finally sailing again. The weight of the world may be on beleaguered CEO Bob Chapek's shoulders, but it's a small world after all.</p>\n<p><b><a href=\"https://laohu8.com/S/TWTR\">Twitter</a></b></p>\n<p>Another shocking name skirting fresh lows is Twitter. The company behind the short-form social platform is in a funk, and even the initial 10% pop that the stock experienced after its CEO stepped down late last month proved fleeting. As of Thursday's close, Twitter is also now just 5% above the fresh low it hit two weeks ago.</p>\n<p>The platform is working. Its daily active users have grown 13% over the past year to 211 million. Ad revenue is growing even faster, and that 41% surge is a testament to both Twitter's engagement and its ability to milk more money out of every user. New leadership should help it continue to evolve, and the recent rollout of premium features for those willing to pay a little to improve the experience should get Twitter moving in the right direction again before long.</p>\n<h4><a href=\"https://laohu8.com/S/TOST\">Toast</a></h4>\n<p>Running a restaurant has changed dramatically just in the past couple of years, and Toast is the no-brainer cloud-based platform that keeps eateries on top of all of the trending revenue streams. It's a one-stop shop for restaurant needs. On the consumer-facing end, it helps process mobile ordering for take-out, manage incoming sales from third-party delivery services, and naturally serve as the point-of-sale for in-restaurant dining. It also helps run customer loyalty programs to keep regulars coming back.</p>\n<p>Toast does even more on the enterprise end, tackling everything from payroll to inventory management. With chains and independent concepts emerging smarter out of the pandemic than they were before, the company simplifies the necessary functions of an eatery in the new normal.</p>\n<p>Despite stellar growth -- revenue has soared 105% through the first nine months of this year -- the recent IPO hit an all-time low on Wednesday. It may be causing indigestion for investors who chased the new stock when it popped to double today's price by early November, but right now it feels more like a dinner bell.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 15:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/17/got-5000-these-3-growth-stocks-are-trading-near-th/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The major market indexes may be near their recent all-time highs, but your portfolio might have missed the memo. There are a lot of stocks struggling outside of the bellwethers that are heavily ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/17/got-5000-these-3-growth-stocks-are-trading-near-th/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4550":"红杉资本持仓","QNETCN":"纳斯达克中美互联网老虎指数","BK4516":"特朗普概念","TWTR":"Twitter","BK4106":"数据处理与外包服务","BK4532":"文艺复兴科技持仓","DIS":"迪士尼","BK4554":"元宇宙及AR概念","BK4077":"互动媒体与服务","TOST":"Toast, Inc.","BK4561":"索罗斯持仓","BK4524":"宅经济概念","BK4551":"寇图资本持仓","BK4508":"社交媒体","BK4108":"电影和娱乐","BK4507":"流媒体概念"},"source_url":"https://www.fool.com/investing/2021/12/17/got-5000-these-3-growth-stocks-are-trading-near-th/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192754259","content_text":"The major market indexes may be near their recent all-time highs, but your portfolio might have missed the memo. There are a lot of stocks struggling outside of the bellwethers that are heavily weighted in the market gauges, and we're not just talking about small and obscure names.\nDisney (NYSE:DIS), Twitter (NYSE:TWTR), and Toast (NYSE:TOST) are all trading within 10% of their 52-week lows. They are market leaders, but investors just aren't feeling the love for the entertainment powerhouse, the social media kingmaker, and the toast of the town in restaurant tech. Let's see why these are three promising ideas for the next $5,000 you want to invest in the market.\nDisney\nDisney's theme parks call themselves the happiest or merriest places on Earth, but shareholders aren't feeling the same way these days. The media maven's stock is less than 5% away from the 52-week low it hit earlier this month.\nIt's pretty surprising to see Disney as a market laggard this year. It's the dominant theme park operator and film studio on the planet, making it a clear beneficiary of the reopening of the economy in 2021. Unfortunately for shareholders, things are never as easy as they seem. Disney+ subscriber growth has slowed recently, and that's problematic since the platform for premium streaming video was the major reason for Disney climbing in 2020.\nDisney near 52-week lows is still a sobering development. The theme parks continue to draw. The top movies this year are largely Disney's handiwork. Even its cruise lines are finally sailing again. The weight of the world may be on beleaguered CEO Bob Chapek's shoulders, but it's a small world after all.\nTwitter\nAnother shocking name skirting fresh lows is Twitter. The company behind the short-form social platform is in a funk, and even the initial 10% pop that the stock experienced after its CEO stepped down late last month proved fleeting. As of Thursday's close, Twitter is also now just 5% above the fresh low it hit two weeks ago.\nThe platform is working. Its daily active users have grown 13% over the past year to 211 million. Ad revenue is growing even faster, and that 41% surge is a testament to both Twitter's engagement and its ability to milk more money out of every user. New leadership should help it continue to evolve, and the recent rollout of premium features for those willing to pay a little to improve the experience should get Twitter moving in the right direction again before long.\nToast\nRunning a restaurant has changed dramatically just in the past couple of years, and Toast is the no-brainer cloud-based platform that keeps eateries on top of all of the trending revenue streams. It's a one-stop shop for restaurant needs. On the consumer-facing end, it helps process mobile ordering for take-out, manage incoming sales from third-party delivery services, and naturally serve as the point-of-sale for in-restaurant dining. It also helps run customer loyalty programs to keep regulars coming back.\nToast does even more on the enterprise end, tackling everything from payroll to inventory management. With chains and independent concepts emerging smarter out of the pandemic than they were before, the company simplifies the necessary functions of an eatery in the new normal.\nDespite stellar growth -- revenue has soared 105% through the first nine months of this year -- the recent IPO hit an all-time low on Wednesday. It may be causing indigestion for investors who chased the new stock when it popped to double today's price by early November, but right now it feels more like a dinner bell.","news_type":1},"isVote":1,"tweetType":1,"viewCount":866,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699311815,"gmtCreate":1639748452488,"gmtModify":1639748453638,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699311815","repostId":"1154435289","repostType":4,"repost":{"id":"1154435289","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1639733312,"share":"https://www.laohu8.com/m/news/1154435289?lang=&edition=full","pubTime":"2021-12-17 17:28","market":"us","language":"en","title":"5 Stocks To Watch For December 17, 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1154435289","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects Darden Restaurants, ","content":"<p>Some of the stocks that may grab investor focus today are:</p>\n<ul>\n <li>Wall Street expects&nbsp;<b>Darden Restaurants, Inc.</b>&nbsp;to report quarterly earnings at $1.44 per share on revenue of $2.23 billion before the opening bell. Darden Restaurants shares slipped 0.8% to $145.99 in after-hours trading.</li>\n <li><b>FedEx Corporation</b>&nbsp;reported better-than-expected results for its second quarter and boosted its FY22 earnings guidance. The company also reported a $5 billion buyback, including $1.5 billion accelerated buyback program. FedEx shares climbed 4.9% to $250.30 in the after-hours trading session.</li>\n <li>Analysts are expecting&nbsp;<b>Winnebago Industries, Inc.</b>&nbsp;to have earned $2.25 per share on revenue of $1.01 billion for the latest quarter. The company will release earnings before the market open. On Thursday, Winnebago’s board approved a quarterly cash dividend of $0.18 per share. Winnebago shares gained 4.6% to $71.00 in after-hours trading.</li>\n</ul>\n<ul>\n <li><b>Steelcase Inc.</b>&nbsp;reported downbeat results for its third quarter and issued weak sales forecast for the current quarter. Steelcase shares dropped 3.7% to $11.09 in the after-hours trading session.</li>\n <li><b>United States Steel Corporation</b>&nbsp;said it projects adjusted earnings before interest, taxes, depreciation and amortization of around $1.65 billion for the fourth quarter, versus analysts’ estimates of $2.13 billion amid a slowdown in orders. United States Steel shares dropped 5.1% to $22.26 in after-hours trading.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For December 17, 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For December 17, 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-17 17:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Some of the stocks that may grab investor focus today are:</p>\n<ul>\n <li>Wall Street expects&nbsp;<b>Darden Restaurants, Inc.</b>&nbsp;to report quarterly earnings at $1.44 per share on revenue of $2.23 billion before the opening bell. Darden Restaurants shares slipped 0.8% to $145.99 in after-hours trading.</li>\n <li><b>FedEx Corporation</b>&nbsp;reported better-than-expected results for its second quarter and boosted its FY22 earnings guidance. The company also reported a $5 billion buyback, including $1.5 billion accelerated buyback program. FedEx shares climbed 4.9% to $250.30 in the after-hours trading session.</li>\n <li>Analysts are expecting&nbsp;<b>Winnebago Industries, Inc.</b>&nbsp;to have earned $2.25 per share on revenue of $1.01 billion for the latest quarter. The company will release earnings before the market open. On Thursday, Winnebago’s board approved a quarterly cash dividend of $0.18 per share. Winnebago shares gained 4.6% to $71.00 in after-hours trading.</li>\n</ul>\n<ul>\n <li><b>Steelcase Inc.</b>&nbsp;reported downbeat results for its third quarter and issued weak sales forecast for the current quarter. Steelcase shares dropped 3.7% to $11.09 in the after-hours trading session.</li>\n <li><b>United States Steel Corporation</b>&nbsp;said it projects adjusted earnings before interest, taxes, depreciation and amortization of around $1.65 billion for the fourth quarter, versus analysts’ estimates of $2.13 billion amid a slowdown in orders. United States Steel shares dropped 5.1% to $22.26 in after-hours trading.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FDX":"联邦快递","SCS":"Steelcase Inc.","X":"美国钢铁","DRI":"达登饭店","WGO":"温尼巴格实业"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154435289","content_text":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects Darden Restaurants, Inc. to report quarterly earnings at $1.44 per share on revenue of $2.23 billion before the opening bell. Darden Restaurants shares slipped 0.8% to $145.99 in after-hours trading.\nFedEx Corporation reported better-than-expected results for its second quarter and boosted its FY22 earnings guidance. The company also reported a $5 billion buyback, including $1.5 billion accelerated buyback program. FedEx shares climbed 4.9% to $250.30 in the after-hours trading session.\nAnalysts are expecting Winnebago Industries, Inc. to have earned $2.25 per share on revenue of $1.01 billion for the latest quarter. The company will release earnings before the market open. On Thursday, Winnebago’s board approved a quarterly cash dividend of $0.18 per share. Winnebago shares gained 4.6% to $71.00 in after-hours trading.\n\n\nSteelcase Inc. reported downbeat results for its third quarter and issued weak sales forecast for the current quarter. Steelcase shares dropped 3.7% to $11.09 in the after-hours trading session.\nUnited States Steel Corporation said it projects adjusted earnings before interest, taxes, depreciation and amortization of around $1.65 billion for the fourth quarter, versus analysts’ estimates of $2.13 billion amid a slowdown in orders. United States Steel shares dropped 5.1% to $22.26 in after-hours trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":631,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699335292,"gmtCreate":1639747930518,"gmtModify":1639747931645,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699335292","repostId":"1138605449","repostType":4,"repost":{"id":"1138605449","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639746084,"share":"https://www.laohu8.com/m/news/1138605449?lang=&edition=full","pubTime":"2021-12-17 21:01","market":"us","language":"en","title":"Toplines Before US Market Open on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1138605449","media":"Tiger Newspress","summary":"U.S. Stock futures headed for a lower open Friday morning after a rout in technology stocks during T","content":"<p>U.S.&nbsp;Stock futures headed for a lower open Friday morning after a rout in technology stocks during Thursday's regular trading day, as investors turned away from growth stocks in anticipation of tighter monetary policy next year.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were down 117 points, or 0.33%, S&amp;P 500 e-minis were down 24 points, or 0.52%, and Nasdaq 100 e-minis were down 153.5 points, or 0.97%.<img src=\"https://static.tigerbbs.com/120d112226a9ec4591babf844729ca58\" tg-width=\"1080\" tg-height=\"376\" width=\"100%\" height=\"auto\">Investors' main focus this week has remained fixed on the Federal Reserve's updated outlook on monetary policy for next year, with the central bank's projections delivered mid-week suggesting the Fed&nbsp;could hike interest rates three times next year.</p>\n<p><b>Stocks making the biggest moves premarket: </b></p>\n<p><b><a href=\"https://laohu8.com/S/DRI\">Darden Restaurants</a></b> – The parent of Olive Garden, Longhorn Steakhouse and other restaurant chains beat estimates by 5 cents with quarterly earnings of $1.48 per share and revenue that also topped forecasts. Same-restaurant sales jumped 34.4%, higher than the 32.6% consensus estimate compiled by StreetAccount, and Darden issued an upbeat forecast. Separately, Darden announced that CEO Eugene Lee will retire in May 2022, to be replaced by current President and Chief Operating Officer Ricardo Cardenas. Darden fell 5% in the premarket.</p>\n<p><b><a href=\"https://laohu8.com/S/WGO\">Winnebago</a></b> – The recreational vehicle maker added 3.4% in premarket trading after a sizable bottom-line beat for its fiscal first quarter. Winnebago earned $3.51 per share, compared with the consensus estimate of $2.26 and revenue that also came in above analyst forecasts.</p>\n<p><b><a href=\"https://laohu8.com/S/FDX\">FedEx</a></b> – The delivery service’s shares rallied 5.9% in the premarket after beating estimates on the top and bottom lines for its latest quarter. FedEx earned an adjusted $4.83 per share, beating the $4.28 consensus estimate, with higher shipping rates helping to make up for increased expenses.</p>\n<p><b><a href=\"https://laohu8.com/S/RIVN\">Rivian Automotive, Inc.</a></b> – The electric vehicle maker lost $1.23 billion for the third quarter stemming from expenses to begin production of its electric pickup truck. It was Rivian’s first quarterly report since going public, and revenue was $1 million from its first deliveries. The stock tumbled 7.9% in premarket trading.</p>\n<p><b><a href=\"https://laohu8.com/S/EPAY\">Bottomline</a></b> – Bottomline shares soared 15.1% in the premarket after the fintech company agreed to be acquired by private equity firm Thoma Bravo for $57 per share in cash, or $2.6 billion.</p>\n<p><b><a href=\"https://laohu8.com/S/CERN\">Cerner</a></b> – The healthcare information-technology company’s stock soared 18.9% in premarket trading after the Wall Street Journal reported that&nbsp;Oracle(ORCL) was in talks to buy Cerner in a potential $30 billion deal. Oracle fell 4.6%.</p>\n<p><b><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a></b> – <b><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a></b> shares fell 2.1% in the premarket after the CDC recommended that adults receive the&nbsp;Pfizer(PFE) or&nbsp;Moderna(MRNA) Covid-19 vaccines rather than the J&amp;J shot. The CDC cited new data showing higher levels of a blood clotting condition than previously thought, although that condition remains rare.</p>\n<p><b><a href=\"https://laohu8.com/S/AFRM\">Affirm Holdings, Inc.</a></b> – The “buy now pay later” company’s stock fell 2.3% in the premarket after the Consumer Financial Protection Bureau said it was launching an inquiry into firms that offer such plans.</p>\n<p><b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> – The drug maker’s stock rose 1.3% in premarket action on a Financial Times report that the European Medicines Agency may approve its Covid-19 vaccine for emergency use as early as next week.</p>\n<p><b><a href=\"https://laohu8.com/S/X\">U.S. Steel</a></b> – The steel maker’s stock slid 4.4% in the premarket after the company issued lower-than-expected current-quarter guidance, with higher expenses and cautious customer buying patterns offsetting improved steel pricing.</p>\n<p><b><a href=\"https://laohu8.com/S/SCS\">Steelcase</a></b> – The office furniture maker reported lower-than-expected profit and revenue for the third quarter, with Steelcase saying its results have been impacted by supply chain issues and higher costs. Steelcase fell 4.4% in premarket trading.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-17 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S.&nbsp;Stock futures headed for a lower open Friday morning after a rout in technology stocks during Thursday's regular trading day, as investors turned away from growth stocks in anticipation of tighter monetary policy next year.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were down 117 points, or 0.33%, S&amp;P 500 e-minis were down 24 points, or 0.52%, and Nasdaq 100 e-minis were down 153.5 points, or 0.97%.<img src=\"https://static.tigerbbs.com/120d112226a9ec4591babf844729ca58\" tg-width=\"1080\" tg-height=\"376\" width=\"100%\" height=\"auto\">Investors' main focus this week has remained fixed on the Federal Reserve's updated outlook on monetary policy for next year, with the central bank's projections delivered mid-week suggesting the Fed&nbsp;could hike interest rates three times next year.</p>\n<p><b>Stocks making the biggest moves premarket: </b></p>\n<p><b><a href=\"https://laohu8.com/S/DRI\">Darden Restaurants</a></b> – The parent of Olive Garden, Longhorn Steakhouse and other restaurant chains beat estimates by 5 cents with quarterly earnings of $1.48 per share and revenue that also topped forecasts. Same-restaurant sales jumped 34.4%, higher than the 32.6% consensus estimate compiled by StreetAccount, and Darden issued an upbeat forecast. Separately, Darden announced that CEO Eugene Lee will retire in May 2022, to be replaced by current President and Chief Operating Officer Ricardo Cardenas. Darden fell 5% in the premarket.</p>\n<p><b><a href=\"https://laohu8.com/S/WGO\">Winnebago</a></b> – The recreational vehicle maker added 3.4% in premarket trading after a sizable bottom-line beat for its fiscal first quarter. Winnebago earned $3.51 per share, compared with the consensus estimate of $2.26 and revenue that also came in above analyst forecasts.</p>\n<p><b><a href=\"https://laohu8.com/S/FDX\">FedEx</a></b> – The delivery service’s shares rallied 5.9% in the premarket after beating estimates on the top and bottom lines for its latest quarter. FedEx earned an adjusted $4.83 per share, beating the $4.28 consensus estimate, with higher shipping rates helping to make up for increased expenses.</p>\n<p><b><a href=\"https://laohu8.com/S/RIVN\">Rivian Automotive, Inc.</a></b> – The electric vehicle maker lost $1.23 billion for the third quarter stemming from expenses to begin production of its electric pickup truck. It was Rivian’s first quarterly report since going public, and revenue was $1 million from its first deliveries. The stock tumbled 7.9% in premarket trading.</p>\n<p><b><a href=\"https://laohu8.com/S/EPAY\">Bottomline</a></b> – Bottomline shares soared 15.1% in the premarket after the fintech company agreed to be acquired by private equity firm Thoma Bravo for $57 per share in cash, or $2.6 billion.</p>\n<p><b><a href=\"https://laohu8.com/S/CERN\">Cerner</a></b> – The healthcare information-technology company’s stock soared 18.9% in premarket trading after the Wall Street Journal reported that&nbsp;Oracle(ORCL) was in talks to buy Cerner in a potential $30 billion deal. Oracle fell 4.6%.</p>\n<p><b><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a></b> – <b><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a></b> shares fell 2.1% in the premarket after the CDC recommended that adults receive the&nbsp;Pfizer(PFE) or&nbsp;Moderna(MRNA) Covid-19 vaccines rather than the J&amp;J shot. The CDC cited new data showing higher levels of a blood clotting condition than previously thought, although that condition remains rare.</p>\n<p><b><a href=\"https://laohu8.com/S/AFRM\">Affirm Holdings, Inc.</a></b> – The “buy now pay later” company’s stock fell 2.3% in the premarket after the Consumer Financial Protection Bureau said it was launching an inquiry into firms that offer such plans.</p>\n<p><b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> – The drug maker’s stock rose 1.3% in premarket action on a Financial Times report that the European Medicines Agency may approve its Covid-19 vaccine for emergency use as early as next week.</p>\n<p><b><a href=\"https://laohu8.com/S/X\">U.S. Steel</a></b> – The steel maker’s stock slid 4.4% in the premarket after the company issued lower-than-expected current-quarter guidance, with higher expenses and cautious customer buying patterns offsetting improved steel pricing.</p>\n<p><b><a href=\"https://laohu8.com/S/SCS\">Steelcase</a></b> – The office furniture maker reported lower-than-expected profit and revenue for the third quarter, with Steelcase saying its results have been impacted by supply chain issues and higher costs. Steelcase fell 4.4% in premarket trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138605449","content_text":"U.S. Stock futures headed for a lower open Friday morning after a rout in technology stocks during Thursday's regular trading day, as investors turned away from growth stocks in anticipation of tighter monetary policy next year.\nAt 8:00 a.m. ET, Dow e-minis were down 117 points, or 0.33%, S&P 500 e-minis were down 24 points, or 0.52%, and Nasdaq 100 e-minis were down 153.5 points, or 0.97%.Investors' main focus this week has remained fixed on the Federal Reserve's updated outlook on monetary policy for next year, with the central bank's projections delivered mid-week suggesting the Fed could hike interest rates three times next year.\nStocks making the biggest moves premarket: \nDarden Restaurants – The parent of Olive Garden, Longhorn Steakhouse and other restaurant chains beat estimates by 5 cents with quarterly earnings of $1.48 per share and revenue that also topped forecasts. Same-restaurant sales jumped 34.4%, higher than the 32.6% consensus estimate compiled by StreetAccount, and Darden issued an upbeat forecast. Separately, Darden announced that CEO Eugene Lee will retire in May 2022, to be replaced by current President and Chief Operating Officer Ricardo Cardenas. Darden fell 5% in the premarket.\nWinnebago – The recreational vehicle maker added 3.4% in premarket trading after a sizable bottom-line beat for its fiscal first quarter. Winnebago earned $3.51 per share, compared with the consensus estimate of $2.26 and revenue that also came in above analyst forecasts.\nFedEx – The delivery service’s shares rallied 5.9% in the premarket after beating estimates on the top and bottom lines for its latest quarter. FedEx earned an adjusted $4.83 per share, beating the $4.28 consensus estimate, with higher shipping rates helping to make up for increased expenses.\nRivian Automotive, Inc. – The electric vehicle maker lost $1.23 billion for the third quarter stemming from expenses to begin production of its electric pickup truck. It was Rivian’s first quarterly report since going public, and revenue was $1 million from its first deliveries. The stock tumbled 7.9% in premarket trading.\nBottomline – Bottomline shares soared 15.1% in the premarket after the fintech company agreed to be acquired by private equity firm Thoma Bravo for $57 per share in cash, or $2.6 billion.\nCerner – The healthcare information-technology company’s stock soared 18.9% in premarket trading after the Wall Street Journal reported that Oracle(ORCL) was in talks to buy Cerner in a potential $30 billion deal. Oracle fell 4.6%.\nJohnson & Johnson – Johnson & Johnson shares fell 2.1% in the premarket after the CDC recommended that adults receive the Pfizer(PFE) or Moderna(MRNA) Covid-19 vaccines rather than the J&J shot. The CDC cited new data showing higher levels of a blood clotting condition than previously thought, although that condition remains rare.\nAffirm Holdings, Inc. – The “buy now pay later” company’s stock fell 2.3% in the premarket after the Consumer Financial Protection Bureau said it was launching an inquiry into firms that offer such plans.\nNovavax – The drug maker’s stock rose 1.3% in premarket action on a Financial Times report that the European Medicines Agency may approve its Covid-19 vaccine for emergency use as early as next week.\nU.S. Steel – The steel maker’s stock slid 4.4% in the premarket after the company issued lower-than-expected current-quarter guidance, with higher expenses and cautious customer buying patterns offsetting improved steel pricing.\nSteelcase – The office furniture maker reported lower-than-expected profit and revenue for the third quarter, with Steelcase saying its results have been impacted by supply chain issues and higher costs. Steelcase fell 4.4% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":666,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690605469,"gmtCreate":1639660809729,"gmtModify":1639660810880,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/690605469","repostId":"1191683541","repostType":4,"repost":{"id":"1191683541","pubTimestamp":1639658241,"share":"https://www.laohu8.com/m/news/1191683541?lang=&edition=full","pubTime":"2021-12-16 20:37","market":"us","language":"en","title":"10 Biggest Price Target Changes For Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1191683541","media":"Benzinga","summary":"Stifel cut the price target on Under Armour, Inc.. from $30 to $24. Under Armour shares fell 0.7% to $22.22 in pre-market trading.RBC Capital lowered the price target on Airbnb, Inc. from $195 to $175. Airbnb shares rose 0.3% to $168.62 in pre-market trading.Morgan Stanley lowered DocuSign, Inc. price target from $350 to $165. DocuSign shares dropped 2.4% to $147.51 in pre-market trading.Barclays cut the price target on Aptiv PLC from $212 to $200. Aptiv shares rose 2.7% to $168.91 in pre-market","content":"<ul>\n <li>Stifel cut the price target on&nbsp;<b>Under Armour, Inc..</b>(NYSE:UAA) from $30 to $24. Under Armour shares fell 0.7% to $22.22 in pre-market trading.</li>\n <li>RBC Capital lowered the price target on&nbsp;<b>Airbnb, Inc.</b>(NASDAQ:ABNB) from $195 to $175. Airbnb shares rose 0.3% to $168.62 in pre-market trading.</li>\n <li>Morgan Stanley cut&nbsp;<b>AT&amp;T Inc.</b>(NYSE:T) price target from $32 to $28. AT&amp;T shares rose 1.7% to $22.55 in pre-market trading.</li>\n <li>Morgan Stanley lowered&nbsp;<b>DocuSign, Inc.</b>(NASDAQ:DOCU) price target from $350 to $165. DocuSign shares dropped 2.4% to $147.51 in pre-market trading.</li>\n <li>Barclays cut the price target on&nbsp;<b>Aptiv PLC</b>(NYSE:APTV) from $212 to $200. Aptiv shares rose 2.7% to $168.91 in pre-market trading.</li>\n <li>Raymond James raised&nbsp;<b>The Progressive Corporation</b>(NYSE:PGR) price target from $105 to $110. Progressive shares rose 4.8% to close at $101.81 on Wednesday.</li>\n <li>Wells Fargo boosted the price target for&nbsp;<b>Magna International Inc.</b>(NYSE:MGA) from $84 to $93. Magna International shares rose 1.7% to $79.04 in pre-market trading.</li>\n <li>B of A Securities reduced the price target for&nbsp;<b>Wayfair Inc.</b>(NYSE:W) from $265 to $175. Wayfair shares dropped 2.4% to $202.28 in pre-market trading.</li>\n <li>HC Wainwright &amp; Co. cut&nbsp;<b>IGM Biosciences, Inc.</b>(NASDAQ:IGMS) price target from $114 to $76. IGM Biosciences shares fell 0.1% to close at $28.35 on Wednesday.</li>\n <li>Needham cut&nbsp;<b>Medtronic plc</b>(NYSE:MDT) price target from $145 to $131. Medtronic shares rose 0.1% to $105.01 in pre-market trading.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 20:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-ratings/price-target/21/12/24641061/10-biggest-price-target-changes-for-thursday><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stifel cut the price target on Under Armour, Inc..(NYSE:UAA) from $30 to $24. Under Armour shares fell 0.7% to $22.22 in pre-market trading.\nRBC Capital lowered the price target on Airbnb, Inc.(NASDAQ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-ratings/price-target/21/12/24641061/10-biggest-price-target-changes-for-thursday\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"T":"美国电话电报","DOCU":"Docusign","ABNB":"爱彼迎"},"source_url":"https://www.benzinga.com/analyst-ratings/price-target/21/12/24641061/10-biggest-price-target-changes-for-thursday","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191683541","content_text":"Stifel cut the price target on Under Armour, Inc..(NYSE:UAA) from $30 to $24. Under Armour shares fell 0.7% to $22.22 in pre-market trading.\nRBC Capital lowered the price target on Airbnb, Inc.(NASDAQ:ABNB) from $195 to $175. Airbnb shares rose 0.3% to $168.62 in pre-market trading.\nMorgan Stanley cut AT&T Inc.(NYSE:T) price target from $32 to $28. AT&T shares rose 1.7% to $22.55 in pre-market trading.\nMorgan Stanley lowered DocuSign, Inc.(NASDAQ:DOCU) price target from $350 to $165. DocuSign shares dropped 2.4% to $147.51 in pre-market trading.\nBarclays cut the price target on Aptiv PLC(NYSE:APTV) from $212 to $200. Aptiv shares rose 2.7% to $168.91 in pre-market trading.\nRaymond James raised The Progressive Corporation(NYSE:PGR) price target from $105 to $110. Progressive shares rose 4.8% to close at $101.81 on Wednesday.\nWells Fargo boosted the price target for Magna International Inc.(NYSE:MGA) from $84 to $93. Magna International shares rose 1.7% to $79.04 in pre-market trading.\nB of A Securities reduced the price target for Wayfair Inc.(NYSE:W) from $265 to $175. Wayfair shares dropped 2.4% to $202.28 in pre-market trading.\nHC Wainwright & Co. cut IGM Biosciences, Inc.(NASDAQ:IGMS) price target from $114 to $76. IGM Biosciences shares fell 0.1% to close at $28.35 on Wednesday.\nNeedham cut Medtronic plc(NYSE:MDT) price target from $145 to $131. Medtronic shares rose 0.1% to $105.01 in pre-market trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":873,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690608287,"gmtCreate":1639660378795,"gmtModify":1639660378795,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Hmmmm","listText":"Hmmmm","text":"Hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690608287","repostId":"1142996286","repostType":4,"isVote":1,"tweetType":1,"viewCount":881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690603041,"gmtCreate":1639660187421,"gmtModify":1639660188515,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690603041","repostId":"1122700546","repostType":4,"repost":{"id":"1122700546","pubTimestamp":1639656448,"share":"https://www.laohu8.com/m/news/1122700546?lang=&edition=full","pubTime":"2021-12-16 20:07","market":"us","language":"en","title":"Shopify rallies after Evercore ISI calls out +25% upside potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1122700546","media":"Seeking Alpha","summary":"Evercore ISI upgrades Shopify(NYSE:SHOP)to an Outperform rating after having it lined up at In Line.","content":"<ul>\n <li>Evercore ISI upgrades Shopify(NYSE:SHOP)to an Outperform rating after having it lined up at In Line.</li>\n <li>Analyst Mark Mahaney says the stock is dislocated at 20% off their YTD highs and with a forward EV/sales multiple of 24X that is at a pre-pandemic level. Mahaney and team also view SHOP as one of the highest quality assets in their coverage, noting the 2021-2023 Revenue CAGR of 34% is the fastest among all the Mega and Large Cap coverage. Growth opportunities and option value are also called out.</li>\n <li>Shares of SHOP are&nbsp;up 3.08%&nbsp;in premarket action to $1,410.26.</li>\n <li>Evercore ISI assigns a price target of $1,770 to rep 29% upside potential and stands above the&nbsp;average Wall Street PT of $1,698.19.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shopify rallies after Evercore ISI calls out +25% upside potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShopify rallies after Evercore ISI calls out +25% upside potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 20:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3780681-shopify-rallies-after-evercore-isi-calls-out-25-upside-potential><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Evercore ISI upgrades Shopify(NYSE:SHOP)to an Outperform rating after having it lined up at In Line.\nAnalyst Mark Mahaney says the stock is dislocated at 20% off their YTD highs and with a forward EV/...</p>\n\n<a href=\"https://seekingalpha.com/news/3780681-shopify-rallies-after-evercore-isi-calls-out-25-upside-potential\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SHOP":"Shopify Inc"},"source_url":"https://seekingalpha.com/news/3780681-shopify-rallies-after-evercore-isi-calls-out-25-upside-potential","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122700546","content_text":"Evercore ISI upgrades Shopify(NYSE:SHOP)to an Outperform rating after having it lined up at In Line.\nAnalyst Mark Mahaney says the stock is dislocated at 20% off their YTD highs and with a forward EV/sales multiple of 24X that is at a pre-pandemic level. Mahaney and team also view SHOP as one of the highest quality assets in their coverage, noting the 2021-2023 Revenue CAGR of 34% is the fastest among all the Mega and Large Cap coverage. Growth opportunities and option value are also called out.\nShares of SHOP are up 3.08% in premarket action to $1,410.26.\nEvercore ISI assigns a price target of $1,770 to rep 29% upside potential and stands above the average Wall Street PT of $1,698.19.","news_type":1},"isVote":1,"tweetType":1,"viewCount":867,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690609850,"gmtCreate":1639660136423,"gmtModify":1639660137549,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690609850","repostId":"1142996286","repostType":4,"isVote":1,"tweetType":1,"viewCount":532,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607919238,"gmtCreate":1639472743238,"gmtModify":1639472744343,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607919238","repostId":"1114636896","repostType":4,"repost":{"id":"1114636896","pubTimestamp":1639439509,"share":"https://www.laohu8.com/m/news/1114636896?lang=&edition=full","pubTime":"2021-12-14 07:51","market":"us","language":"en","title":"Tesla Stock Is in a Bear Market Again. What’s Next for Musk’s EV Firm.","url":"https://stock-news.laohu8.com/highlight/detail?id=1114636896","media":"Barrons","summary":"Shares of electric-vehicle leader Tesla crossed into bear-market territory today. That statement is ","content":"<p>Shares of electric-vehicle leader&nbsp;Tesla&nbsp;crossed into bear-market territory&nbsp;today. That statement is technically true, but also a little tiring. Stocks, individually, don’t have bear or bull markets. That terms should be reserved for, well, the overall market. Still, the big dip in a mega-cap stock is noteworthy leaving investors wondering what might come next.</p>\n<p>Tesla (ticker: TSLA) stock closed down 5% at $966.41. The&nbsp;S&amp;P 500 index&nbsp;and&nbsp;Dow Jones Industrial Average&nbsp;both closed down 0.9%.</p>\n<p>The Monday dip sent the company’s market cap below $1 trillion based on the number of shares outstanding, excluding management stock options. Shares are down 21% from the Nov. 4 closing high of $1,229.91. Shares are down 22% from the intraday high of $1,243.49.</p>\n<p>Whether or not bear markets should be measured from a closing high or an intraday high is the source of debate on Wall Street. But again, the debate doesn’t really matter in this instance because individual stocks don’t have bull and bear markets.</p>\n<p>Whether it’s a bear market or not isn’t the point for individual investors. The pain of a 20% drop is real.</p>\n<p>One of the last times Tesla stock closed in bear-market territory was February 2021. (Yes, <i>Barron’s</i> wrote about the single stock bear market then, too.) Back then, interest rates were rising and highly valued tech stocks took it on the chin. Higher rates hurt the valuation of shares of faster-growing companies more than those of slow-growing mature companies—that’s just the way the math of higher interest rates works out.</p>\n<p>Back then it took about six months for the stock to retake its old highs. If that were to happen again, bullish investors would be waiting until June 2022 to see Tesla stock hit $1,300.</p>\n<p>That would be a long wait for bulls, and while there is no way to know if that scenario will even unfold, there is a lot going on that could move the stock in the coming couple of months. Bullish and bearish Tesla investors will be watching for the startup of two new plants in Germany and Texas, the impact of those new plants on profit margins, the start of deliveries of the Tesla Cybertruck and the overall growth of EVs in the U.S., Europe, and China.</p>\n<p>With all that coming, it raising the question of why the shares are struggling.</p>\n<p>Two things might be at work. First, CEO Elon Musk is still selling stock. It creates an overhang. Some bulls might wait to buy until the large sales are over. Musk has at least 5 million or 6 million shares left to sell associated with his expiring stock options. He will probably be done selling by the end of 2021, but he might just Tweet out when he’s done. At current pace, we figure by year-end.</p>\n<p>Second, there is the issue of Musk being named Time’s Person of the Year.Amazon.com&nbsp;(AMZN) founder Jeff Bezos won that distinction in 1999, near a multiyear peak in that stock. Amazon shares went on to slide, and some investors think Tesla stock could do the same.</p>\n<p>The Amazon comparison with Tesla doesn’t quite match up, however. The two companies are at very different stages of development when their top executives won Time’s distinction. Amazon had a market capitalization of $27 billion back then. Tesla’s market cap is now hovering around $1 trillion.</p>\n<p>Still, it’s a belief, and traders do odd things from time to time, justified or not. When stocks move upward, or downward, momentum traders will jump on the trend for whatever reason.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Stock Is in a Bear Market Again. What’s Next for Musk’s EV Firm.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Stock Is in a Bear Market Again. What’s Next for Musk’s EV Firm.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-14 07:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/tesla-stock-bear-musk-51639436863?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of electric-vehicle leader Tesla crossed into bear-market territory today. That statement is technically true, but also a little tiring. Stocks, individually, don’t have bear or bull markets. ...</p>\n\n<a href=\"https://www.barrons.com/articles/tesla-stock-bear-musk-51639436863?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.barrons.com/articles/tesla-stock-bear-musk-51639436863?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114636896","content_text":"Shares of electric-vehicle leader Tesla crossed into bear-market territory today. That statement is technically true, but also a little tiring. Stocks, individually, don’t have bear or bull markets. That terms should be reserved for, well, the overall market. Still, the big dip in a mega-cap stock is noteworthy leaving investors wondering what might come next.\nTesla (ticker: TSLA) stock closed down 5% at $966.41. The S&P 500 index and Dow Jones Industrial Average both closed down 0.9%.\nThe Monday dip sent the company’s market cap below $1 trillion based on the number of shares outstanding, excluding management stock options. Shares are down 21% from the Nov. 4 closing high of $1,229.91. Shares are down 22% from the intraday high of $1,243.49.\nWhether or not bear markets should be measured from a closing high or an intraday high is the source of debate on Wall Street. But again, the debate doesn’t really matter in this instance because individual stocks don’t have bull and bear markets.\nWhether it’s a bear market or not isn’t the point for individual investors. The pain of a 20% drop is real.\nOne of the last times Tesla stock closed in bear-market territory was February 2021. (Yes, Barron’s wrote about the single stock bear market then, too.) Back then, interest rates were rising and highly valued tech stocks took it on the chin. Higher rates hurt the valuation of shares of faster-growing companies more than those of slow-growing mature companies—that’s just the way the math of higher interest rates works out.\nBack then it took about six months for the stock to retake its old highs. If that were to happen again, bullish investors would be waiting until June 2022 to see Tesla stock hit $1,300.\nThat would be a long wait for bulls, and while there is no way to know if that scenario will even unfold, there is a lot going on that could move the stock in the coming couple of months. Bullish and bearish Tesla investors will be watching for the startup of two new plants in Germany and Texas, the impact of those new plants on profit margins, the start of deliveries of the Tesla Cybertruck and the overall growth of EVs in the U.S., Europe, and China.\nWith all that coming, it raising the question of why the shares are struggling.\nTwo things might be at work. First, CEO Elon Musk is still selling stock. It creates an overhang. Some bulls might wait to buy until the large sales are over. Musk has at least 5 million or 6 million shares left to sell associated with his expiring stock options. He will probably be done selling by the end of 2021, but he might just Tweet out when he’s done. At current pace, we figure by year-end.\nSecond, there is the issue of Musk being named Time’s Person of the Year.Amazon.com (AMZN) founder Jeff Bezos won that distinction in 1999, near a multiyear peak in that stock. Amazon shares went on to slide, and some investors think Tesla stock could do the same.\nThe Amazon comparison with Tesla doesn’t quite match up, however. The two companies are at very different stages of development when their top executives won Time’s distinction. Amazon had a market capitalization of $27 billion back then. Tesla’s market cap is now hovering around $1 trillion.\nStill, it’s a belief, and traders do odd things from time to time, justified or not. When stocks move upward, or downward, momentum traders will jump on the trend for whatever reason.","news_type":1},"isVote":1,"tweetType":1,"viewCount":200,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604284528,"gmtCreate":1639403527473,"gmtModify":1639403980729,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/604284528","repostId":"1101330061","repostType":4,"repost":{"id":"1101330061","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639402663,"share":"https://www.laohu8.com/m/news/1101330061?lang=&edition=full","pubTime":"2021-12-13 21:37","market":"us","language":"en","title":"Veru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI","url":"https://stock-news.laohu8.com/highlight/detail?id=1101330061","media":"Tiger Newspress","summary":"Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.The company today ann","content":"<p>Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.<img src=\"https://static.tigerbbs.com/fa70bd1f3f0b778ea773bf713c99c679\" tg-width=\"774\" tg-height=\"570\" referrerpolicy=\"no-referrer\">The&nbsp;company&nbsp;today&nbsp;announced that the U.S. Food and Drug Administration (FDA) has approved ENTADFITM&nbsp;for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia (BPH).</p>\n<p>ENTADFI (finasteride and tadalafil) capsule for oral use has also been shown to be more effective to treat urinary tract symptoms caused by BPH with less potential for adverse sexual side effects compared to finasteride monotherapy. ENTADFI dosing is one capsule orally once a day, and the FDA-approved indication is to initiate treatment of the signs and symptoms of benign prostatic hyperplasia in men with an enlarged prostate for up to 26 weeks.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-13 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.<img src=\"https://static.tigerbbs.com/fa70bd1f3f0b778ea773bf713c99c679\" tg-width=\"774\" tg-height=\"570\" referrerpolicy=\"no-referrer\">The&nbsp;company&nbsp;today&nbsp;announced that the U.S. Food and Drug Administration (FDA) has approved ENTADFITM&nbsp;for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia (BPH).</p>\n<p>ENTADFI (finasteride and tadalafil) capsule for oral use has also been shown to be more effective to treat urinary tract symptoms caused by BPH with less potential for adverse sexual side effects compared to finasteride monotherapy. ENTADFI dosing is one capsule orally once a day, and the FDA-approved indication is to initiate treatment of the signs and symptoms of benign prostatic hyperplasia in men with an enlarged prostate for up to 26 weeks.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VERU":"Veru Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101330061","content_text":"Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.The company today announced that the U.S. Food and Drug Administration (FDA) has approved ENTADFITM for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia (BPH).\nENTADFI (finasteride and tadalafil) capsule for oral use has also been shown to be more effective to treat urinary tract symptoms caused by BPH with less potential for adverse sexual side effects compared to finasteride monotherapy. ENTADFI dosing is one capsule orally once a day, and the FDA-approved indication is to initiate treatment of the signs and symptoms of benign prostatic hyperplasia in men with an enlarged prostate for up to 26 weeks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":221,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605640297,"gmtCreate":1639160477225,"gmtModify":1639160478352,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605640297","repostId":"1133027099","repostType":4,"repost":{"id":"1133027099","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639152670,"share":"https://www.laohu8.com/m/news/1133027099?lang=&edition=full","pubTime":"2021-12-11 00:11","market":"us","language":"en","title":"Sea Ltd stock dropped more than 5% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133027099","media":"Tiger Newspress","summary":"Sea Ltd stock dropped more than 5% in morning trading.","content":"<p>Sea Ltd stock dropped more than 5% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f6295277426435ac2c7135ba73dfbdef\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea Ltd stock dropped more than 5% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea Ltd stock dropped more than 5% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-11 00:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sea Ltd stock dropped more than 5% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f6295277426435ac2c7135ba73dfbdef\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133027099","content_text":"Sea Ltd stock dropped more than 5% in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602877662,"gmtCreate":1639010952150,"gmtModify":1639010953069,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602877662","repostId":"1192089081","repostType":4,"repost":{"id":"1192089081","pubTimestamp":1639008258,"share":"https://www.laohu8.com/m/news/1192089081?lang=&edition=full","pubTime":"2021-12-09 08:04","market":"sg","language":"en","title":"Rebound Anticipated For Singapore Stock Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1192089081","media":"RTTNews","summary":"The Singapore stock market on Wednesday snapped the three-day winning streak in which it had collected almost 45 points or 1.4 percent. The Straits Times Index now sits just beneath the 3,130-point plateau although it may tick higher again on Thursday.The global forecast for the Asian markets is cautiously optimistic, again supported by oil and technology companies. The European markets were down and the U.S. bourses were up and the Asian markets figure to follow the latter lead.The STI finished","content":"<p>The Singapore stock market on Wednesday snapped the three-day winning streak in which it had collected almost 45 points or 1.4 percent. The Straits Times Index now sits just beneath the 3,130-point plateau although it may tick higher again on Thursday.</p>\n<p>The global forecast for the Asian markets is cautiously optimistic, again supported by oil and technology companies. The European markets were down and the U.S. bourses were up and the Asian markets figure to follow the latter lead.</p>\n<p>The STI finished slightly lower on Wednesday following mixed performances from the financial shares and industrial stocks.</p>\n<p>For the day, the index dipped 4.89 points or 0.16 percent to finish at 3,129.77 after trading between 3,124.31 and 3,140.75. Volume was 1.11 billion shares worth 1.04 billion Singapore dollars. There were 223 gainers and 202 decliners.</p>\n<p>Among the actives, CapitaLand Integrated Commercial Trust sank 0.49 percent, while City Developments was up 0.14 percent, Comfort DelGro retreated 0.71 percent, DBS Group dipped 0.22 percent, Genting Singapore added 0.65 percent, Keppel Corp rose 0.39 percent, Oversea-Chinese Banking Corporation fell 0.26 percent, SATS tanked 1.27 percent, SembCorp Industries tumbled 1.00 percent, Singapore Airlines gained 0.40 percent, Singapore Exchange declined 0.95 percent, Singapore Press Holdings lost 0.43 percent, Singapore Technologies Engineering skidded 0.53 percent, SingTel jumped 1.24 percent, United Overseas Bank collected 0.41 percent, Wilmar International dropped 0.48 percent, Yangzijiang Shipbuilding plunged 1.52 percent and Dairy Farm International, Mapletree Commercial Trust, Mapletree Logistics Trust, Ascendas REIT and Thai Beverage were unchanged.</p>\n<p>The lead from Wall Street is positive as the major averages opened mixed on Wednesday, shook off a midday slump and finished in the green.</p>\n<p>The Dow added 35.32 points or 0.10 percent to finish at 35,754.75, while the NASDAQ jumped 100.07 points or 0.64 percent to end at 15,786.99 and the S&amp;P 500 rose 14.46 points or 0.31 percent to close at 4,701.21.</p>\n<p>The choppy trading seen for most of the day came as traders expressed some uncertainty about the near-term outlook for the markets following recent volatility.</p>\n<p>With concerns about the impact of the Omicron variant easing, traders are now looking ahead to next week's Federal Reserve's monetary policy announcement. Reports suggest the Fed could decide to double the pace of tapering its asset purchase program to $30 billion per month.</p>\n<p>Some positive sentiment was generated by comments from Pfizer (PFE) and BioNTech (BNTX) regarding the effectiveness of their Covid vaccine as preliminary laboratory studies have demonstrated that three doses of their vaccine neutralize the Omicron variant.</p>\n<p>Crude oil futures settled higher on Wednesday after the Energy Information Administration (EIA) reported a drop in U.S. crude inventories last week. West Texas Intermediate Crude oil futures for January ended higher by $0.31 or 0.4 percent at $72.36 a barrel.</p>","source":"lsy1626938412129","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rebound Anticipated For Singapore Stock Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRebound Anticipated For Singapore Stock Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-09 08:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.rttnews.com/3247905/rebound-anticipated-for-singapore-stock-market.aspx?type=acom><strong>RTTNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Singapore stock market on Wednesday snapped the three-day winning streak in which it had collected almost 45 points or 1.4 percent. The Straits Times Index now sits just beneath the 3,130-point ...</p>\n\n<a href=\"https://www.rttnews.com/3247905/rebound-anticipated-for-singapore-stock-market.aspx?type=acom\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.rttnews.com/3247905/rebound-anticipated-for-singapore-stock-market.aspx?type=acom","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192089081","content_text":"The Singapore stock market on Wednesday snapped the three-day winning streak in which it had collected almost 45 points or 1.4 percent. The Straits Times Index now sits just beneath the 3,130-point plateau although it may tick higher again on Thursday.\nThe global forecast for the Asian markets is cautiously optimistic, again supported by oil and technology companies. The European markets were down and the U.S. bourses were up and the Asian markets figure to follow the latter lead.\nThe STI finished slightly lower on Wednesday following mixed performances from the financial shares and industrial stocks.\nFor the day, the index dipped 4.89 points or 0.16 percent to finish at 3,129.77 after trading between 3,124.31 and 3,140.75. Volume was 1.11 billion shares worth 1.04 billion Singapore dollars. There were 223 gainers and 202 decliners.\nAmong the actives, CapitaLand Integrated Commercial Trust sank 0.49 percent, while City Developments was up 0.14 percent, Comfort DelGro retreated 0.71 percent, DBS Group dipped 0.22 percent, Genting Singapore added 0.65 percent, Keppel Corp rose 0.39 percent, Oversea-Chinese Banking Corporation fell 0.26 percent, SATS tanked 1.27 percent, SembCorp Industries tumbled 1.00 percent, Singapore Airlines gained 0.40 percent, Singapore Exchange declined 0.95 percent, Singapore Press Holdings lost 0.43 percent, Singapore Technologies Engineering skidded 0.53 percent, SingTel jumped 1.24 percent, United Overseas Bank collected 0.41 percent, Wilmar International dropped 0.48 percent, Yangzijiang Shipbuilding plunged 1.52 percent and Dairy Farm International, Mapletree Commercial Trust, Mapletree Logistics Trust, Ascendas REIT and Thai Beverage were unchanged.\nThe lead from Wall Street is positive as the major averages opened mixed on Wednesday, shook off a midday slump and finished in the green.\nThe Dow added 35.32 points or 0.10 percent to finish at 35,754.75, while the NASDAQ jumped 100.07 points or 0.64 percent to end at 15,786.99 and the S&P 500 rose 14.46 points or 0.31 percent to close at 4,701.21.\nThe choppy trading seen for most of the day came as traders expressed some uncertainty about the near-term outlook for the markets following recent volatility.\nWith concerns about the impact of the Omicron variant easing, traders are now looking ahead to next week's Federal Reserve's monetary policy announcement. Reports suggest the Fed could decide to double the pace of tapering its asset purchase program to $30 billion per month.\nSome positive sentiment was generated by comments from Pfizer (PFE) and BioNTech (BNTX) regarding the effectiveness of their Covid vaccine as preliminary laboratory studies have demonstrated that three doses of their vaccine neutralize the Omicron variant.\nCrude oil futures settled higher on Wednesday after the Energy Information Administration (EIA) reported a drop in U.S. crude inventories last week. West Texas Intermediate Crude oil futures for January ended higher by $0.31 or 0.4 percent at $72.36 a barrel.","news_type":1},"isVote":1,"tweetType":1,"viewCount":283,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606465004,"gmtCreate":1638921201264,"gmtModify":1638921202238,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606465004","repostId":"1142645155","repostType":4,"repost":{"id":"1142645155","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638890012,"share":"https://www.laohu8.com/m/news/1142645155?lang=&edition=full","pubTime":"2021-12-07 23:13","market":"us","language":"en","title":"Pinduoduo shares surged 11% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1142645155","media":"Tiger Newspress","summary":"Pinduoduo shares surged 11% in morning trading after Macquarie gave pinduoduo a market beating ratin","content":"<p>Pinduoduo shares surged 11% in morning trading&nbsp;after&nbsp;Macquarie gave pinduoduo a market beating rating with a target price of $95.</p>\n<p><img src=\"https://static.tigerbbs.com/38c15dca491bd8741f8ac3af099bdeb7\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pinduoduo shares surged 11% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPinduoduo shares surged 11% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-07 23:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pinduoduo shares surged 11% in morning trading&nbsp;after&nbsp;Macquarie gave pinduoduo a market beating rating with a target price of $95.</p>\n<p><img src=\"https://static.tigerbbs.com/38c15dca491bd8741f8ac3af099bdeb7\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PDD":"拼多多"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142645155","content_text":"Pinduoduo shares surged 11% in morning trading after Macquarie gave pinduoduo a market beating rating with a target price of $95.","news_type":1},"isVote":1,"tweetType":1,"viewCount":260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606185457,"gmtCreate":1638843254914,"gmtModify":1638843255865,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606185457","repostId":"1133458146","repostType":4,"repost":{"id":"1133458146","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638837591,"share":"https://www.laohu8.com/m/news/1133458146?lang=&edition=full","pubTime":"2021-12-07 08:39","market":"us","language":"en","title":"Intel shares surged more than 7% in after-hours trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133458146","media":"Tiger Newspress","summary":"Intel shares surged more than 7% in after-hours trading.Intel Corp is planning to publicly list shar","content":"<p>Intel&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;7%&nbsp;in&nbsp;after-hours&nbsp;trading.<img src=\"https://static.tigerbbs.com/6646a6cbd4f0e04c695a379c7768d260\" tg-width=\"735\" tg-height=\"649\" width=\"100%\" height=\"auto\">Intel Corp&nbsp;is planning to publicly list shares in its self-driving-car unit <a href=\"https://laohu8.com/S/MBLY\">Mobileye</a>, which could value the unit at north of $50 billion ,the Wall Street Journal reported on Monday, citing people familiar with the matter.</p>\n<p>However, there are no guarantees Intel will ultimately follow through with an offering, the report said&nbsp;adding that the announcement is expected as soon as this week.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel shares surged more than 7% in after-hours trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel shares surged more than 7% in after-hours trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-07 08:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Intel&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;7%&nbsp;in&nbsp;after-hours&nbsp;trading.<img src=\"https://static.tigerbbs.com/6646a6cbd4f0e04c695a379c7768d260\" tg-width=\"735\" tg-height=\"649\" width=\"100%\" height=\"auto\">Intel Corp&nbsp;is planning to publicly list shares in its self-driving-car unit <a href=\"https://laohu8.com/S/MBLY\">Mobileye</a>, which could value the unit at north of $50 billion ,the Wall Street Journal reported on Monday, citing people familiar with the matter.</p>\n<p>However, there are no guarantees Intel will ultimately follow through with an offering, the report said&nbsp;adding that the announcement is expected as soon as this week.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INTC":"英特尔"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133458146","content_text":"Intel shares surged more than 7% in after-hours trading.Intel Corp is planning to publicly list shares in its self-driving-car unit Mobileye, which could value the unit at north of $50 billion ,the Wall Street Journal reported on Monday, citing people familiar with the matter.\nHowever, there are no guarantees Intel will ultimately follow through with an offering, the report said adding that the announcement is expected as soon as this week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":292,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608448102,"gmtCreate":1638783361438,"gmtModify":1638783366193,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608448102","repostId":"1178940634","repostType":4,"repost":{"id":"1178940634","pubTimestamp":1638748983,"share":"https://www.laohu8.com/m/news/1178940634?lang=&edition=full","pubTime":"2021-12-06 08:03","market":"sg","language":"en","title":"Singapore Bourse Expected To Remain Rangebound On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1178940634","media":"RTTNews","summary":"The Singapore stock market has moved higher in two of three trading days since the end of the six-da","content":"<p>The Singapore stock market has moved higher in two of three trading days since the end of the six-day losing streak in which it had plummeted almost 200 points or 6.4 percent. The Straits Times Index now sits just above the 3,100-point plateau although it's expected to turn lower again on Monday.</p>\n<p></p>\n<p>The global forecast for the Asian markets is negative on coronavirus and economic concerns, with oil and technology stocks likely to lead the way lower. The European and U.S. markets finished solidly under water and the Asian markets are expected to open in similar fashion.</p>\n<p></p>\n<p>The STI finished modestly higher on Friday following gains from the industrials and properties, while the financials were mixed.</p>\n<p></p>\n<p>For the day, the index rose 9.82 points or 0.32 percent to finish at 3,101.93 after trading between 3,080.29 and 3,109.64. Volume was 1.04 billion shares worth 1.13 billion Singapore dollars. There were 269 gainers and 194 decliners.</p>\n<p></p>\n<p>Among the actives, Ascendas REIT added 0.68 percent, while CapitaLand Integrated Commercial Trust shed 0.48 percent, City Developments and Wilmar International both advanced 0.74 percent, Comfort DelGro accelerated 2.19 percent, Dairy Farm International and Genting Singapore both jumped 2.01 percent, DBS Group lost 0.25 percent, Keppel Corp rose 0.39 percent, Oversea-Chinese Banking Corporation eased 0.09 percent, SATS surged 2.62 percent, SembCorp Industries soared 2.58 percent, Singapore Airlines gained 0.62 percent, Singapore Exchange spiked 2.43 percent, Singapore Technologies Engineering increased 0.27 percent, Thai Beverage rallied 0.76 percent, United Overseas Bank collected 0.46 percent, Yangzijiang Shipbuilding climbed 0.78 percent and Mapletree Commercial Trust, Mapletree Logistics Trust, Singapore Press Holdings and SingTel were unchanged.</p>\n<p></p>\n<p>The lead from Wall Street is soft as the major averages opened slightly higher on Friday but quickly turned lower and spent the remainder of the day in negative territory.</p>\n<p></p>\n<p>The Dow shed 59/72 points or 0.17 percent to finish at 34,580.08, while the NASDAQ plummeted 295.83 points or 1.92 percent to close at 15,085.47 and the S&amp;P 500 lost 38.67 points or 0.84 percent to end at 4,538.43. For the week, the NASDAQ tumbled 2.6 percent, the S&amp;P lost 1.2 percent and the Dow fell 0.9 percent.</p>\n<p></p>\n<p>The losses extended the volatility seen throughout the week, with stocks showing wild swings in reaction to the Omicron variant of the coronavirus. After the first confirmed case in the U.S. earlier in the week, the new variant has now been detected in at least five states.</p>\n<p></p>\n<p>Traders also reacted to the Labor Department report showing weaker than expected U.S. job growth in November, although the jobless rate fell to 4.2 percent - its lowest since February 2020.</p>\n<p></p>\n<p>While the disappointing job growth has raised some concerns about the economic outlook amid the emergence of the Omicron variant, the Federal Reserve is not expected to deviate from accelerating the tapering of its asset purchases.</p>\n<p></p>\n<p>Crude oil futures pared early gains and settled lower Friday amid uncertainty about the outlook for energy demand due to fresh restrictions following the spread of the new coronavirus variant Omicron in several countries. West Texas Intermediate Crude oil futures for January ended down by $0.24 or 0.4 percent at $66.26 a barrel.</p>","source":"lsy1626938412129","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Bourse Expected To Remain Rangebound On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Bourse Expected To Remain Rangebound On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-06 08:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.rttnews.com/3246867/singapore-bourse-expected-to-remain-rangebound-on-monday.aspx?type=acom><strong>RTTNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Singapore stock market has moved higher in two of three trading days since the end of the six-day losing streak in which it had plummeted almost 200 points or 6.4 percent. The Straits Times Index ...</p>\n\n<a href=\"https://www.rttnews.com/3246867/singapore-bourse-expected-to-remain-rangebound-on-monday.aspx?type=acom\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.rttnews.com/3246867/singapore-bourse-expected-to-remain-rangebound-on-monday.aspx?type=acom","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178940634","content_text":"The Singapore stock market has moved higher in two of three trading days since the end of the six-day losing streak in which it had plummeted almost 200 points or 6.4 percent. The Straits Times Index now sits just above the 3,100-point plateau although it's expected to turn lower again on Monday.\n\nThe global forecast for the Asian markets is negative on coronavirus and economic concerns, with oil and technology stocks likely to lead the way lower. The European and U.S. markets finished solidly under water and the Asian markets are expected to open in similar fashion.\n\nThe STI finished modestly higher on Friday following gains from the industrials and properties, while the financials were mixed.\n\nFor the day, the index rose 9.82 points or 0.32 percent to finish at 3,101.93 after trading between 3,080.29 and 3,109.64. Volume was 1.04 billion shares worth 1.13 billion Singapore dollars. There were 269 gainers and 194 decliners.\n\nAmong the actives, Ascendas REIT added 0.68 percent, while CapitaLand Integrated Commercial Trust shed 0.48 percent, City Developments and Wilmar International both advanced 0.74 percent, Comfort DelGro accelerated 2.19 percent, Dairy Farm International and Genting Singapore both jumped 2.01 percent, DBS Group lost 0.25 percent, Keppel Corp rose 0.39 percent, Oversea-Chinese Banking Corporation eased 0.09 percent, SATS surged 2.62 percent, SembCorp Industries soared 2.58 percent, Singapore Airlines gained 0.62 percent, Singapore Exchange spiked 2.43 percent, Singapore Technologies Engineering increased 0.27 percent, Thai Beverage rallied 0.76 percent, United Overseas Bank collected 0.46 percent, Yangzijiang Shipbuilding climbed 0.78 percent and Mapletree Commercial Trust, Mapletree Logistics Trust, Singapore Press Holdings and SingTel were unchanged.\n\nThe lead from Wall Street is soft as the major averages opened slightly higher on Friday but quickly turned lower and spent the remainder of the day in negative territory.\n\nThe Dow shed 59/72 points or 0.17 percent to finish at 34,580.08, while the NASDAQ plummeted 295.83 points or 1.92 percent to close at 15,085.47 and the S&P 500 lost 38.67 points or 0.84 percent to end at 4,538.43. For the week, the NASDAQ tumbled 2.6 percent, the S&P lost 1.2 percent and the Dow fell 0.9 percent.\n\nThe losses extended the volatility seen throughout the week, with stocks showing wild swings in reaction to the Omicron variant of the coronavirus. After the first confirmed case in the U.S. earlier in the week, the new variant has now been detected in at least five states.\n\nTraders also reacted to the Labor Department report showing weaker than expected U.S. job growth in November, although the jobless rate fell to 4.2 percent - its lowest since February 2020.\n\nWhile the disappointing job growth has raised some concerns about the economic outlook amid the emergence of the Omicron variant, the Federal Reserve is not expected to deviate from accelerating the tapering of its asset purchases.\n\nCrude oil futures pared early gains and settled lower Friday amid uncertainty about the outlook for energy demand due to fresh restrictions following the spread of the new coronavirus variant Omicron in several countries. West Texas Intermediate Crude oil futures for January ended down by $0.24 or 0.4 percent at $66.26 a barrel.","news_type":1},"isVote":1,"tweetType":1,"viewCount":305,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601390339,"gmtCreate":1638489328116,"gmtModify":1638489328586,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/601390339","repostId":"2188548587","repostType":4,"repost":{"id":"2188548587","pubTimestamp":1639005844,"share":"https://www.laohu8.com/m/news/2188548587?lang=&edition=full","pubTime":"2021-12-09 07:24","market":"us","language":"en","title":"After-Hours Stock Movers 12/02: (SMAR) (TLYS) (JOAN) Higher; (DOCU) (OLLI) (ASAN) Lower (more...)","url":"https://stock-news.laohu8.com/highlight/detail?id=2188548587","media":"StreetInsider","summary":"After-Hours Movers:\nDocusign 27% LOWER; reported Q3 EPS of $0.58, $0.12 better than the analyst esti","content":"<p>After-Hours Movers:</p>\n<p><a href=\"https://laohu8.com/S/DOCU\">Docusign</a> 27% LOWER; reported Q3 EPS of $0.58, $0.12 better than the analyst estimate of $0.46. Revenue for the quarter came in at $545.5 million versus the consensus estimate of $530.63 million. DocuSign Inc. sees Q4 2022 revenue of $557-563 million, versus the consensus of $573.79 million. DocuSign Inc. sees FY2022 revenue of $2.083-2.089 million, versus the consensus of $2.09 million.</p>\n<p><a href=\"https://laohu8.com/S/OLLI\">Ollie's Bargain Outlet</a> 18.2% LOWER; reported Q3 EPS of $0.34, $0.13 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $383.5 million versus the consensus estimate of $415.12 million. Ollie's Bargain Outlet sees FY2021 EPS of $2.30-$2.35, versus the consensus of $2.71. Ollie's Bargain Outlet sees FY2021 revenue of $1.762-1.772 billion, versus the consensus of $1.83 billion.</p>\n<p><a href=\"https://laohu8.com/S/SMAR\">Smartsheet</a> 16.4% HIGHER; reported Q3 EPS of ($0.03), $0.07 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $144.6 million versus the consensus estimate of $139.97 million.</p>\n<p><a href=\"https://laohu8.com/S/ASAN\">Asana, Inc.</a> 13.7% LOWER; reported Q3 EPS of ($0.23), $0.03 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $100.3 million versus the consensus estimate of $93.69 million. Asana, Inc. sees Q4 2022 EPS of ($0.28)-($0.27), versus the consensus of ($0.27). Asana, Inc. sees Q4 2022 revenue of $104.5-105.5 million, versus the consensus of $98.74 million. Asana, Inc. sees FY2022 EPS of ($0.96)-($0.95), versus the consensus of ($1.00). Asana, Inc. sees FY2022 revenue of $371-372 million, versus the consensus of $358.75 million.</p>\n<p><a href=\"https://laohu8.com/S/SWBI\">Smith And Wesson Brands Inc</a> 12.8% LOWER; reported Q2 EPS of $1.13, $0.19 worse than the analyst estimate of $1.32. Revenue for the quarter came in at $230.5 million versus the consensus estimate of $267.56 million.</p>\n<p><a href=\"https://laohu8.com/S/TLYS\">Tilly's</a> 12.6% HIGHER; reported Q3 EPS of $0.66, $0.33 better than the analyst estimate of $0.33. Revenue for the quarter came in at $206.1 million versus the consensus estimate of $184.24 million. Tilly's, Inc. sees Q4 2021 EPS of $0.42-$0.50, versus the consensus of $0.33. Tilly's, Inc. sees Q4 2021 revenue of $210-215 million, versus the consensus of $197 million.</p>\n<p><a href=\"https://laohu8.com/S/JOAN\">JOANN Inc.</a> 11.6% HIGHER; reported Q3 EPS of $0.73, $0.09 better than the analyst estimate of $0.64. Revenue for the quarter came in at $611 million versus the consensus estimate of $619.58 million.</p>\n<p><a href=\"https://laohu8.com/S/MRVL\">Marvell Technology</a> 11.6% HIGHER; reported Q3 EPS of $0.43, $0.05 better than the analyst estimate of $0.38. Revenue for the quarter came in at $1.21 billion versus the consensus estimate of $1.15 billion. Marvell Technology sees Q4 2022 EPS of $0.45-$0.51, versus the consensus of ($0.42). Marvell Technology sees Q4 2022 revenue of $1.32 billion +/- 3%, versus the consensus of $1.21 billion.</p>\n<p><a href=\"https://laohu8.com/S/DOMO\">Domo Inc.</a> 10.2% LOWER; reported Q3 EPS of ($0.32), $0.02 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $65.1 million versus the consensus estimate of $64.31 million. Domo, Inc. sees Q4 2022 EPS of ($0.37)-($0.41), versus the consensus of ($0.41). Domo, Inc. sees Q4 2022 revenue of $66.5-67.5 million, versus the consensus of $67.71 million. Domo, Inc. sees FY2022 EPS of ($1.26)-($1.30), versus the consensus of ($1.32). Domo, Inc. sees FY2022 revenue of $254.5-255.5 million, versus the consensus of $254.72 million.</p>\n<p><a href=\"https://laohu8.com/S/OOMA\">Ooma</a> 6.9% LOWER; reported Q3 EPS of $0.13, $0.04 better than the analyst estimate of $0.09. Revenue for the quarter came in at $49.2 million versus the consensus estimate of $48.02 million. Ooma sees Q4 2022 EPS of $0.09-$0.11, versus the consensus of $0.10. Ooma sees Q4 2022 revenue of $49.7-50.2 million, versus the consensus of $48.77 million. Ooma sees FY2022 EPS of $0.47-$0.49, versus the consensus of $0.44. Ooma sees FY2022 revenue of $191.5-192 million, versus the consensus of $189.42 million.</p>\n<p><a href=\"https://laohu8.com/S/YEXT\">Yext Inc.</a> 6.2% HIGHER; reported Q3 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $99.5 million versus the consensus estimate of $98.25 million. Yext, Inc. sees Q4 2022 EPS of ($0.10)-($0.08), versus the consensus of ($0.07). Yext, Inc. sees Q4 2022 revenue of $100-102 million, versus the consensus of $99.15 million.</p>\n<p><a href=\"https://laohu8.com/S/SPWH\">Sportsman’s Warehouse</a> 5.6% LOWER; The company and Great Outdoors Group Terminate Merger</p>\n<p><a href=\"https://laohu8.com/S/GWH\">ESS Tech Inc.</a> HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $28.00.</p>\n<p><a href=\"https://laohu8.com/S/ULTA\">Ulta Salon</a> 5.2% HIGHER; reported Q3 EPS of $3.94, $1.52 better than the analyst estimate of $2.42. Revenue for the quarter came in at $2 billion versus the consensus estimate of $1.86 billion. Ulta Salon sees FY2021 EPS of $16.70-$17.10, versus the consensus of $15.19. Ulta Salon sees FY2021 revenue of $8.5-8.6 billion, versus the consensus of $8.35 billion.</p>\n<p><a href=\"https://laohu8.com/S/APP\">AppLovin Corporation</a> 4.2% LOWER; announced that certain of AppLovins stockholders, including KKR Denali Holdings L.P (the Selling Stockholders), intend to offer for sale in an underwritten secondary offering 6,500,000 shares of the Companys Class A common stock.</p>\n<p><a href=\"https://laohu8.com/S/RJF\">Raymond James</a> 3.5% HIGHER; Board of Directors declared a quarterly cash dividend on shares of its common stock of $0.34 per share, payable January 18, 2022 to shareholders of record on January 4, 2022. This is a 31% increase over the previous dividend of $0.26 per share paid on October 15, 2021. The Board also authorized repurchase of the company’s shares of common stock in an aggregate amount of up to $1 billion.</p>\n<p><a href=\"https://laohu8.com/S/GWRE\">Guidewire Software</a> (NYSE: GWRE) 2.4% HIGHER; reported Q1 EPS of ($0.21), $0.04 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $165.9 million versus the consensus estimate of $164.76 million. Guidewire Software sees Q2 2022 revenue of $195-199 million, versus the consensus of $190 million. Guidewire Software sees FY2022 revenue of $780-790 million, versus the consensus of $786 million.</p>\n<p><a href=\"https://laohu8.com/S/XRAY\">Dentsply Sirona</a> 2% HIGHER; CEO, Donald Casey, bought 20,000 shares on 12/01 at $49.78.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers 12/02: (SMAR) (TLYS) (JOAN) Higher; (DOCU) (OLLI) (ASAN) Lower (more...)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers 12/02: (SMAR) (TLYS) (JOAN) Higher; (DOCU) (OLLI) (ASAN) Lower (more...)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-09 07:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19304721><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Movers:\nDocusign 27% LOWER; reported Q3 EPS of $0.58, $0.12 better than the analyst estimate of $0.46. Revenue for the quarter came in at $545.5 million versus the consensus estimate of $...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19304721\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4528":"SaaS概念","DOCU":"Docusign","BK4023":"应用软件","BK4200":"专卖店","OLLI":"Ollie's Bargain Outlet Holdings, Inc.","ASAN":"阿莎娜","BK4114":"综合货品商店","BK4094":"服装零售","SMAR":"Smartsheet","TLYS":"Tilly’s","JOAN":"JOANN Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19304721","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188548587","content_text":"After-Hours Movers:\nDocusign 27% LOWER; reported Q3 EPS of $0.58, $0.12 better than the analyst estimate of $0.46. Revenue for the quarter came in at $545.5 million versus the consensus estimate of $530.63 million. DocuSign Inc. sees Q4 2022 revenue of $557-563 million, versus the consensus of $573.79 million. DocuSign Inc. sees FY2022 revenue of $2.083-2.089 million, versus the consensus of $2.09 million.\nOllie's Bargain Outlet 18.2% LOWER; reported Q3 EPS of $0.34, $0.13 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $383.5 million versus the consensus estimate of $415.12 million. Ollie's Bargain Outlet sees FY2021 EPS of $2.30-$2.35, versus the consensus of $2.71. Ollie's Bargain Outlet sees FY2021 revenue of $1.762-1.772 billion, versus the consensus of $1.83 billion.\nSmartsheet 16.4% HIGHER; reported Q3 EPS of ($0.03), $0.07 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $144.6 million versus the consensus estimate of $139.97 million.\nAsana, Inc. 13.7% LOWER; reported Q3 EPS of ($0.23), $0.03 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $100.3 million versus the consensus estimate of $93.69 million. Asana, Inc. sees Q4 2022 EPS of ($0.28)-($0.27), versus the consensus of ($0.27). Asana, Inc. sees Q4 2022 revenue of $104.5-105.5 million, versus the consensus of $98.74 million. Asana, Inc. sees FY2022 EPS of ($0.96)-($0.95), versus the consensus of ($1.00). Asana, Inc. sees FY2022 revenue of $371-372 million, versus the consensus of $358.75 million.\nSmith And Wesson Brands Inc 12.8% LOWER; reported Q2 EPS of $1.13, $0.19 worse than the analyst estimate of $1.32. Revenue for the quarter came in at $230.5 million versus the consensus estimate of $267.56 million.\nTilly's 12.6% HIGHER; reported Q3 EPS of $0.66, $0.33 better than the analyst estimate of $0.33. Revenue for the quarter came in at $206.1 million versus the consensus estimate of $184.24 million. Tilly's, Inc. sees Q4 2021 EPS of $0.42-$0.50, versus the consensus of $0.33. Tilly's, Inc. sees Q4 2021 revenue of $210-215 million, versus the consensus of $197 million.\nJOANN Inc. 11.6% HIGHER; reported Q3 EPS of $0.73, $0.09 better than the analyst estimate of $0.64. Revenue for the quarter came in at $611 million versus the consensus estimate of $619.58 million.\nMarvell Technology 11.6% HIGHER; reported Q3 EPS of $0.43, $0.05 better than the analyst estimate of $0.38. Revenue for the quarter came in at $1.21 billion versus the consensus estimate of $1.15 billion. Marvell Technology sees Q4 2022 EPS of $0.45-$0.51, versus the consensus of ($0.42). Marvell Technology sees Q4 2022 revenue of $1.32 billion +/- 3%, versus the consensus of $1.21 billion.\nDomo Inc. 10.2% LOWER; reported Q3 EPS of ($0.32), $0.02 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $65.1 million versus the consensus estimate of $64.31 million. Domo, Inc. sees Q4 2022 EPS of ($0.37)-($0.41), versus the consensus of ($0.41). Domo, Inc. sees Q4 2022 revenue of $66.5-67.5 million, versus the consensus of $67.71 million. Domo, Inc. sees FY2022 EPS of ($1.26)-($1.30), versus the consensus of ($1.32). Domo, Inc. sees FY2022 revenue of $254.5-255.5 million, versus the consensus of $254.72 million.\nOoma 6.9% LOWER; reported Q3 EPS of $0.13, $0.04 better than the analyst estimate of $0.09. Revenue for the quarter came in at $49.2 million versus the consensus estimate of $48.02 million. Ooma sees Q4 2022 EPS of $0.09-$0.11, versus the consensus of $0.10. Ooma sees Q4 2022 revenue of $49.7-50.2 million, versus the consensus of $48.77 million. Ooma sees FY2022 EPS of $0.47-$0.49, versus the consensus of $0.44. Ooma sees FY2022 revenue of $191.5-192 million, versus the consensus of $189.42 million.\nYext Inc. 6.2% HIGHER; reported Q3 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $99.5 million versus the consensus estimate of $98.25 million. Yext, Inc. sees Q4 2022 EPS of ($0.10)-($0.08), versus the consensus of ($0.07). Yext, Inc. sees Q4 2022 revenue of $100-102 million, versus the consensus of $99.15 million.\nSportsman’s Warehouse 5.6% LOWER; The company and Great Outdoors Group Terminate Merger\nESS Tech Inc. HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $28.00.\nUlta Salon 5.2% HIGHER; reported Q3 EPS of $3.94, $1.52 better than the analyst estimate of $2.42. Revenue for the quarter came in at $2 billion versus the consensus estimate of $1.86 billion. Ulta Salon sees FY2021 EPS of $16.70-$17.10, versus the consensus of $15.19. Ulta Salon sees FY2021 revenue of $8.5-8.6 billion, versus the consensus of $8.35 billion.\nAppLovin Corporation 4.2% LOWER; announced that certain of AppLovins stockholders, including KKR Denali Holdings L.P (the Selling Stockholders), intend to offer for sale in an underwritten secondary offering 6,500,000 shares of the Companys Class A common stock.\nRaymond James 3.5% HIGHER; Board of Directors declared a quarterly cash dividend on shares of its common stock of $0.34 per share, payable January 18, 2022 to shareholders of record on January 4, 2022. This is a 31% increase over the previous dividend of $0.26 per share paid on October 15, 2021. The Board also authorized repurchase of the company’s shares of common stock in an aggregate amount of up to $1 billion.\nGuidewire Software (NYSE: GWRE) 2.4% HIGHER; reported Q1 EPS of ($0.21), $0.04 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $165.9 million versus the consensus estimate of $164.76 million. Guidewire Software sees Q2 2022 revenue of $195-199 million, versus the consensus of $190 million. Guidewire Software sees FY2022 revenue of $780-790 million, versus the consensus of $786 million.\nDentsply Sirona 2% HIGHER; CEO, Donald Casey, bought 20,000 shares on 12/01 at $49.78.","news_type":1},"isVote":1,"tweetType":1,"viewCount":145,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603520446,"gmtCreate":1638429891300,"gmtModify":1638429904315,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603520446","repostId":"1197973971","repostType":4,"repost":{"id":"1197973971","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638429281,"share":"https://www.laohu8.com/m/news/1197973971?lang=&edition=full","pubTime":"2021-12-02 15:14","market":"us","language":"en","title":"Glaxo says its vaccine retains activity against key Omicron mutations","url":"https://stock-news.laohu8.com/highlight/detail?id=1197973971","media":"Tiger Newspress","summary":"GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced an update to bioRxiv, a preprint ser","content":"<p>GlaxoSmithKline plc&nbsp;and Vir Biotechnology, Inc.&nbsp;today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations[1]&nbsp;of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.</p>\n<p><b>George Scangos, PhD, Chief Executive Officer of Vir, said:</b>“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”</p>\n<p><b>Dr Hal Barron, Chief Scientific Officer and President R&amp;D, GSK, said:</b>“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though very early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”</p>\n<p><b>About sotrovimab</b></p>\n<p>Sotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.</p>\n<p>Updated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).</p>\n<p><b>About the sotrovimab clinical development programme</b></p>\n<ul>\n <li>COMET-ICE: a Phase III, multi-centre, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalised and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p&lt;0.001) in hospitalisation for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published in<i>The New England Journal of Medicine</i>on 27 October 2021 and final data were pre-published on 8 November 2021 on<i>medRxiv</i>.</li>\n <li>COMET-TAIL: a Phase III, randomised, multi-centre, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised adult and paediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.</li>\n <li>COMET-PEAK: a Phase II, randomised, multi-centre, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.</li>\n <li>GSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis programme will take place in due course.</li>\n</ul>\n<p><b>About global access to sotrovimab</b></p>\n<ul>\n <li>Sotrovimab is authorised for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorisations for sotrovimab have been granted in a dozen countries.</li>\n <li>GSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe</li>\n <li>COVID-19.</li>\n <li>Sotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.</li>\n</ul>\n<p><b>Sotrovimab in the United States</b></p>\n<p>The following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorised use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providers, and fullFact Sheet for Patients, Parents, and Caregivers.</p>\n<p>Sotrovimab has been authorized by the U.S. FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.</p>\n<p>Sotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</p>\n<p><b>Authorized Use</b></p>\n<p>The U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.</p>\n<p><b>Limitations of Authorized Use</b></p>\n<p>Sotrovimab is not authorized for use in patients:</p>\n<ul>\n <li>who are hospitalized due to COVID-19, OR</li>\n <li>who require oxygen therapy due to COVID-19, OR</li>\n <li>who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)</li>\n</ul>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID 19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation.</p>\n<p><b>Important Safety Information</b></p>\n<p><b>CONTRAINDICATIONS</b></p>\n<p>Sotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.</p>\n<p><b>WARNINGS AND PRECAUTIONS</b></p>\n<p>There are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.</p>\n<p><b>Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions</b></p>\n<p>Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.</p>\n<p>Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.</p>\n<p>Signs and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.</p>\n<p>Consider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.</p>\n<p>Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.</p>\n<p><b>Clinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration</b></p>\n<p>Clinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.</p>\n<p><b>Limitations of Benefit and Potential for Risk in Patients with Severe COVID‑19</b></p>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19, OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.</p>\n<p><b>ADVERSE EVENTS</b></p>\n<p>Hypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.</p>\n<p>The most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.</p>\n<p><b>USE IN SPECIFIC POPULATIONS</b></p>\n<p><b>Pregnancy</b></p>\n<p>There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.</p>\n<p><b>Lactation</b></p>\n<p>There are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant, or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.</p>\n<p><b>About the GSK and Vir collaboration</b></p>\n<p>In April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.</p>\n<p><b>GSK commitment to tackling COVID-19</b></p>\n<p>GSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organisations.</p>\n<p>GSK is collaborating with several organisations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi S.A., Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.</p>\n<p>GSK is also working with mRNA specialist, CureVac N.V., to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.</p>\n<p>GSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.</p>\n<p><b>Vir’s commitment to COVID-19</b></p>\n<p>Vir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo says its vaccine retains activity against key Omicron mutations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo says its vaccine retains activity against key Omicron mutations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 15:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GlaxoSmithKline plc&nbsp;and Vir Biotechnology, Inc.&nbsp;today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations[1]&nbsp;of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.</p>\n<p><b>George Scangos, PhD, Chief Executive Officer of Vir, said:</b>“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”</p>\n<p><b>Dr Hal Barron, Chief Scientific Officer and President R&amp;D, GSK, said:</b>“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though very early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”</p>\n<p><b>About sotrovimab</b></p>\n<p>Sotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.</p>\n<p>Updated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).</p>\n<p><b>About the sotrovimab clinical development programme</b></p>\n<ul>\n <li>COMET-ICE: a Phase III, multi-centre, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalised and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p&lt;0.001) in hospitalisation for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published in<i>The New England Journal of Medicine</i>on 27 October 2021 and final data were pre-published on 8 November 2021 on<i>medRxiv</i>.</li>\n <li>COMET-TAIL: a Phase III, randomised, multi-centre, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised adult and paediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.</li>\n <li>COMET-PEAK: a Phase II, randomised, multi-centre, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.</li>\n <li>GSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis programme will take place in due course.</li>\n</ul>\n<p><b>About global access to sotrovimab</b></p>\n<ul>\n <li>Sotrovimab is authorised for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorisations for sotrovimab have been granted in a dozen countries.</li>\n <li>GSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe</li>\n <li>COVID-19.</li>\n <li>Sotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.</li>\n</ul>\n<p><b>Sotrovimab in the United States</b></p>\n<p>The following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorised use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providers, and fullFact Sheet for Patients, Parents, and Caregivers.</p>\n<p>Sotrovimab has been authorized by the U.S. FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.</p>\n<p>Sotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</p>\n<p><b>Authorized Use</b></p>\n<p>The U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.</p>\n<p><b>Limitations of Authorized Use</b></p>\n<p>Sotrovimab is not authorized for use in patients:</p>\n<ul>\n <li>who are hospitalized due to COVID-19, OR</li>\n <li>who require oxygen therapy due to COVID-19, OR</li>\n <li>who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)</li>\n</ul>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID 19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation.</p>\n<p><b>Important Safety Information</b></p>\n<p><b>CONTRAINDICATIONS</b></p>\n<p>Sotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.</p>\n<p><b>WARNINGS AND PRECAUTIONS</b></p>\n<p>There are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.</p>\n<p><b>Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions</b></p>\n<p>Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.</p>\n<p>Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.</p>\n<p>Signs and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.</p>\n<p>Consider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.</p>\n<p>Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.</p>\n<p><b>Clinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration</b></p>\n<p>Clinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.</p>\n<p><b>Limitations of Benefit and Potential for Risk in Patients with Severe COVID‑19</b></p>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19, OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.</p>\n<p><b>ADVERSE EVENTS</b></p>\n<p>Hypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.</p>\n<p>The most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.</p>\n<p><b>USE IN SPECIFIC POPULATIONS</b></p>\n<p><b>Pregnancy</b></p>\n<p>There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.</p>\n<p><b>Lactation</b></p>\n<p>There are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant, or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.</p>\n<p><b>About the GSK and Vir collaboration</b></p>\n<p>In April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.</p>\n<p><b>GSK commitment to tackling COVID-19</b></p>\n<p>GSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organisations.</p>\n<p>GSK is collaborating with several organisations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi S.A., Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.</p>\n<p>GSK is also working with mRNA specialist, CureVac N.V., to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.</p>\n<p>GSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.</p>\n<p><b>Vir’s commitment to COVID-19</b></p>\n<p>Vir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197973971","content_text":"GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations[1] of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.\nGeorge Scangos, PhD, Chief Executive Officer of Vir, said:“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”\nDr Hal Barron, Chief Scientific Officer and President R&D, GSK, said:“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though very early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”\nAbout sotrovimab\nSotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.\nUpdated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).\nAbout the sotrovimab clinical development programme\n\nCOMET-ICE: a Phase III, multi-centre, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalised and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p<0.001) in hospitalisation for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published inThe New England Journal of Medicineon 27 October 2021 and final data were pre-published on 8 November 2021 onmedRxiv.\nCOMET-TAIL: a Phase III, randomised, multi-centre, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised adult and paediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.\nCOMET-PEAK: a Phase II, randomised, multi-centre, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.\nGSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis programme will take place in due course.\n\nAbout global access to sotrovimab\n\nSotrovimab is authorised for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorisations for sotrovimab have been granted in a dozen countries.\nGSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe\nCOVID-19.\nSotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.\n\nSotrovimab in the United States\nThe following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorised use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providers, and fullFact Sheet for Patients, Parents, and Caregivers.\nSotrovimab has been authorized by the U.S. FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.\nSotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.\nAuthorized Use\nThe U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.\nLimitations of Authorized Use\nSotrovimab is not authorized for use in patients:\n\nwho are hospitalized due to COVID-19, OR\nwho require oxygen therapy due to COVID-19, OR\nwho require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)\n\nBenefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID 19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation.\nImportant Safety Information\nCONTRAINDICATIONS\nSotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.\nWARNINGS AND PRECAUTIONS\nThere are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.\nHypersensitivity Including Anaphylaxis and Infusion-Related Reactions\nSerious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.\nInfusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.\nSigns and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.\nConsider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.\nHypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.\nClinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration\nClinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.\nLimitations of Benefit and Potential for Risk in Patients with Severe COVID‑19\nBenefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19, OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.\nADVERSE EVENTS\nHypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.\nThe most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.\nUSE IN SPECIFIC POPULATIONS\nPregnancy\nThere are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.\nLactation\nThere are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant, or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.\nAbout the GSK and Vir collaboration\nIn April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.\nGSK commitment to tackling COVID-19\nGSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organisations.\nGSK is collaborating with several organisations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi S.A., Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.\nGSK is also working with mRNA specialist, CureVac N.V., to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.\nGSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.\nVir’s commitment to COVID-19\nVir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.","news_type":1},"isVote":1,"tweetType":1,"viewCount":194,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600405958,"gmtCreate":1638182154411,"gmtModify":1638182155906,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600405958","repostId":"1173411638","repostType":4,"isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":842704456,"gmtCreate":1636241652933,"gmtModify":1636241654329,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/842704456","repostId":"2181374735","repostType":4,"repost":{"id":"2181374735","pubTimestamp":1636200960,"share":"https://www.laohu8.com/m/news/2181374735?lang=&edition=full","pubTime":"2021-11-06 20:16","market":"us","language":"en","title":"Buffett's Berkshire Hathaway boosts operating profit, lower stock gains hurt net results","url":"https://stock-news.laohu8.com/highlight/detail?id=2181374735","media":"StreetInsider","summary":"(Reuters) - Warren Buffett's Berkshire Hathaway Inc said on Saturday it has extended its rebound fro","content":"<p>(Reuters) - Warren Buffett's Berkshire Hathaway Inc said on Saturday it has extended its rebound from the early stages of the pandemic, with improved results in many businesses offsetting a greater loss from insurance underwriting.</p>\n<p>Berkshire also said it repurchased $7.6 billion of its own stock in the third quarter, reflecting its need to put some cash to work as stock prices regularly set new highs and purchases of whole companies appear too expensive.</p>\n<p>Quarterly operating profit rose 18% to $6.47 billion compared with $5.48 billion in the year-earlier period.</p>\n<p>Net income declined 66% to $10.3 billion, or $6,882 per Class A share, from $30.1 billion, reflecting lower unrealized gains on Berkshire's common stock holdings including Apple Inc and $Bank of America Corp(BAC-N)$.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Buffett's Berkshire Hathaway boosts operating profit, lower stock gains hurt net results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBuffett's Berkshire Hathaway boosts operating profit, lower stock gains hurt net results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-06 20:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19172264><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Warren Buffett's Berkshire Hathaway Inc said on Saturday it has extended its rebound from the early stages of the pandemic, with improved results in many businesses offsetting a greater ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19172264\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.A":"伯克希尔","BRK.B":"伯克希尔B"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19172264","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2181374735","content_text":"(Reuters) - Warren Buffett's Berkshire Hathaway Inc said on Saturday it has extended its rebound from the early stages of the pandemic, with improved results in many businesses offsetting a greater loss from insurance underwriting.\nBerkshire also said it repurchased $7.6 billion of its own stock in the third quarter, reflecting its need to put some cash to work as stock prices regularly set new highs and purchases of whole companies appear too expensive.\nQuarterly operating profit rose 18% to $6.47 billion compared with $5.48 billion in the year-earlier period.\nNet income declined 66% to $10.3 billion, or $6,882 per Class A share, from $30.1 billion, reflecting lower unrealized gains on Berkshire's common stock holdings including Apple Inc and $Bank of America Corp(BAC-N)$.","news_type":1},"isVote":1,"tweetType":1,"viewCount":23,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876509944,"gmtCreate":1637327756316,"gmtModify":1637327776139,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/876509944","repostId":"1138047553","repostType":4,"repost":{"id":"1138047553","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637327403,"share":"https://www.laohu8.com/m/news/1138047553?lang=&edition=full","pubTime":"2021-11-19 21:10","market":"us","language":"en","title":"Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older","url":"https://stock-news.laohu8.com/highlight/detail?id=1138047553","media":"Tiger Newspress","summary":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of C","content":"<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p>\n<p>Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p>\n<p>“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p>\n<p>The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p>\n<p>The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p>\n<p>As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138047553","content_text":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.\n\nModerna, Inc. today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”\nThe booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.\nThe FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.\nAs a next step, theU.S. Centers for Disease Controland Prevention’s (CDC) Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.","news_type":1},"isVote":1,"tweetType":1,"viewCount":201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872874197,"gmtCreate":1637492364994,"gmtModify":1637492365418,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"I dun believe it","listText":"I dun believe it","text":"I dun believe it","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/872874197","repostId":"2184782893","repostType":4,"repost":{"id":"2184782893","pubTimestamp":1637464884,"share":"https://www.laohu8.com/m/news/2184782893?lang=&edition=full","pubTime":"2021-11-21 11:21","market":"us","language":"en","title":"3 Top Chip Stocks Ready for Bull Runs","url":"https://stock-news.laohu8.com/highlight/detail?id=2184782893","media":"Motley Fool","summary":"ASML, UMC, and Micron could all still have a lot of upside potential.","content":"<p>The global chip shortage has been generating strong tailwinds for the semiconductor sector over the past year. However, it might be difficult for investors to separate the winners from the losers if they don't understand how the semiconductor supply chain works.</p>\n<p>Today, I'll highlight three chip stocks that operate in very different parts of the semiconductor market, why they're all growing, and why they could still generate even bigger returns next year.</p>\n<h2>1. ASML</h2>\n<p><b>ASML Holding</b> (NASDAQ:ASML) is a Dutch semiconductor equipment maker. It's the world's largest manufacturer of lithography machines, which are used to etch circuit patterns onto silicon wafers. It's also the only manufacturer of high-end extreme ultraviolet (EUV) lithography machines, which are required to manufacture the world's smallest chips.</p>\n<p>The world's most advanced chip foundries -- including <b>Taiwan Semiconductor Manufacturing</b> (NYSE:TSM), <b>Samsung</b>, and <b>Intel</b> (NASDAQ:INTC) -- all use ASML's EUV machines, which cost about $150,000 each and require several planes to ship. ASML's dominance of this crucial chipmaking technology, which it refined over the past three decades, makes it a linchpin of the global semiconductor market.</p>\n<p>ASML's revenue rose 8% in 2019 and 18% in 2020, and it anticipates about 35% growth this year. It's selling EUV systems as rapidly as it can produce them, and a growing mix of those higher-margin devices boosted its gross margin from 44.7% in 2019 to 52.2% in the first nine months of 2021.</p>\n<p>ASML's stock price has more than doubled over the past 12 months, and it isn't cheap at 45 times forward earnings. However, this stock could still have plenty of upside potential as the chip shortage drags on -- since it will be impossible to resolve the crisis without buying significantly more machines from ASML.</p>\n<h2>2. UMC</h2>\n<p>ASML's top client is TSMC, the world's largest contract chipmaker and another linchpin of the semiconductor market. However, TSMC's smaller rival <b>United Microelectronics</b> (NYSE:UMC) is a more underrated play on the same trend.</p>\n<p>Unlike TSMC -- which manufactures the world's smallest chips for fabless chipmakers like <b>Advanced Micro Devices</b> and<b> Apple</b> -- UMC primarily manufactures older, larger, and cheaper chips for cars, Internet of Things (IoT) devices, and other gadgets.</p>\n<p>These chips aren't as powerful as TSMC's top-tier chips, but they're arguably just as essential. UMC's plants are already operating at their maximum capacities, but the company faces less pressure to aggressively upgrade its plants than TSMC, Samsung, or Intel, which are all engaged in the costly \"process race\" to manufacture smaller and more advanced chips.</p>\n<p>UMC ranks a distant third in the foundry market behind TSMC and Samsung, but it still generates impressive growth: Its revenue rose 4% in 2019 and jumped 25% in 2020, and analysts expect 18% growth this year.</p>\n<p>UMC's stock has more than doubled over the past 12 months, but it still looks reasonably valued at 22 times forward earnings. Like ASML, UMC will continue to profit from the chip shortage. Moreover, the traffic jam at TSMC and other top foundries could eventually divert more lower-end orders to UMC.</p>\n<h2>3. Micron</h2>\n<p>Lastly, I believe <b>Micron Technology </b>(NASDAQ:MU) -- <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the world's leading producers of DRAM and NAND memory chips -- is currently undervalued at eight times forward earnings. Micron's stock has risen nearly 30% over the past 12 months, but it's stalled out in recent months amid fears of a cyclical slowdown.</p>\n<p>Micron's revenue fell 8% in fiscal 2020 (which ended last September) as a global glut of memory chips caused market prices to plunge. But in fiscal 2021, its revenue rose 29% as those supplies and prices stabilized.</p>\n<p>Micron wasn't directly affected by the chip shortage, since it manufactures its own chips instead of outsourcing them to third-party foundries. However, it expects shortages of other PC components -- including CPUs and GPUs -- to indirectly curb the market's near-term demand for its memory chips. That warning, along with a softer-than-expected forecast for the first quarter, spooked investors last month.</p>\n<p>Nonetheless, analysts still expect Micron's revenue and earnings to rise 15% and 44%, respectively, this year, as it benefits from the secular expansion of the gaming, data center, cloud, 5G, and automotive markets. Those catalysts might also spark a \"super cycle\" in memory chip upgrades, which could last much longer than previous cycles and propel Micron's stock to fresh highs next year.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Top Chip Stocks Ready for Bull Runs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Top Chip Stocks Ready for Bull Runs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-21 11:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/20/3-top-chip-stocks-ready-for-a-bull-run/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The global chip shortage has been generating strong tailwinds for the semiconductor sector over the past year. However, it might be difficult for investors to separate the winners from the losers if ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/20/3-top-chip-stocks-ready-for-a-bull-run/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4147":"半导体设备","03165":"华夏欧优股对冲","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","UMC":"联电","BK4535":"淡马锡持仓","BK4527":"明星科技股","BK4141":"半导体产品","03145":"华夏亚洲高息股","BK4550":"红杉资本持仓","BK4526":"热门中概股","BK4503":"景林资产持仓","TSM":"台积电","MU":"美光科技","BK4505":"高瓴资本持仓","INTC":"英特尔","BK4512":"苹果概念","ASML":"阿斯麦","BK4548":"巴美列捷福持仓","BK4529":"IDC概念","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓"},"source_url":"https://www.fool.com/investing/2021/11/20/3-top-chip-stocks-ready-for-a-bull-run/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2184782893","content_text":"The global chip shortage has been generating strong tailwinds for the semiconductor sector over the past year. However, it might be difficult for investors to separate the winners from the losers if they don't understand how the semiconductor supply chain works.\nToday, I'll highlight three chip stocks that operate in very different parts of the semiconductor market, why they're all growing, and why they could still generate even bigger returns next year.\n1. ASML\nASML Holding (NASDAQ:ASML) is a Dutch semiconductor equipment maker. It's the world's largest manufacturer of lithography machines, which are used to etch circuit patterns onto silicon wafers. It's also the only manufacturer of high-end extreme ultraviolet (EUV) lithography machines, which are required to manufacture the world's smallest chips.\nThe world's most advanced chip foundries -- including Taiwan Semiconductor Manufacturing (NYSE:TSM), Samsung, and Intel (NASDAQ:INTC) -- all use ASML's EUV machines, which cost about $150,000 each and require several planes to ship. ASML's dominance of this crucial chipmaking technology, which it refined over the past three decades, makes it a linchpin of the global semiconductor market.\nASML's revenue rose 8% in 2019 and 18% in 2020, and it anticipates about 35% growth this year. It's selling EUV systems as rapidly as it can produce them, and a growing mix of those higher-margin devices boosted its gross margin from 44.7% in 2019 to 52.2% in the first nine months of 2021.\nASML's stock price has more than doubled over the past 12 months, and it isn't cheap at 45 times forward earnings. However, this stock could still have plenty of upside potential as the chip shortage drags on -- since it will be impossible to resolve the crisis without buying significantly more machines from ASML.\n2. UMC\nASML's top client is TSMC, the world's largest contract chipmaker and another linchpin of the semiconductor market. However, TSMC's smaller rival United Microelectronics (NYSE:UMC) is a more underrated play on the same trend.\nUnlike TSMC -- which manufactures the world's smallest chips for fabless chipmakers like Advanced Micro Devices and Apple -- UMC primarily manufactures older, larger, and cheaper chips for cars, Internet of Things (IoT) devices, and other gadgets.\nThese chips aren't as powerful as TSMC's top-tier chips, but they're arguably just as essential. UMC's plants are already operating at their maximum capacities, but the company faces less pressure to aggressively upgrade its plants than TSMC, Samsung, or Intel, which are all engaged in the costly \"process race\" to manufacture smaller and more advanced chips.\nUMC ranks a distant third in the foundry market behind TSMC and Samsung, but it still generates impressive growth: Its revenue rose 4% in 2019 and jumped 25% in 2020, and analysts expect 18% growth this year.\nUMC's stock has more than doubled over the past 12 months, but it still looks reasonably valued at 22 times forward earnings. Like ASML, UMC will continue to profit from the chip shortage. Moreover, the traffic jam at TSMC and other top foundries could eventually divert more lower-end orders to UMC.\n3. Micron\nLastly, I believe Micron Technology (NASDAQ:MU) -- one of the world's leading producers of DRAM and NAND memory chips -- is currently undervalued at eight times forward earnings. Micron's stock has risen nearly 30% over the past 12 months, but it's stalled out in recent months amid fears of a cyclical slowdown.\nMicron's revenue fell 8% in fiscal 2020 (which ended last September) as a global glut of memory chips caused market prices to plunge. But in fiscal 2021, its revenue rose 29% as those supplies and prices stabilized.\nMicron wasn't directly affected by the chip shortage, since it manufactures its own chips instead of outsourcing them to third-party foundries. However, it expects shortages of other PC components -- including CPUs and GPUs -- to indirectly curb the market's near-term demand for its memory chips. That warning, along with a softer-than-expected forecast for the first quarter, spooked investors last month.\nNonetheless, analysts still expect Micron's revenue and earnings to rise 15% and 44%, respectively, this year, as it benefits from the secular expansion of the gaming, data center, cloud, 5G, and automotive markets. Those catalysts might also spark a \"super cycle\" in memory chip upgrades, which could last much longer than previous cycles and propel Micron's stock to fresh highs next year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":26,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864125293,"gmtCreate":1633076360568,"gmtModify":1633076361565,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/864125293","repostId":"2172951249","repostType":4,"repost":{"id":"2172951249","pubTimestamp":1633063493,"share":"https://www.laohu8.com/m/news/2172951249?lang=&edition=full","pubTime":"2021-10-01 12:44","market":"us","language":"en","title":"Billionaire Bill Ackman is smoking 'mentor' Warren Buffett with these income stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2172951249","media":"MoneyWise","summary":"Dividend stocks might look boring, but they can provide exciting returns.\nJust ask famed activist in","content":"<p><img src=\"https://static.tigerbbs.com/968262da7f9e673173261c3b2753bbcd\" tg-width=\"1800\" tg-height=\"800\" referrerpolicy=\"no-referrer\"></p>\n<p>Dividend stocks might look boring, but they can provide exciting returns.</p>\n<p>Just ask famed activist investor and self-proclaimed Warren Buffett acolyte Bill Ackman.</p>\n<p>His hedge fund Pershing Square Holdings has delivered annualized total returns of more than 30% over the last three years, substantially outperforming the S&amp;P 500 and even Buffett’s own Berkshire Hathaway.</p>\n<p>And he did it largely by owning dividend stocks.</p>\n<p>According to Pershing’s latest 13F filing with the Securities Exchange Commission, nearly 60% of its holdings by market value are invested in dividend stocks.</p>\n<p>Let’s take a look at three stocks in Ackman’s portfolio that regulary dish out cash to investors — <a href=\"https://laohu8.com/S/AONE.U\">one</a> of them could be worth buying with your spare change.</p>\n<h2><a href=\"https://laohu8.com/S/QSR\">Restaurant Brands International Inc</a> (QSR)</h2>\n<p><img src=\"https://static.tigerbbs.com/ab0e3bda7c2635779ea2e4385b71b4f5\" tg-width=\"1200\" tg-height=\"500\" referrerpolicy=\"no-referrer\">Tony Prato/Shutterstock</p>\n<p>Leading off the list is Restaurant Brands International, a fast-food holding company formed in 2014 by the merger between Burger King and Canadian coffee chain <a href=\"https://laohu8.com/S/THI\">Tim Hortons</a>.</p>\n<p>In 2017, the company added Popeyes Louisiana Kitchen to its portfolio.</p>\n<p>Like most restaurant stocks, Restaurant Brands shares tumbled during the pandemic-induced market sell-off in early 2020. But the stock has since made a strong recovery.</p>\n<p>That rebound is backed by substantial improvements in the company’s business. According to the latest earnings report, same-store sales — a key measure of a retailer’s health — increased 27.6%.</p>\n<p>Adjusted earnings came in at $0.77 per share for the quarter, more than double the $0.33 per share it earned in the year-ago period. The amount also covered the company’s quarterly dividend payment of $0.53 per share with ease.</p>\n<p>Restaurant Brands is offering a healthy annual dividend yield of 3.4%, which is a return investors can earn even if they're investing with spare nickels and dimes.</p>\n<p>For comparison, that’s a higher yield than fast-food restaurant giants McDonald’s (2.26%), Starbucks (1.6%), and Yum! Brands (1.6%).</p>\n<h2>Lowe’s Companies Inc (LOW)</h2>\n<p><img src=\"https://static.tigerbbs.com/9156dee5d6fe15d87a22b5b32ec030c4\" tg-width=\"1200\" tg-height=\"500\" referrerpolicy=\"no-referrer\">Ken Wolter/Shutterstock</p>\n<p>Lowe’s is Bill Ackman’s largest holding by market value, and the position has served the billionaire investor quite well.</p>\n<p>Shares of the home improvement retail giant are up 29% year to date. The S&amp;P 500 has returned 16% over the same period.</p>\n<p>What’s more impressive than Lowe’s near-term stock price performance is how the company’s dividend has grown over the years.</p>\n<p>The economy moves in cycles, but Lowe’s payout has only gone up. In fact, the company has increased its payout to shareholders every year for the past 59 years.</p>\n<p>Decades of dividend hikes has brought Lowe’s quarterly dividend to $0.80 per share, translating to an annual yield of 1.5%.</p>\n<p>Note that its competitors are also dividend-paying companies: Home Depot yields 2.0%, Target pays 1.5%, while Walmart offers an annual yield of 1.6%.</p>\n<p>Due to Lowe’s rally over the past year, its shares now trade at over $200. But you can get a piece of the company using a popular stock trading app that allows you to buy fractions of shares with as much money as you’re willing to spend.</p>\n<h2>Agilent Technologies Inc (A)</h2>\n<p><img src=\"https://static.tigerbbs.com/bb79764fc5df837d32b32e674c6d4ec9\" tg-width=\"1200\" tg-height=\"500\" referrerpolicy=\"no-referrer\">Elnur/Shutterstock</p>\n<p>Agilent isn’t a household name, but within its own industry, the company is a force to be reckoned with.</p>\n<p>Agilent provides bio-analyitical and electronic measurement solutions to a wide variety of industries including communications, life sciences, and chemical analysis.</p>\n<p>Headquartered in Santa Clara, Calif., the company’s products are used by 265,000 labs around the world. In Agilent’s fiscal 2020, it brought in $5.34 billion of total revenue.</p>\n<p>And in the most recent quarter, revenue grew 26% year-over-year to $1.59 billion.</p>\n<p>Given this kind of performance, you’d think Agilent shares would be soaring. But while the stock has returned a solid 60% over the past year, it has pulled back about 10% since the peak in early September.</p>\n<p>On the dividend front, Agilent offers an annual yield of 0.5%, which may not seem like much. But the company has an excellent track record when it comes to returning cash to investors: Since 2014, Agilent’s per share quarterly payout has increased by 106%.</p>\n<h2>Rental income stream?</h2>\n<p>The neat thing with dividend stocks is that they provide a way for investors to earn a steady income stream regardless of what the economy is doing.</p>\n<p>Of course, you don’t have to limit yourself to the stock market to do that.</p>\n<p>For instance, one investing service makes it possible to lock in a steady rental income stream by investing in premium real estate properties — from commercial developments in LA to residential buildings in NYC.</p>\n<p>You’ll gain exposure to high-end properties that big-time real estate moguls usually have access to, and you’ll receive regular payouts in the form of quarterly dividend distributions.</p>\n<p><i>This article provides information only and should not be construed as advice. It is provided without warranty of any kind.</i></p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Billionaire Bill Ackman is smoking 'mentor' Warren Buffett with these income stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBillionaire Bill Ackman is smoking 'mentor' Warren Buffett with these income stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-01 12:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/billionaire-bill-ackman-smoking-mentor-201900070.html><strong>MoneyWise</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dividend stocks might look boring, but they can provide exciting returns.\nJust ask famed activist investor and self-proclaimed Warren Buffett acolyte Bill Ackman.\nHis hedge fund Pershing Square ...</p>\n\n<a href=\"https://finance.yahoo.com/news/billionaire-bill-ackman-smoking-mentor-201900070.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QSR":"餐饮品牌国际","MCD":"麦当劳","YUM":"百胜餐饮集团","LOW":"劳氏","WMT":"沃尔玛","HD":"家得宝","A":"安捷伦科技","TGT":"塔吉特","SBUX":"星巴克"},"source_url":"https://finance.yahoo.com/news/billionaire-bill-ackman-smoking-mentor-201900070.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2172951249","content_text":"Dividend stocks might look boring, but they can provide exciting returns.\nJust ask famed activist investor and self-proclaimed Warren Buffett acolyte Bill Ackman.\nHis hedge fund Pershing Square Holdings has delivered annualized total returns of more than 30% over the last three years, substantially outperforming the S&P 500 and even Buffett’s own Berkshire Hathaway.\nAnd he did it largely by owning dividend stocks.\nAccording to Pershing’s latest 13F filing with the Securities Exchange Commission, nearly 60% of its holdings by market value are invested in dividend stocks.\nLet’s take a look at three stocks in Ackman’s portfolio that regulary dish out cash to investors — one of them could be worth buying with your spare change.\nRestaurant Brands International Inc (QSR)\nTony Prato/Shutterstock\nLeading off the list is Restaurant Brands International, a fast-food holding company formed in 2014 by the merger between Burger King and Canadian coffee chain Tim Hortons.\nIn 2017, the company added Popeyes Louisiana Kitchen to its portfolio.\nLike most restaurant stocks, Restaurant Brands shares tumbled during the pandemic-induced market sell-off in early 2020. But the stock has since made a strong recovery.\nThat rebound is backed by substantial improvements in the company’s business. According to the latest earnings report, same-store sales — a key measure of a retailer’s health — increased 27.6%.\nAdjusted earnings came in at $0.77 per share for the quarter, more than double the $0.33 per share it earned in the year-ago period. The amount also covered the company’s quarterly dividend payment of $0.53 per share with ease.\nRestaurant Brands is offering a healthy annual dividend yield of 3.4%, which is a return investors can earn even if they're investing with spare nickels and dimes.\nFor comparison, that’s a higher yield than fast-food restaurant giants McDonald’s (2.26%), Starbucks (1.6%), and Yum! Brands (1.6%).\nLowe’s Companies Inc (LOW)\nKen Wolter/Shutterstock\nLowe’s is Bill Ackman’s largest holding by market value, and the position has served the billionaire investor quite well.\nShares of the home improvement retail giant are up 29% year to date. The S&P 500 has returned 16% over the same period.\nWhat’s more impressive than Lowe’s near-term stock price performance is how the company’s dividend has grown over the years.\nThe economy moves in cycles, but Lowe’s payout has only gone up. In fact, the company has increased its payout to shareholders every year for the past 59 years.\nDecades of dividend hikes has brought Lowe’s quarterly dividend to $0.80 per share, translating to an annual yield of 1.5%.\nNote that its competitors are also dividend-paying companies: Home Depot yields 2.0%, Target pays 1.5%, while Walmart offers an annual yield of 1.6%.\nDue to Lowe’s rally over the past year, its shares now trade at over $200. But you can get a piece of the company using a popular stock trading app that allows you to buy fractions of shares with as much money as you’re willing to spend.\nAgilent Technologies Inc (A)\nElnur/Shutterstock\nAgilent isn’t a household name, but within its own industry, the company is a force to be reckoned with.\nAgilent provides bio-analyitical and electronic measurement solutions to a wide variety of industries including communications, life sciences, and chemical analysis.\nHeadquartered in Santa Clara, Calif., the company’s products are used by 265,000 labs around the world. In Agilent’s fiscal 2020, it brought in $5.34 billion of total revenue.\nAnd in the most recent quarter, revenue grew 26% year-over-year to $1.59 billion.\nGiven this kind of performance, you’d think Agilent shares would be soaring. But while the stock has returned a solid 60% over the past year, it has pulled back about 10% since the peak in early September.\nOn the dividend front, Agilent offers an annual yield of 0.5%, which may not seem like much. But the company has an excellent track record when it comes to returning cash to investors: Since 2014, Agilent’s per share quarterly payout has increased by 106%.\nRental income stream?\nThe neat thing with dividend stocks is that they provide a way for investors to earn a steady income stream regardless of what the economy is doing.\nOf course, you don’t have to limit yourself to the stock market to do that.\nFor instance, one investing service makes it possible to lock in a steady rental income stream by investing in premium real estate properties — from commercial developments in LA to residential buildings in NYC.\nYou’ll gain exposure to high-end properties that big-time real estate moguls usually have access to, and you’ll receive regular payouts in the form of quarterly dividend distributions.\nThis article provides information only and should not be construed as advice. It is provided without warranty of any kind.","news_type":1},"isVote":1,"tweetType":1,"viewCount":82,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690605469,"gmtCreate":1639660809729,"gmtModify":1639660810880,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/690605469","repostId":"1191683541","repostType":4,"repost":{"id":"1191683541","pubTimestamp":1639658241,"share":"https://www.laohu8.com/m/news/1191683541?lang=&edition=full","pubTime":"2021-12-16 20:37","market":"us","language":"en","title":"10 Biggest Price Target Changes For Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1191683541","media":"Benzinga","summary":"Stifel cut the price target on Under Armour, Inc.. from $30 to $24. Under Armour shares fell 0.7% to $22.22 in pre-market trading.RBC Capital lowered the price target on Airbnb, Inc. from $195 to $175. Airbnb shares rose 0.3% to $168.62 in pre-market trading.Morgan Stanley lowered DocuSign, Inc. price target from $350 to $165. DocuSign shares dropped 2.4% to $147.51 in pre-market trading.Barclays cut the price target on Aptiv PLC from $212 to $200. Aptiv shares rose 2.7% to $168.91 in pre-market","content":"<ul>\n <li>Stifel cut the price target on&nbsp;<b>Under Armour, Inc..</b>(NYSE:UAA) from $30 to $24. Under Armour shares fell 0.7% to $22.22 in pre-market trading.</li>\n <li>RBC Capital lowered the price target on&nbsp;<b>Airbnb, Inc.</b>(NASDAQ:ABNB) from $195 to $175. Airbnb shares rose 0.3% to $168.62 in pre-market trading.</li>\n <li>Morgan Stanley cut&nbsp;<b>AT&amp;T Inc.</b>(NYSE:T) price target from $32 to $28. AT&amp;T shares rose 1.7% to $22.55 in pre-market trading.</li>\n <li>Morgan Stanley lowered&nbsp;<b>DocuSign, Inc.</b>(NASDAQ:DOCU) price target from $350 to $165. DocuSign shares dropped 2.4% to $147.51 in pre-market trading.</li>\n <li>Barclays cut the price target on&nbsp;<b>Aptiv PLC</b>(NYSE:APTV) from $212 to $200. Aptiv shares rose 2.7% to $168.91 in pre-market trading.</li>\n <li>Raymond James raised&nbsp;<b>The Progressive Corporation</b>(NYSE:PGR) price target from $105 to $110. Progressive shares rose 4.8% to close at $101.81 on Wednesday.</li>\n <li>Wells Fargo boosted the price target for&nbsp;<b>Magna International Inc.</b>(NYSE:MGA) from $84 to $93. Magna International shares rose 1.7% to $79.04 in pre-market trading.</li>\n <li>B of A Securities reduced the price target for&nbsp;<b>Wayfair Inc.</b>(NYSE:W) from $265 to $175. Wayfair shares dropped 2.4% to $202.28 in pre-market trading.</li>\n <li>HC Wainwright &amp; Co. cut&nbsp;<b>IGM Biosciences, Inc.</b>(NASDAQ:IGMS) price target from $114 to $76. IGM Biosciences shares fell 0.1% to close at $28.35 on Wednesday.</li>\n <li>Needham cut&nbsp;<b>Medtronic plc</b>(NYSE:MDT) price target from $145 to $131. Medtronic shares rose 0.1% to $105.01 in pre-market trading.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 20:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-ratings/price-target/21/12/24641061/10-biggest-price-target-changes-for-thursday><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stifel cut the price target on Under Armour, Inc..(NYSE:UAA) from $30 to $24. Under Armour shares fell 0.7% to $22.22 in pre-market trading.\nRBC Capital lowered the price target on Airbnb, Inc.(NASDAQ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-ratings/price-target/21/12/24641061/10-biggest-price-target-changes-for-thursday\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"T":"美国电话电报","DOCU":"Docusign","ABNB":"爱彼迎"},"source_url":"https://www.benzinga.com/analyst-ratings/price-target/21/12/24641061/10-biggest-price-target-changes-for-thursday","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191683541","content_text":"Stifel cut the price target on Under Armour, Inc..(NYSE:UAA) from $30 to $24. Under Armour shares fell 0.7% to $22.22 in pre-market trading.\nRBC Capital lowered the price target on Airbnb, Inc.(NASDAQ:ABNB) from $195 to $175. Airbnb shares rose 0.3% to $168.62 in pre-market trading.\nMorgan Stanley cut AT&T Inc.(NYSE:T) price target from $32 to $28. AT&T shares rose 1.7% to $22.55 in pre-market trading.\nMorgan Stanley lowered DocuSign, Inc.(NASDAQ:DOCU) price target from $350 to $165. DocuSign shares dropped 2.4% to $147.51 in pre-market trading.\nBarclays cut the price target on Aptiv PLC(NYSE:APTV) from $212 to $200. Aptiv shares rose 2.7% to $168.91 in pre-market trading.\nRaymond James raised The Progressive Corporation(NYSE:PGR) price target from $105 to $110. Progressive shares rose 4.8% to close at $101.81 on Wednesday.\nWells Fargo boosted the price target for Magna International Inc.(NYSE:MGA) from $84 to $93. Magna International shares rose 1.7% to $79.04 in pre-market trading.\nB of A Securities reduced the price target for Wayfair Inc.(NYSE:W) from $265 to $175. Wayfair shares dropped 2.4% to $202.28 in pre-market trading.\nHC Wainwright & Co. cut IGM Biosciences, Inc.(NASDAQ:IGMS) price target from $114 to $76. IGM Biosciences shares fell 0.1% to close at $28.35 on Wednesday.\nNeedham cut Medtronic plc(NYSE:MDT) price target from $145 to $131. Medtronic shares rose 0.1% to $105.01 in pre-market trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":873,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604284528,"gmtCreate":1639403527473,"gmtModify":1639403980729,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/604284528","repostId":"1101330061","repostType":4,"repost":{"id":"1101330061","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639402663,"share":"https://www.laohu8.com/m/news/1101330061?lang=&edition=full","pubTime":"2021-12-13 21:37","market":"us","language":"en","title":"Veru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI","url":"https://stock-news.laohu8.com/highlight/detail?id=1101330061","media":"Tiger Newspress","summary":"Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.The company today ann","content":"<p>Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.<img src=\"https://static.tigerbbs.com/fa70bd1f3f0b778ea773bf713c99c679\" tg-width=\"774\" tg-height=\"570\" referrerpolicy=\"no-referrer\">The&nbsp;company&nbsp;today&nbsp;announced that the U.S. Food and Drug Administration (FDA) has approved ENTADFITM&nbsp;for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia (BPH).</p>\n<p>ENTADFI (finasteride and tadalafil) capsule for oral use has also been shown to be more effective to treat urinary tract symptoms caused by BPH with less potential for adverse sexual side effects compared to finasteride monotherapy. ENTADFI dosing is one capsule orally once a day, and the FDA-approved indication is to initiate treatment of the signs and symptoms of benign prostatic hyperplasia in men with an enlarged prostate for up to 26 weeks.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-13 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.<img src=\"https://static.tigerbbs.com/fa70bd1f3f0b778ea773bf713c99c679\" tg-width=\"774\" tg-height=\"570\" referrerpolicy=\"no-referrer\">The&nbsp;company&nbsp;today&nbsp;announced that the U.S. Food and Drug Administration (FDA) has approved ENTADFITM&nbsp;for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia (BPH).</p>\n<p>ENTADFI (finasteride and tadalafil) capsule for oral use has also been shown to be more effective to treat urinary tract symptoms caused by BPH with less potential for adverse sexual side effects compared to finasteride monotherapy. ENTADFI dosing is one capsule orally once a day, and the FDA-approved indication is to initiate treatment of the signs and symptoms of benign prostatic hyperplasia in men with an enlarged prostate for up to 26 weeks.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VERU":"Veru Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101330061","content_text":"Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.The company today announced that the U.S. Food and Drug Administration (FDA) has approved ENTADFITM for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia (BPH).\nENTADFI (finasteride and tadalafil) capsule for oral use has also been shown to be more effective to treat urinary tract symptoms caused by BPH with less potential for adverse sexual side effects compared to finasteride monotherapy. ENTADFI dosing is one capsule orally once a day, and the FDA-approved indication is to initiate treatment of the signs and symptoms of benign prostatic hyperplasia in men with an enlarged prostate for up to 26 weeks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":221,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605640297,"gmtCreate":1639160477225,"gmtModify":1639160478352,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605640297","repostId":"1133027099","repostType":4,"repost":{"id":"1133027099","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639152670,"share":"https://www.laohu8.com/m/news/1133027099?lang=&edition=full","pubTime":"2021-12-11 00:11","market":"us","language":"en","title":"Sea Ltd stock dropped more than 5% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1133027099","media":"Tiger Newspress","summary":"Sea Ltd stock dropped more than 5% in morning trading.","content":"<p>Sea Ltd stock dropped more than 5% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f6295277426435ac2c7135ba73dfbdef\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea Ltd stock dropped more than 5% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea Ltd stock dropped more than 5% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-11 00:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sea Ltd stock dropped more than 5% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f6295277426435ac2c7135ba73dfbdef\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133027099","content_text":"Sea Ltd stock dropped more than 5% in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":840566249,"gmtCreate":1635661104951,"gmtModify":1635661105328,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/840566249","repostId":"2179226336","repostType":4,"repost":{"id":"2179226336","pubTimestamp":1635644521,"share":"https://www.laohu8.com/m/news/2179226336?lang=&edition=full","pubTime":"2021-10-31 09:42","market":"hk","language":"en","title":"Opinion: Big Tech is still headed for its biggest year ever, but Apple and Amazon could cut into fourth quarter profits","url":"https://stock-news.laohu8.com/highlight/detail?id=2179226336","media":"Market watch","summary":"Supply-chain and staffing issues will bring down the growth rates a bit for Apple and Amazon, but Go","content":"<p>Supply-chain and staffing issues will bring down the growth rates a bit for <a href=\"https://laohu8.com/S/AAPL\">Apple</a> and Amazon, but Google and <a href=\"https://laohu8.com/S/MSFT\">Microsoft</a> are still headed for huge holiday seasons to wrap up the year</p>\n<p>Big Tech is still on track forits biggest year of sales ever by a wide distance, but holiday issues at Apple Inc. and <a href=\"https://laohu8.com/S/AMZN\">Amazon.com</a> Inc. could mean a profit decline.</p>\n<p>The fourth quarter is definitely going to be lighter than Wall Street had previously expected,because of constraints that both AppleAAPL,-1.82%and AmazonAMZN,-2.15%talked about Thursday in the global supply chain, which are affecting their ability to meet the strong consumer demand for their products.</p>\n<p>While revenue for both the full year and fourth quarter of 2021 is expected to see strong double-digit growth again, net income is going to take a huge hit for both the year and the quarter, depending on how much money Amazon ends up spending.</p>\n<p><b>Full earnings coverage:Apple sales missedandAmazon’s earnings were nearly cut in half</b></p>\n<p>But two other members of the five-headed Big Tech monster are poised to outperform previous expectations. <a href=\"https://laohu8.com/S/GOOG\">Alphabet</a> Inc.GOOG,+1.47%GOOGL,+1.51%is now expected to see the biggest growth in sales — Wall Street is forecasting total revenue for <a href=\"https://laohu8.com/S/GOOGL\">Alphabet</a> to grow about 26% to around $71.8 billion, before deducting traffic acquisition costs (TAC), in the December quarter. Google’s ad business was mostly undeterred by the changes in Apple’s privacy settings for the iPhone that afflicted other internet companies.</p>\n<p>“With many investors looking outside of U.S. internet given the plethora of potential headwinds (IDFA, supply chain) and negative media headlines, Google kept the course and did what they needed to do,” said Bernstein Research analyst Mark Shmulik in a note to clients. “The 3Q print isn’t the massive blowout many of you have perhaps grown accustomed to these past few quarters, but it also wasn’t a miss.”</p>\n<p><b>More from Therese:Apple’s ad-megeddon is affecting Snap, <a href=\"https://laohu8.com/S/FB\">Facebook</a> and Google differently</b></p>\n<p>This compares to projected revenue growth rates for the fourth quarter in the teens for Amazon (10%), Facebook Inc.FB,+2.10%(19%) and Microsoft Corp.MSFT,+2.24%(17.5%). All of these growth rates, with the exception of Amazon, are still better than the S&amp;P 500SPX,+0.19%projected revenue growth of 11.65% for the fourth quarter. Combined, the calendar fourth quarter revenue for these five companies is forecast at $412.2 billion, up 16.2% from $354.5 billion a year ago.</p>\n<p>Net income, though, will be down to single-digit growth, thanks to Amazon’s hefty spending on product fulfillment, including big employee hires. The combined net income of the Big Five for the fourth quarter is projected at $79.9 billion, a bump up of only 2.7% from $77.8 billion in the year ago quarter. The S&amp;P 500 will see better far earnings growth of 21.15%</p>\n<p>And if there is a miss overall, we could see a decline on the year. Net income is expected to only be up very slightly right now, just over 1% to $228.3 billion from $224.8 billion for calendar 2020.That’s also much lower than the projections at mid-year,of net income coming in right around $300 billion, and could even come in flat to down, based on Amazon’s potential-downside forecast and any other surprise issues that come up for others in the Big 5.</p>\n<p>For the full year 2021, including recent changes to estimates after Thursday’s shortfalls, combined revenue for Alphabet, Amazon, Apple, Facebook and Microsoft is now expected to reach approximately $1.398 trillion, based on Factset estimates. That will still put 2021 on track to be Big Tech’s biggest year ever, with growth of 26.9% from $1.102 trillion in calendar 2020.</p>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> may have seen the best times in tech already this year and until the global supply chain issues are resolved, the consumer-focused companies are probably going to be too volatile to really depend on. Tech is a varied sector, though, and the color in last week’s earnings calls suggested companies are still spending andshould sustain enterprise tech names through the choppy fourth-quarter waters.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Opinion: Big Tech is still headed for its biggest year ever, but Apple and Amazon could cut into fourth quarter profits</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOpinion: Big Tech is still headed for its biggest year ever, but Apple and Amazon could cut into fourth quarter profits\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-31 09:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/><strong>Market watch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Supply-chain and staffing issues will bring down the growth rates a bit for Apple and Amazon, but Google and Microsoft are still headed for huge holiday seasons to wrap up the year\nBig Tech is still ...</p>\n\n<a href=\"https://www.marketwatch.com/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","AAPL":"苹果"},"source_url":"https://www.marketwatch.com/","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"2179226336","content_text":"Supply-chain and staffing issues will bring down the growth rates a bit for Apple and Amazon, but Google and Microsoft are still headed for huge holiday seasons to wrap up the year\nBig Tech is still on track forits biggest year of sales ever by a wide distance, but holiday issues at Apple Inc. and Amazon.com Inc. could mean a profit decline.\nThe fourth quarter is definitely going to be lighter than Wall Street had previously expected,because of constraints that both AppleAAPL,-1.82%and AmazonAMZN,-2.15%talked about Thursday in the global supply chain, which are affecting their ability to meet the strong consumer demand for their products.\nWhile revenue for both the full year and fourth quarter of 2021 is expected to see strong double-digit growth again, net income is going to take a huge hit for both the year and the quarter, depending on how much money Amazon ends up spending.\nFull earnings coverage:Apple sales missedandAmazon’s earnings were nearly cut in half\nBut two other members of the five-headed Big Tech monster are poised to outperform previous expectations. Alphabet Inc.GOOG,+1.47%GOOGL,+1.51%is now expected to see the biggest growth in sales — Wall Street is forecasting total revenue for Alphabet to grow about 26% to around $71.8 billion, before deducting traffic acquisition costs (TAC), in the December quarter. Google’s ad business was mostly undeterred by the changes in Apple’s privacy settings for the iPhone that afflicted other internet companies.\n“With many investors looking outside of U.S. internet given the plethora of potential headwinds (IDFA, supply chain) and negative media headlines, Google kept the course and did what they needed to do,” said Bernstein Research analyst Mark Shmulik in a note to clients. “The 3Q print isn’t the massive blowout many of you have perhaps grown accustomed to these past few quarters, but it also wasn’t a miss.”\nMore from Therese:Apple’s ad-megeddon is affecting Snap, Facebook and Google differently\nThis compares to projected revenue growth rates for the fourth quarter in the teens for Amazon (10%), Facebook Inc.FB,+2.10%(19%) and Microsoft Corp.MSFT,+2.24%(17.5%). All of these growth rates, with the exception of Amazon, are still better than the S&P 500SPX,+0.19%projected revenue growth of 11.65% for the fourth quarter. Combined, the calendar fourth quarter revenue for these five companies is forecast at $412.2 billion, up 16.2% from $354.5 billion a year ago.\nNet income, though, will be down to single-digit growth, thanks to Amazon’s hefty spending on product fulfillment, including big employee hires. The combined net income of the Big Five for the fourth quarter is projected at $79.9 billion, a bump up of only 2.7% from $77.8 billion in the year ago quarter. The S&P 500 will see better far earnings growth of 21.15%\nAnd if there is a miss overall, we could see a decline on the year. Net income is expected to only be up very slightly right now, just over 1% to $228.3 billion from $224.8 billion for calendar 2020.That’s also much lower than the projections at mid-year,of net income coming in right around $300 billion, and could even come in flat to down, based on Amazon’s potential-downside forecast and any other surprise issues that come up for others in the Big 5.\nFor the full year 2021, including recent changes to estimates after Thursday’s shortfalls, combined revenue for Alphabet, Amazon, Apple, Facebook and Microsoft is now expected to reach approximately $1.398 trillion, based on Factset estimates. That will still put 2021 on track to be Big Tech’s biggest year ever, with growth of 26.9% from $1.102 trillion in calendar 2020.\nInvestors may have seen the best times in tech already this year and until the global supply chain issues are resolved, the consumer-focused companies are probably going to be too volatile to really depend on. Tech is a varied sector, though, and the color in last week’s earnings calls suggested companies are still spending andshould sustain enterprise tech names through the choppy fourth-quarter waters.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853243645,"gmtCreate":1634819063566,"gmtModify":1634819074078,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/853243645","repostId":"1192205953","repostType":4,"repost":{"id":"1192205953","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634818772,"share":"https://www.laohu8.com/m/news/1192205953?lang=&edition=full","pubTime":"2021-10-21 20:19","market":"us","language":"en","title":"Toplines Before US Market Open on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1192205953","media":"Tiger Newspress","summary":"Stock futures edged lower Thursday morning, with the major indexes hovering slightly below all-time ","content":"<p>Stock futures edged lower Thursday morning, with the major indexes hovering slightly below all-time highs as a parade of strong earnings results helped buoy equity prices earlier this week.</p>\n<p><img src=\"https://static.tigerbbs.com/4be1cf44a88f742bce145b6a6868682f\" tg-width=\"286\" tg-height=\"117\" width=\"100%\" height=\"auto\">At 8:00 a.m. ET, Dow e-minis were&nbsp;down&nbsp;108&nbsp;points, or 0.3%, S&amp;P 500 e-minis were&nbsp;down&nbsp;13.75 points, or 0.3%, and Nasdaq 100 e-minis were down&nbsp;61&nbsp;points, or 0.4%.</p>\n<p>IBM&nbsp;slipped 4.7% after it missed market estimates for quarterly revenue as its managed infrastructure business suffered from a decline in orders.</p>\n<p>Tesla fell 1% in premarket trading as it said on Wednesday its upcoming factories and supply-chain headwinds would put pressure on its margins after it beat Wall Street expectations for third-quarter revenue.</p>\n<p>AT&amp;T rose 1% after the telecom operator's quarterly revenue and monthly phone bill paying subscriber additions beat market expectations.</p>\n<p>Dow gained 1.1% after it posted a more than a five-fold jump in third-quarter profit as economic recovery boosted prices for chemicals.</p>\n<p>In currencies,the euro was little changed at $1.1640,the British pound fell 0.1% to $1.3810,the Japanese yen rose 0.3% to 114.02 per dollar.</p>\n<p>In bonds,the yield on 10-year Treasuries was little changed at 1.66%,Germany’s 10-year yield advanced two basis points to -0.11%,Britain’s 10-year yield advanced four basis points to 1.18%.</p>\n<p>In commodities,West Texas Intermediate crude fell 0.8% to $82.75 a barrel,Gold futures were little changed.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-21 20:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Stock futures edged lower Thursday morning, with the major indexes hovering slightly below all-time highs as a parade of strong earnings results helped buoy equity prices earlier this week.</p>\n<p><img src=\"https://static.tigerbbs.com/4be1cf44a88f742bce145b6a6868682f\" tg-width=\"286\" tg-height=\"117\" width=\"100%\" height=\"auto\">At 8:00 a.m. ET, Dow e-minis were&nbsp;down&nbsp;108&nbsp;points, or 0.3%, S&amp;P 500 e-minis were&nbsp;down&nbsp;13.75 points, or 0.3%, and Nasdaq 100 e-minis were down&nbsp;61&nbsp;points, or 0.4%.</p>\n<p>IBM&nbsp;slipped 4.7% after it missed market estimates for quarterly revenue as its managed infrastructure business suffered from a decline in orders.</p>\n<p>Tesla fell 1% in premarket trading as it said on Wednesday its upcoming factories and supply-chain headwinds would put pressure on its margins after it beat Wall Street expectations for third-quarter revenue.</p>\n<p>AT&amp;T rose 1% after the telecom operator's quarterly revenue and monthly phone bill paying subscriber additions beat market expectations.</p>\n<p>Dow gained 1.1% after it posted a more than a five-fold jump in third-quarter profit as economic recovery boosted prices for chemicals.</p>\n<p>In currencies,the euro was little changed at $1.1640,the British pound fell 0.1% to $1.3810,the Japanese yen rose 0.3% to 114.02 per dollar.</p>\n<p>In bonds,the yield on 10-year Treasuries was little changed at 1.66%,Germany’s 10-year yield advanced two basis points to -0.11%,Britain’s 10-year yield advanced four basis points to 1.18%.</p>\n<p>In commodities,West Texas Intermediate crude fell 0.8% to $82.75 a barrel,Gold futures were little changed.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","TSLA":"特斯拉","IBM":"IBM"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192205953","content_text":"Stock futures edged lower Thursday morning, with the major indexes hovering slightly below all-time highs as a parade of strong earnings results helped buoy equity prices earlier this week.\nAt 8:00 a.m. ET, Dow e-minis were down 108 points, or 0.3%, S&P 500 e-minis were down 13.75 points, or 0.3%, and Nasdaq 100 e-minis were down 61 points, or 0.4%.\nIBM slipped 4.7% after it missed market estimates for quarterly revenue as its managed infrastructure business suffered from a decline in orders.\nTesla fell 1% in premarket trading as it said on Wednesday its upcoming factories and supply-chain headwinds would put pressure on its margins after it beat Wall Street expectations for third-quarter revenue.\nAT&T rose 1% after the telecom operator's quarterly revenue and monthly phone bill paying subscriber additions beat market expectations.\nDow gained 1.1% after it posted a more than a five-fold jump in third-quarter profit as economic recovery boosted prices for chemicals.\nIn currencies,the euro was little changed at $1.1640,the British pound fell 0.1% to $1.3810,the Japanese yen rose 0.3% to 114.02 per dollar.\nIn bonds,the yield on 10-year Treasuries was little changed at 1.66%,Germany’s 10-year yield advanced two basis points to -0.11%,Britain’s 10-year yield advanced four basis points to 1.18%.\nIn commodities,West Texas Intermediate crude fell 0.8% to $82.75 a barrel,Gold futures were little changed.","news_type":1},"isVote":1,"tweetType":1,"viewCount":15,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849484348,"gmtCreate":1635773946331,"gmtModify":1635773946809,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849484348","repostId":"2179250221","repostType":4,"repost":{"id":"2179250221","pubTimestamp":1635721559,"share":"https://www.laohu8.com/m/news/2179250221?lang=&edition=full","pubTime":"2021-11-01 07:05","market":"us","language":"en","title":"Federal Reserve decision, October jobs report: What to know this week","url":"https://stock-news.laohu8.com/highlight/detail?id=2179250221","media":"Yahoo Finance","summary":"The Federal Reserve's forthcoming monetary policy meeting will be in focus this week, and may set th","content":"<p><img src=\"https://static.tigerbbs.com/790c3fdfdc38fa2b5b3a13d89fb1959a\" tg-width=\"1878\" tg-height=\"2940\" width=\"100%\" height=\"auto\"></p>\n<p>The Federal Reserve's forthcoming monetary policy meeting will be in focus this week, and may set the stage for a long-awaited announcement of asset-purchase tapering. Meanwhile, traders will also await more data on the U.S. economic recovery with the Labor Department's monthly jobs report later this week.</p>\n<p>The Federal Open Market Committee's (FOMC) November meeting will take place from Tuesday to Wednesday, with the policy statement and press conference from the meeting serving as the central bank's penultimate opportunity this year to announce formal plans to begin rolling back its crisis-era quantitative easing program. For the past year-and-a-half, the central bank has been purchasing $120 billion per month in agency mortgage-backed securities and Treasuries, as <a href=\"https://laohu8.com/S/AONE.U\">one</a> major tool to support the economy during the pandemic.</p>\n<p>In late September, the FOMC's latest monetary policy statement and press conference from Federal Reserve Chair Jerome <a href=\"https://laohu8.com/S/POWL\">Powell</a> suggested the central bank was apt to announce the start of tapering before year-end, and continue the tapering process until \"around the middle of next year.\"</p>\n<p>\"The upcoming FOMC meeting will be important for three reasons: 1) the announcement of tapering; 2) guidance around what tapering means for the path of hikes; and 3) nuanced changes in views around inflation risks given recent data,\" wrote <a href=\"https://laohu8.com/S/BAC\">Bank of America</a> economist Michelle Meyer in a note.</p>\n<p>\"The statement that announces the new pace of asset purchases will be followed by a note regarding flexibility stating that asset purchases are not on a pre-set course and will depend on the outlook for the labor market and inflation as well as an assessment of the efficacy of asset purchases,\" she predicted.</p>\n<p>She noted that Powell may also use the press conference to reiterate that the end of tapering would not necessarily indicate the start of rate hikes, and that both policy actions are distinct. In previous public remarks, Powell has already made a similar point in previous public remarks, saying, \"the timing and pace of the coming reduction in asset purchases will not be intended to carry a direct signal regarding the timing of interest rate liftoff.\"</p>\n<p>Given the market has been anticipating the start to tapering for months now, speculation around when the Fed will make a move on interest rates has become a point of particular interest to investors. <a href=\"https://laohu8.com/S/ISBC\">Investors</a> and economists have mulled whether the Fed may need to act more quickly than previously telegraphed on adjusting interest rates to stave off inflation, which has proven more long-lasting than some had suggested.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f0f0ae63a784eef5578397df02340483\" tg-width=\"4932\" tg-height=\"3288\" referrerpolicy=\"no-referrer\"><span>WASHINGTON, DC - SEPTEMBER 24: Federal Reserve Board Chairman Jerome Powell testifies during a Senate Banking Committee hearing on Capitol Hill on September 24, 2020 in Washington, DC. Powell and U.S. Treasury Secretary Steve Mnuchin are testifying about the CARES Act and the economic effects of the coronavirus pandemic. (Photo by Drew Angerer/Getty Images)Drew Angerer via Getty Images</span></p>\n<p>In September, core personal consumption expenditures — the Fed's preferred gauge of underlying inflation — rose 3.6% over last year for a fourth consecutive month, coming in at the fastest clip since 1991. And earlier this month, Powell acknowledged in public remarks that the supply chain constraints and shortages that spurred the latest rise in prices are \"likely to last longer than previously expected, likely well into next year.\"</p>\n<p>While the central bank will not release an updated Summary of Economic Projections with their policy statement on Wednesday, the latest projections from the September meeting suggested the committee was split on rate hikes for 2022, with nine members seeing no rate hikes by the end of next year while the other nine members saw at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> hike.</p>\n<p>\"I think the Fed has pretty well determined to start the taper pretty quickly. We expect them to announce it next week and then start it soon thereafter, so that's pretty well carved in stone,\" Kathy Jones, <a href=\"https://laohu8.com/S/SCHW\">Charles Schwab</a> chief fixed income strategist, told Yahoo Finance Live last week. \"I think the big debate now is how quickly the Fed moves toward actually raising rates. The expectation in the market has really shifted to expecting as many as two rate hikes in 2022 and 2023 ... that’s a pretty aggressive pace of tightening.\"</p>\n<h2>October jobs report</h2>\n<p>One of this week's most closely watched pieces of economic data will be the October jobs report, which is due for release on Friday from the Labor Department.</p>\n<p>Economists are looking to see a pick-up in the pace of hiring for October after a disappointing print in September, when just 194,000 non-farm payrolls returned versus the half million expected. Over the past two months, payroll gains averaged at just 280,000. The unemployment rate is expected to take another small step toward pre-pandemic levels in October as well, with the jobless rate anticipated to dip to 4.7% from 4.8% the prior month.</p>\n<p>Still, the labor market has still fallen short its pre-pandemic conditions on a number of fronts. The unemployment rate has yet to return to its 50-year low of 3.5% from February 2020. And as of September, the civilian labor force was still down by about 3.1 million individuals from pre-virus levels.</p>\n<p>One factor weighing on the labor market in August and September was the Delta variant, which may have deterred some workers from seeking employment in person for risk of infection. And an ongoing element dragging on the labor market's recovery has been a mismatch of supply and demand, with employers struggling to fill a near-record number of job openings while voluntary quits jumped to a historically high level.</p>\n<p>\"Next week’s October payrolls report will shed light on whether supply eased on diminishing constraints or if the labor market continues to face headwinds for now,\" wrote Rubeela Farooqi, chief U.S. economist for High Frequency Economics, in a note last week.</p>\n<p>But some data from the past couple weeks has reflected favorably on conditions in the labor market in October. Weekly new unemployment claims broke below 300,000 for the first time since the start of the pandemic during the survey week for the October jobs report, or the week that includes the 12th of the month. And in the Conference Board's October Consumer Confidence Index, just 10.6% of consumers said jobs were \"hard to get,\" down from 13.0% in September. That brought the Conference Board's closely watched labor market differential, or percentage of consumers saying jobs are \"hard to get\" subtracted from the percentage saying jobs \"are plentiful,\" to 45, or its highest level since 2000.</p>\n<h2>Economic calendar</h2>\n<ul>\n <li><p><b>Monday: </b><a href=\"https://laohu8.com/S/MRKT\">Markit</a> U.S. Manufacturing PMI, Oct. final (59.3 expected, 59.2 in September); Constructing spending, month-over-month, September (0.4% expected, 0.0% in August); ISM Manufacturing Index, Oct. (60.5 expected, 61.1 in September)</p></li>\n <li><p><b>Tuesday: </b><i>No notable reports scheduled for release</i></p></li>\n <li><p><b>Wednesday: </b>MBA Mortgage Applications, week ended Oct. 29 (0.3% during prior week); ADP Employment Change, Oct. (400,000 expected, 568,000 in September); ISM Services Index, October (62.0 expected, 61.9 in September); Factory Orders, September (-0.1% expected, 1.2% in August); Durable goods orders, September final (-0.4% in prior print; Durable goods orders excluding transportation, September final (0.4% in prior print); Non-defense capital goods orders excluding aircraft, September final (0.8% in prior print); Markit U.S. Services PMI, October final (58.2 expected, 58.2 in prior print); Markit U.S. Composite PMI, October final (57.3 in prior print); Federal Open Market Committee monetary policy decision</p></li>\n <li><p><b>Thursday: </b>Challenger job cuts, year-over-year, October (-84.9% in September); Initial jobless claims, week ended Oct. 30 (275,000 expected, 281,000 during prior week); Continuing claims, week ended Oct. 23 (2.147 million expected, 2.243 million during prior week); Non-farm productivity, Q3 preliminary (-3.2% expected, 2.1% in <a href=\"https://laohu8.com/S/QTWO\">Q2</a>); <a href=\"https://laohu8.com/S/UNT\">Unit</a> Labor Costs, Q3 preliminary (6.9% expected, 1.3% in Q2); Trade balance, September (-$80.1 billion expected, -$73.3 billion in August)</p></li>\n <li><p><b>Friday: </b>Change in non-farm payrolls, October (450,000 expected, 194,000 in September); Unemployment rate, October (4.7% expected, 4.8% in September); Average hourly earnings, month-over-month, October (4.7% expected, 4.8% in September); Average hourly earnings, year-over-year, October (4.9% expected, 4.6% in September); Labor Force Participation Rate, October (61.8% expected, 61.6% in September); Consumer Credit, September ($16.200 billion expected, $14.379 million in August)</p></li>\n</ul>\n<h2>Earnings calendar</h2>\n<ul>\n <li><p><b>Monday: </b><a href=\"https://laohu8.com/S/CLX\">Clorox</a> (CLX), <a href=\"https://laohu8.com/S/CAR\">Avis Budget</a> Group (<a href=\"https://laohu8.com/S/00699\">CAR</a>), ZoomInfo Technologies (ZI), <a href=\"https://laohu8.com/S/CHGG\">Chegg Inc</a>. (CHGG), <a href=\"https://laohu8.com/S/FANG\">Diamondback Energy</a> (FANG), The <a href=\"https://laohu8.com/S/SPG\">Simon Property</a> Group (SPG) after market close</p></li>\n <li><p><b>Tuesday: </b><a href=\"https://laohu8.com/S/UA.C\">Under Armour</a> (UAA), <a href=\"https://laohu8.com/S/EL\">Estee Lauder</a> (EL), <a href=\"https://laohu8.com/S/RL\">Ralph Lauren</a> (RL), Apollo Global Management (APO), Corsair Gaming (CRSR), <a href=\"https://laohu8.com/S/BLMN\">Bloomin' Brands</a> (BLMN), <a href=\"https://laohu8.com/S/COP\">ConocoPhillips</a> (COP), <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE), <a href=\"https://laohu8.com/S/GRPN\">Groupon</a> (GPN), <a href=\"https://laohu8.com/S/MPC\">Marathon</a> Petroleum (MPC) before market open; <a href=\"https://laohu8.com/S/MDLZ\">Mondelez</a> (MDLZ), T-Mobile (TMUS), <a href=\"https://laohu8.com/S/AKAM\">Akamai</a> (AKAM), <a href=\"https://laohu8.com/S/ATVI\">Activision Blizzard</a> (ATVI), Lyft (LYFT), <a href=\"https://laohu8.com/S/MTCH\">Match</a> Group (MTCH), <a href=\"https://laohu8.com/S/DVN\">Devon</a> Energy (DVN), <a href=\"https://laohu8.com/S/CHK\">Chesapeake</a> Energy (CHK), Coursera (COUR), <a href=\"https://laohu8.com/S/Z\">Zillow</a> Group (ZG), <a href=\"https://laohu8.com/S/AMGN\">Amgen</a> (AMGN) after market close</p></li>\n <li><p><b>Wednesday: </b><a href=\"https://laohu8.com/S/HUM\">Humana</a> (HUM), <a href=\"https://laohu8.com/S/DISCA\">Discovery</a> Inc. (DISCA), The <a href=\"https://laohu8.com/S/NYT\">New York Times</a> (NYT), <a href=\"https://laohu8.com/S/NCLH\">Norwegian Cruise Line</a> Holdings (NCLH), <a href=\"https://laohu8.com/S/MAR\">Marriott</a> International (MAR), <a href=\"https://laohu8.com/S/CVS\">CVS Health</a> Corp. (CVS), <a href=\"https://laohu8.com/S/SBGI\">Sinclair Broadcast Group</a> (SBGI) before market open; <a href=\"https://laohu8.com/S/BKNG\">Booking Holdings</a> (BKNG), <a href=\"https://laohu8.com/S/QRVO\">Qorvo</a> (QRVO), The <a href=\"https://laohu8.com/S/ALL\">Allstate</a> Corp. (ALL), <a href=\"https://laohu8.com/S/MGM\">MGM Resorts International</a> (MGM), $Take-<a href=\"https://laohu8.com/S/TWOA.U\">Two</a> Interactive Software(TTWO)$ (TTWO), <a href=\"https://laohu8.com/S/EA\">Electronic Arts</a> (EA), Vimeo (VMEO), <a href=\"https://laohu8.com/S/ETSY\">Etsy</a> (ETSY), <a href=\"https://laohu8.com/S/GDDY\">GoDaddy</a> (GDDY), <a href=\"https://laohu8.com/S/MRO\">Marathon</a> Oil Corp. (MRO), Roku (ROKU), <a href=\"https://laohu8.com/S/QCOM\">Qualcomm</a> (QCOM) after market close</p></li>\n <li><p><b>Thursday: </b><a href=\"https://laohu8.com/S/CI\">Cigna</a> (CI), <a href=\"https://laohu8.com/S/W\">Wayfair</a> (W), ViacomCBS (VIAC), Nikola (NKLA), <a href=\"https://laohu8.com/S/DEX.AU\">Duke</a> Energy (DUK), <a href=\"https://laohu8.com/S/CTXS\">Citrix</a> Systems (CTXS), <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> (REGN), <a href=\"https://laohu8.com/S/HBI\">Hanesbrands</a> (HBI), Moderna (MRNA), <a href=\"https://laohu8.com/S/PLNT\">Planet Fitness</a> (PLNT), Vulcan Material (VMC), <a href=\"https://laohu8.com/S/K\">Kellogg</a> (K), <a href=\"https://laohu8.com/S/SQ\">Square</a> (SQ), Cloudflare (NET), <a href=\"https://laohu8.com/S/OXY\">Occidental</a> Petroleum (OXY), <a href=\"https://laohu8.com/S/UBER\">Uber</a> Technologies (UBER), <a href=\"https://laohu8.com/S/AFG\">American</a> International Group (AIG), <a href=\"https://laohu8.com/S/SHAK\">Shake Shack</a> (SHAK), iHeartMedia (IHRT), <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> (NVAX), IAC Interactive Corp. (IAC), Peloton (PTON), Dropbox (DBX), DataDog (DDOG), Pinterest (PINS), <a href=\"https://laohu8.com/S/SWKS\">Skyworks Solutions</a> (SWKS), <a href=\"https://laohu8.com/S/EXPE\">Expedia</a> (EXPE), Rocket Cos. (RKT), <a href=\"https://laohu8.com/S/LYV\">Live Nation Entertainment</a> (LYV), Airbnb (ABNB)</p></li>\n <li><p><b>Friday: </b><a href=\"https://laohu8.com/S/WYNN\">Wynn</a> Resorts (WYNN), Dish Networks (DISH), Dominion Energy (D), DraftKings (DKNG), <a href=\"https://laohu8.com/S/GT\">Goodyear</a> Tire and Rubber (GT), <a href=\"https://laohu8.com/S/CNK\">Cinemark</a> Holdings (CNK) before market open</p></li>\n</ul>","source":"yahoofinance_au","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Federal Reserve decision, October jobs report: What to know this week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFederal Reserve decision, October jobs report: What to know this week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-01 07:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/federal-reserve-meeting-october-jobs-report-what-to-know-this-week-151259921.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Federal Reserve's forthcoming monetary policy meeting will be in focus this week, and may set the stage for a long-awaited announcement of asset-purchase tapering. Meanwhile, traders will also ...</p>\n\n<a href=\"https://finance.yahoo.com/news/federal-reserve-meeting-october-jobs-report-what-to-know-this-week-151259921.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞",".IXIC":"NASDAQ Composite","EL":"雅诗兰黛","BLMN":"Bloomin' Brands","CLX":"高乐氏","UBER":"优步",".SPX":"S&P 500 Index","COP":"康菲石油","APO":"阿波罗全球管理","ATVI":"动视暴雪",".DJI":"道琼斯","CRSR":"Corsair Gaming, Inc.","RL":"拉夫劳伦"},"source_url":"https://finance.yahoo.com/news/federal-reserve-meeting-october-jobs-report-what-to-know-this-week-151259921.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2179250221","content_text":"The Federal Reserve's forthcoming monetary policy meeting will be in focus this week, and may set the stage for a long-awaited announcement of asset-purchase tapering. Meanwhile, traders will also await more data on the U.S. economic recovery with the Labor Department's monthly jobs report later this week.\nThe Federal Open Market Committee's (FOMC) November meeting will take place from Tuesday to Wednesday, with the policy statement and press conference from the meeting serving as the central bank's penultimate opportunity this year to announce formal plans to begin rolling back its crisis-era quantitative easing program. For the past year-and-a-half, the central bank has been purchasing $120 billion per month in agency mortgage-backed securities and Treasuries, as one major tool to support the economy during the pandemic.\nIn late September, the FOMC's latest monetary policy statement and press conference from Federal Reserve Chair Jerome Powell suggested the central bank was apt to announce the start of tapering before year-end, and continue the tapering process until \"around the middle of next year.\"\n\"The upcoming FOMC meeting will be important for three reasons: 1) the announcement of tapering; 2) guidance around what tapering means for the path of hikes; and 3) nuanced changes in views around inflation risks given recent data,\" wrote Bank of America economist Michelle Meyer in a note.\n\"The statement that announces the new pace of asset purchases will be followed by a note regarding flexibility stating that asset purchases are not on a pre-set course and will depend on the outlook for the labor market and inflation as well as an assessment of the efficacy of asset purchases,\" she predicted.\nShe noted that Powell may also use the press conference to reiterate that the end of tapering would not necessarily indicate the start of rate hikes, and that both policy actions are distinct. In previous public remarks, Powell has already made a similar point in previous public remarks, saying, \"the timing and pace of the coming reduction in asset purchases will not be intended to carry a direct signal regarding the timing of interest rate liftoff.\"\nGiven the market has been anticipating the start to tapering for months now, speculation around when the Fed will make a move on interest rates has become a point of particular interest to investors. Investors and economists have mulled whether the Fed may need to act more quickly than previously telegraphed on adjusting interest rates to stave off inflation, which has proven more long-lasting than some had suggested.\nWASHINGTON, DC - SEPTEMBER 24: Federal Reserve Board Chairman Jerome Powell testifies during a Senate Banking Committee hearing on Capitol Hill on September 24, 2020 in Washington, DC. Powell and U.S. Treasury Secretary Steve Mnuchin are testifying about the CARES Act and the economic effects of the coronavirus pandemic. (Photo by Drew Angerer/Getty Images)Drew Angerer via Getty Images\nIn September, core personal consumption expenditures — the Fed's preferred gauge of underlying inflation — rose 3.6% over last year for a fourth consecutive month, coming in at the fastest clip since 1991. And earlier this month, Powell acknowledged in public remarks that the supply chain constraints and shortages that spurred the latest rise in prices are \"likely to last longer than previously expected, likely well into next year.\"\nWhile the central bank will not release an updated Summary of Economic Projections with their policy statement on Wednesday, the latest projections from the September meeting suggested the committee was split on rate hikes for 2022, with nine members seeing no rate hikes by the end of next year while the other nine members saw at least one hike.\n\"I think the Fed has pretty well determined to start the taper pretty quickly. We expect them to announce it next week and then start it soon thereafter, so that's pretty well carved in stone,\" Kathy Jones, Charles Schwab chief fixed income strategist, told Yahoo Finance Live last week. \"I think the big debate now is how quickly the Fed moves toward actually raising rates. The expectation in the market has really shifted to expecting as many as two rate hikes in 2022 and 2023 ... that’s a pretty aggressive pace of tightening.\"\nOctober jobs report\nOne of this week's most closely watched pieces of economic data will be the October jobs report, which is due for release on Friday from the Labor Department.\nEconomists are looking to see a pick-up in the pace of hiring for October after a disappointing print in September, when just 194,000 non-farm payrolls returned versus the half million expected. Over the past two months, payroll gains averaged at just 280,000. The unemployment rate is expected to take another small step toward pre-pandemic levels in October as well, with the jobless rate anticipated to dip to 4.7% from 4.8% the prior month.\nStill, the labor market has still fallen short its pre-pandemic conditions on a number of fronts. The unemployment rate has yet to return to its 50-year low of 3.5% from February 2020. And as of September, the civilian labor force was still down by about 3.1 million individuals from pre-virus levels.\nOne factor weighing on the labor market in August and September was the Delta variant, which may have deterred some workers from seeking employment in person for risk of infection. And an ongoing element dragging on the labor market's recovery has been a mismatch of supply and demand, with employers struggling to fill a near-record number of job openings while voluntary quits jumped to a historically high level.\n\"Next week’s October payrolls report will shed light on whether supply eased on diminishing constraints or if the labor market continues to face headwinds for now,\" wrote Rubeela Farooqi, chief U.S. economist for High Frequency Economics, in a note last week.\nBut some data from the past couple weeks has reflected favorably on conditions in the labor market in October. Weekly new unemployment claims broke below 300,000 for the first time since the start of the pandemic during the survey week for the October jobs report, or the week that includes the 12th of the month. And in the Conference Board's October Consumer Confidence Index, just 10.6% of consumers said jobs were \"hard to get,\" down from 13.0% in September. That brought the Conference Board's closely watched labor market differential, or percentage of consumers saying jobs are \"hard to get\" subtracted from the percentage saying jobs \"are plentiful,\" to 45, or its highest level since 2000.\nEconomic calendar\n\nMonday: Markit U.S. Manufacturing PMI, Oct. final (59.3 expected, 59.2 in September); Constructing spending, month-over-month, September (0.4% expected, 0.0% in August); ISM Manufacturing Index, Oct. (60.5 expected, 61.1 in September)\nTuesday: No notable reports scheduled for release\nWednesday: MBA Mortgage Applications, week ended Oct. 29 (0.3% during prior week); ADP Employment Change, Oct. (400,000 expected, 568,000 in September); ISM Services Index, October (62.0 expected, 61.9 in September); Factory Orders, September (-0.1% expected, 1.2% in August); Durable goods orders, September final (-0.4% in prior print; Durable goods orders excluding transportation, September final (0.4% in prior print); Non-defense capital goods orders excluding aircraft, September final (0.8% in prior print); Markit U.S. Services PMI, October final (58.2 expected, 58.2 in prior print); Markit U.S. Composite PMI, October final (57.3 in prior print); Federal Open Market Committee monetary policy decision\nThursday: Challenger job cuts, year-over-year, October (-84.9% in September); Initial jobless claims, week ended Oct. 30 (275,000 expected, 281,000 during prior week); Continuing claims, week ended Oct. 23 (2.147 million expected, 2.243 million during prior week); Non-farm productivity, Q3 preliminary (-3.2% expected, 2.1% in Q2); Unit Labor Costs, Q3 preliminary (6.9% expected, 1.3% in Q2); Trade balance, September (-$80.1 billion expected, -$73.3 billion in August)\nFriday: Change in non-farm payrolls, October (450,000 expected, 194,000 in September); Unemployment rate, October (4.7% expected, 4.8% in September); Average hourly earnings, month-over-month, October (4.7% expected, 4.8% in September); Average hourly earnings, year-over-year, October (4.9% expected, 4.6% in September); Labor Force Participation Rate, October (61.8% expected, 61.6% in September); Consumer Credit, September ($16.200 billion expected, $14.379 million in August)\n\nEarnings calendar\n\nMonday: Clorox (CLX), Avis Budget Group (CAR), ZoomInfo Technologies (ZI), Chegg Inc. (CHGG), Diamondback Energy (FANG), The Simon Property Group (SPG) after market close\nTuesday: Under Armour (UAA), Estee Lauder (EL), Ralph Lauren (RL), Apollo Global Management (APO), Corsair Gaming (CRSR), Bloomin' Brands (BLMN), ConocoPhillips (COP), Pfizer (PFE), Groupon (GPN), Marathon Petroleum (MPC) before market open; Mondelez (MDLZ), T-Mobile (TMUS), Akamai (AKAM), Activision Blizzard (ATVI), Lyft (LYFT), Match Group (MTCH), Devon Energy (DVN), Chesapeake Energy (CHK), Coursera (COUR), Zillow Group (ZG), Amgen (AMGN) after market close\nWednesday: Humana (HUM), Discovery Inc. (DISCA), The New York Times (NYT), Norwegian Cruise Line Holdings (NCLH), Marriott International (MAR), CVS Health Corp. (CVS), Sinclair Broadcast Group (SBGI) before market open; Booking Holdings (BKNG), Qorvo (QRVO), The Allstate Corp. (ALL), MGM Resorts International (MGM), $Take-Two Interactive Software(TTWO)$ (TTWO), Electronic Arts (EA), Vimeo (VMEO), Etsy (ETSY), GoDaddy (GDDY), Marathon Oil Corp. (MRO), Roku (ROKU), Qualcomm (QCOM) after market close\nThursday: Cigna (CI), Wayfair (W), ViacomCBS (VIAC), Nikola (NKLA), Duke Energy (DUK), Citrix Systems (CTXS), Regeneron Pharmaceuticals (REGN), Hanesbrands (HBI), Moderna (MRNA), Planet Fitness (PLNT), Vulcan Material (VMC), Kellogg (K), Square (SQ), Cloudflare (NET), Occidental Petroleum (OXY), Uber Technologies (UBER), American International Group (AIG), Shake Shack (SHAK), iHeartMedia (IHRT), Novavax (NVAX), IAC Interactive Corp. (IAC), Peloton (PTON), Dropbox (DBX), DataDog (DDOG), Pinterest (PINS), Skyworks Solutions (SWKS), Expedia (EXPE), Rocket Cos. (RKT), Live Nation Entertainment (LYV), Airbnb (ABNB)\nFriday: Wynn Resorts (WYNN), Dish Networks (DISH), Dominion Energy (D), DraftKings (DKNG), Goodyear Tire and Rubber (GT), Cinemark Holdings (CNK) before market open","news_type":1},"isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":820903135,"gmtCreate":1633334639752,"gmtModify":1633334640919,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820903135","repostId":"1145081858","repostType":4,"repost":{"id":"1145081858","pubTimestamp":1633271769,"share":"https://www.laohu8.com/m/news/1145081858?lang=&edition=full","pubTime":"2021-10-03 22:36","market":"us","language":"en","title":"Top Performing ETFs For September 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1145081858","media":"The Street","summary":"Energy funds dominate as the cyclical reflation trade returns.","content":"<p>September will almost certainly be a month that most equity investors would soon forget. The S&amp;P 500's (SPY) loss of 4% was the first monthly loss for the large-cap index since January 2021 and the biggest monthly loss since the March 2020 COVID bear market that saw a loss of 12%.</p>\n<p>Tech stocks, which investors have often sought out in times of uncertainty, performed even worse by falling 6%. Long-term Treasuries also fell by more than 2% creating one of those unusual environments where stocks and bonds were both falling at the same time. It's essentially a reversal of the behavior we saw after the March interest rate peak where both groups actually gained more than 10% at the same time.</p>\n<p>One group that didn't suffer, however, was energy. Not every cyclical sector enjoyed the same success - industrials and materials have still been laggards - but the broad energy sector gained more than 10%. A few factors are at play here. OPEC has been hesitant to fully open up the crude oil production floodgates and that's helped keep the supply/demand curve imbalanced. It's gotten to the point now where there is a legitimate energy supply crunch that could last into the winter months. Energy prices are skyrocketing and that's been good for explorers and drillers, but it's creating a mini-crisis worldwide that could take some time to unwind. Add in the ongoing supply chain bottlenecks and we've got an unstable macro backdrop.</p>\n<p>Global energy demand, however, is expected to continue looking strong, especially as we get closer to the holiday travel season. The Fed has essentially confirmed that the U.S. economic recovery (with a few hiccups) is mostly on track to the point where the central bank is likely going to begin withdrawing some of its support later this year. The government's inability to reach a resolution on the debt ceiling about two weeks before it's scheduled to run out of money will likely add to volatility in the 4th quarter and the struggles for U.S. equities reflect a lack of optimism.</p>\n<p>Here's the list of the top performing ETFs for the month of September 2021.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b98338b73b9e0d8cbbf746866e4dd038\" tg-width=\"1200\" tg-height=\"404\" width=\"100%\" height=\"auto\"><span>Top Performing ETFs for September 2021</span></p>\n<p>Every ETF on this list, with the exception of only a few, are tied to the energy sector in some way. Energy prices, crude oil and natural gas in particular, have been rising quickly and that's reflected in the gains of commodity-linked products, including the<b>United States Natural Gas Fund (UNG)</b>, the<b>United States 12 Month Natural Gas Fund (UNL)</b>, the<b>United States Brent Oil Fund (BNO)</b>, the<b>Invesco DB Oil Fund (DBO)</b>, the<b>United States Oil Fund (USO)</b>, the<b>Invesco DB Energy Fund (DBE)</b>and the<b>United States 12 Month Oil Fund (USL)</b>. In case you were wondering, the \"12 month\" funds spread out their exposures to contracts with expirations from 1 to 12 months out. The others, at least before the energy market crash last year, mostly focused on the nearest-month expiration contracts but have since expanded their strategies to avoid the chances such a debacle happens again. Natural gas prices, in particular, have been taking off as some forecasters have begun predicting a cold snap for this winter. Crude oil prices are settled in around $75 a barrel today, but a spike towards $100, while unlikely, is still not out of the question.</p>\n<p>On the equity side, we've got all sorts of funds focused on specific areas of the energy space and the broad sector in general. The<b>Energy Select Sector SPDR ETF (XLE)</b>is the biggest name, but the<b>Invesco S&amp;P 500 Equal Weight Energy ETF (RYE)</b>, the<b>Fidelity MSCI Energy ETF (FENY)</b>, the<b>Vanguard Energy ETF (VDE)</b>and the<b>iShares Energy ETF (IYE)</b>are all represented with gains of at least 8%.</p>\n<p>The explorers were the best performing subgroup to be found within energy, but clean energy ETFs are nowhere to be found. Among the winners: the<b>VanEck Vectors Unconventional Oil &amp; Gas ETF (FRAK)</b>, the<b>Invesco Dynamic Energy Exploration &amp; Production ETF (PXE)</b>, the<b>SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production ETF (XOP)</b>and the<b>iShares U.S. Oil &amp; Gas Explorers &amp; Producers ETF (IEO)</b>all delivered gains of at least 15% on the month.</p>\n<p>A fund that has made regular appearances on both the top and performing ETF lists, the<b>Breakwave Dry Bulk Shipping ETF (BDRY)</b>, is back on the leaderboard again with a 27% gain. Supply chain issues, again, are the main driver as ships still remain stranded in harbors for weeks at a time waiting to dock and delivery their loads. Shipping issues, which were originally expected to be only short-term in nature, I think could easily last into summer 2022 or beyond. Shipping costs are likely to remain sky high and that could play into BDRY's hands, but expect a LOT of volatility in this fund for a while.</p>\n<p>Other ETFs worth noting:</p>\n<p>Uranium ETFs have taken advantage of soaring prices over the past two months. The price of an ounce of uranium went from $30 in mid-August to as high as $50 recently before pulling back to its current level around $43. The<b>Global X Uranium ETF (URA)</b>is the best-known name of the group, returning more than 13%, but the<b>North Shore Global Uranium Mining ETF (URNM)</b>, a fund that has been around for nearly 2 years but is comparatively smaller, was the bigger winner logging a 22% return.</p>\n<p>China ETFs have done poorly,but that didn't stop the<b>Global X MSCI China Utilities ETF (CHIU)</b>from logging a 10% gain. The outperformance of a defensive sector, such as utilities, isn't surprising but the degree of outperformance perhaps is. CHIU nearly matched the monthly performance of the<b>Global X MSCI China Energy ETF (CHIE)</b>in September.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Performing ETFs For September 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Performing ETFs For September 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-03 22:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/etffocus/market-intelligence/top-performing-etfs-for-september-2021><strong>The Street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>September will almost certainly be a month that most equity investors would soon forget. The S&P 500's (SPY) loss of 4% was the first monthly loss for the large-cap index since January 2021 and the ...</p>\n\n<a href=\"https://www.thestreet.com/etffocus/market-intelligence/top-performing-etfs-for-september-2021\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XOP":"油气开采指数ETF-SPDR S&P","UNG":"美国天然气基金","USO":"美国原油ETF","UNL":"United States 12 Month Natural Gas Fund LP"},"source_url":"https://www.thestreet.com/etffocus/market-intelligence/top-performing-etfs-for-september-2021","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1145081858","content_text":"September will almost certainly be a month that most equity investors would soon forget. The S&P 500's (SPY) loss of 4% was the first monthly loss for the large-cap index since January 2021 and the biggest monthly loss since the March 2020 COVID bear market that saw a loss of 12%.\nTech stocks, which investors have often sought out in times of uncertainty, performed even worse by falling 6%. Long-term Treasuries also fell by more than 2% creating one of those unusual environments where stocks and bonds were both falling at the same time. It's essentially a reversal of the behavior we saw after the March interest rate peak where both groups actually gained more than 10% at the same time.\nOne group that didn't suffer, however, was energy. Not every cyclical sector enjoyed the same success - industrials and materials have still been laggards - but the broad energy sector gained more than 10%. A few factors are at play here. OPEC has been hesitant to fully open up the crude oil production floodgates and that's helped keep the supply/demand curve imbalanced. It's gotten to the point now where there is a legitimate energy supply crunch that could last into the winter months. Energy prices are skyrocketing and that's been good for explorers and drillers, but it's creating a mini-crisis worldwide that could take some time to unwind. Add in the ongoing supply chain bottlenecks and we've got an unstable macro backdrop.\nGlobal energy demand, however, is expected to continue looking strong, especially as we get closer to the holiday travel season. The Fed has essentially confirmed that the U.S. economic recovery (with a few hiccups) is mostly on track to the point where the central bank is likely going to begin withdrawing some of its support later this year. The government's inability to reach a resolution on the debt ceiling about two weeks before it's scheduled to run out of money will likely add to volatility in the 4th quarter and the struggles for U.S. equities reflect a lack of optimism.\nHere's the list of the top performing ETFs for the month of September 2021.\nTop Performing ETFs for September 2021\nEvery ETF on this list, with the exception of only a few, are tied to the energy sector in some way. Energy prices, crude oil and natural gas in particular, have been rising quickly and that's reflected in the gains of commodity-linked products, including theUnited States Natural Gas Fund (UNG), theUnited States 12 Month Natural Gas Fund (UNL), theUnited States Brent Oil Fund (BNO), theInvesco DB Oil Fund (DBO), theUnited States Oil Fund (USO), theInvesco DB Energy Fund (DBE)and theUnited States 12 Month Oil Fund (USL). In case you were wondering, the \"12 month\" funds spread out their exposures to contracts with expirations from 1 to 12 months out. The others, at least before the energy market crash last year, mostly focused on the nearest-month expiration contracts but have since expanded their strategies to avoid the chances such a debacle happens again. Natural gas prices, in particular, have been taking off as some forecasters have begun predicting a cold snap for this winter. Crude oil prices are settled in around $75 a barrel today, but a spike towards $100, while unlikely, is still not out of the question.\nOn the equity side, we've got all sorts of funds focused on specific areas of the energy space and the broad sector in general. TheEnergy Select Sector SPDR ETF (XLE)is the biggest name, but theInvesco S&P 500 Equal Weight Energy ETF (RYE), theFidelity MSCI Energy ETF (FENY), theVanguard Energy ETF (VDE)and theiShares Energy ETF (IYE)are all represented with gains of at least 8%.\nThe explorers were the best performing subgroup to be found within energy, but clean energy ETFs are nowhere to be found. Among the winners: theVanEck Vectors Unconventional Oil & Gas ETF (FRAK), theInvesco Dynamic Energy Exploration & Production ETF (PXE), theSPDR S&P Oil & Gas Exploration & Production ETF (XOP)and theiShares U.S. Oil & Gas Explorers & Producers ETF (IEO)all delivered gains of at least 15% on the month.\nA fund that has made regular appearances on both the top and performing ETF lists, theBreakwave Dry Bulk Shipping ETF (BDRY), is back on the leaderboard again with a 27% gain. Supply chain issues, again, are the main driver as ships still remain stranded in harbors for weeks at a time waiting to dock and delivery their loads. Shipping issues, which were originally expected to be only short-term in nature, I think could easily last into summer 2022 or beyond. Shipping costs are likely to remain sky high and that could play into BDRY's hands, but expect a LOT of volatility in this fund for a while.\nOther ETFs worth noting:\nUranium ETFs have taken advantage of soaring prices over the past two months. The price of an ounce of uranium went from $30 in mid-August to as high as $50 recently before pulling back to its current level around $43. TheGlobal X Uranium ETF (URA)is the best-known name of the group, returning more than 13%, but theNorth Shore Global Uranium Mining ETF (URNM), a fund that has been around for nearly 2 years but is comparatively smaller, was the bigger winner logging a 22% return.\nChina ETFs have done poorly,but that didn't stop theGlobal X MSCI China Utilities ETF (CHIU)from logging a 10% gain. The outperformance of a defensive sector, such as utilities, isn't surprising but the degree of outperformance perhaps is. CHIU nearly matched the monthly performance of theGlobal X MSCI China Energy ETF (CHIE)in September.","news_type":1},"isVote":1,"tweetType":1,"viewCount":150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867629576,"gmtCreate":1633256670125,"gmtModify":1633256671346,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/867629576","repostId":"1195986801","repostType":4,"repost":{"id":"1195986801","pubTimestamp":1633237941,"share":"https://www.laohu8.com/m/news/1195986801?lang=&edition=full","pubTime":"2021-10-03 13:12","market":"hk","language":"en","title":"Why Tesla's Q3 Numbers Are 'Eye Popping' and Hard to Poke Holes In","url":"https://stock-news.laohu8.com/highlight/detail?id=1195986801","media":"Benzinga","summary":"Tesla, Inc. reported Saturday record quarterly deliveries despite the surrounding turbulence. An analyst at Wedbush Securities sees the performance as \"massive.\". The Tesla Analyst:Daniel Ives maintained an Outperform rating and $1,000 price target for Tesla shares.The Tesla Thesis:Tesla's third-quarter deliveries of 241,000 beat even the bull-case whisper number on the Street, analyst Ives said in a note. The strength, the analyst said, was driven byrobust Model 3/Y salesof 232, 000.Total produ","content":"<p><b>Tesla, Inc.</b>&nbsp;reported&nbsp;Saturday record quarterly deliveries despite the surrounding turbulence. An analyst at Wedbush Securities sees the performance as \"massive.\"</p>\n<p><b>The Tesla Analyst:</b>Daniel Ives maintained an Outperform rating and $1,000 price target for Tesla shares.</p>\n<p><b>The Tesla Thesis:</b>Tesla's third-quarter deliveries of 241,000 beat even the bull-case whisper number on the Street, analyst Ives said in a note. The strength, the analyst said, was driven byrobust Model 3/Y salesof 232, 000.</p>\n<p>Total production in the quarter was 238,000, about 10,000 ahead of Wedbush's and Street estimates, the analyst said.</p>\n<p>\"Taking a step back, with the chip shortage a major overhang on the auto space and logistical issues globally, these delivery numbers were \"eye-popping\" and speak&nbsp;to an EV demand trajectory that looks quite robust for Tesla heading into 4Q and 2022,\" Ives wrote in the note.</p>\n<p>Wedbush's estimate of 150,000 deliveries for September, according to the analyst, is a clear indicator of the green tidal wave taking hold for Tesla across the board. China demand may have rebounded in the quarter and will be a focus for the bulls digesting these results, he added.</p>\n<p>\"In a nutshell, these numbers are hard to poke holes in and will be a major feather in the cap for the bulls on Monday morning and should improve broader sentiment on the EV space as a whole,\" Wedbush said.</p>\n<p><b>Tesla Price Action:</b>Tesla shares closed Friday's session down 0.03% at $775.22 and were down an incremental 0.03% in after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Tesla's Q3 Numbers Are 'Eye Popping' and Hard to Poke Holes In</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Tesla's Q3 Numbers Are 'Eye Popping' and Hard to Poke Holes In\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-03 13:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-ratings/analyst-color/21/10/23207870/why-teslas-q3-numbers-are-eye-popping-and-hard-to-poke-holes-in><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla, Inc. reported Saturday record quarterly deliveries despite the surrounding turbulence. An analyst at Wedbush Securities sees the performance as \"massive.\"\nThe Tesla Analyst:Daniel Ives ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/21/10/23207870/why-teslas-q3-numbers-are-eye-popping-and-hard-to-poke-holes-in\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.benzinga.com/analyst-ratings/analyst-color/21/10/23207870/why-teslas-q3-numbers-are-eye-popping-and-hard-to-poke-holes-in","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195986801","content_text":"Tesla, Inc. reported Saturday record quarterly deliveries despite the surrounding turbulence. An analyst at Wedbush Securities sees the performance as \"massive.\"\nThe Tesla Analyst:Daniel Ives maintained an Outperform rating and $1,000 price target for Tesla shares.\nThe Tesla Thesis:Tesla's third-quarter deliveries of 241,000 beat even the bull-case whisper number on the Street, analyst Ives said in a note. The strength, the analyst said, was driven byrobust Model 3/Y salesof 232, 000.\nTotal production in the quarter was 238,000, about 10,000 ahead of Wedbush's and Street estimates, the analyst said.\n\"Taking a step back, with the chip shortage a major overhang on the auto space and logistical issues globally, these delivery numbers were \"eye-popping\" and speak to an EV demand trajectory that looks quite robust for Tesla heading into 4Q and 2022,\" Ives wrote in the note.\nWedbush's estimate of 150,000 deliveries for September, according to the analyst, is a clear indicator of the green tidal wave taking hold for Tesla across the board. China demand may have rebounded in the quarter and will be a focus for the bulls digesting these results, he added.\n\"In a nutshell, these numbers are hard to poke holes in and will be a major feather in the cap for the bulls on Monday morning and should improve broader sentiment on the EV space as a whole,\" Wedbush said.\nTesla Price Action:Tesla shares closed Friday's session down 0.03% at $775.22 and were down an incremental 0.03% in after-hours trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862381651,"gmtCreate":1632837762506,"gmtModify":1632837762782,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862381651","repostId":"2170672462","repostType":4,"repost":{"id":"2170672462","pubTimestamp":1632835246,"share":"https://www.laohu8.com/m/news/2170672462?lang=&edition=full","pubTime":"2021-09-28 21:20","market":"us","language":"en","title":"Got $1,000? 5 Perfect Stocks to Buy for the Fourth Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2170672462","media":"Motley Fool","summary":"Bargains can still be found, even with the broader market near an all-time high.","content":"<p>If investors thought the coronavirus crash was historic, the bounce-back rally from the March 2020 bottom has been even more impressive. The benchmark <b>S&amp;P 500</b> took less than 17 months to double from its lows, and it's now gone 10 months without so much as a 5% downside correction. Patience is truly paying off for long-term investors.</p>\n<p>But just because the broader market is a stone's throw from a record high doesn't mean investors can't still find bargains. If you've got $1,000 ready to invest, which won't be needed for bill or emergencies, the following five stocks would make for perfect buys for the fourth quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8cf8fd6cbc9120f885acecdfb00d5835\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Novavax</h2>\n<p>While I'm generally not a fan of chasing the coronavirus stocks after they've catapulted into the stratosphere, clinical-stage biotech stock <b>Novavax</b> (NASDAQ:NVAX) is the rare exception. It's unlikely to remain a clinical-stage company for much longer and could offer clear advantages that'll help it become a top vaccine player.</p>\n<p>The company's coronavirus disease 2019 (COVID-19) vaccine, NVX-CoV2373, led to an 89.7% vaccine efficacy (VE) in a large-scale trial in the U.K. earlier this year, and it produced a nearly identical 90.4% VE in a large-scale trial in the U.S. and Mexico in June. This initial efficacy, coupled with the less-than-stellar uptake from <b>AstraZeneca</b>'s and <b>Johnson &amp; Johnson</b>'s COVID-19 vaccines, should open the door for Novavax to become the No. 3 player in developed markets.</p>\n<p>Also working in Novavax's favor is the mutability of the SARS-CoV-2 virus that causes COVID-19. Novavax's drug-development platform is capable of quickly bringing variant-specific vaccines to trial, if necessary. The company could also benefit from the need for booster shots, depending on how long vaccine-based immunity lasts.</p>\n<p>Novavax has an opportunity to beat its peers to market with a combination COVID-19/influenza vaccine, as well. This could be a differentiating vaccine that really allows the company to stand out.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d9e4dd60375f8f383f0c222a7633a4\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Exelixis</h2>\n<p>Biotech stocks are a common theme on this list of perfect stocks to buy for the fourth quarter. Cancer drug developer <b>Exelixis</b> (NASDAQ:EXEL) offers the right blend of growth and value to make patient investors richer.</p>\n<p>The superstar for Exelixis continues to be cancer drug Cabometyx, which derives the bulk of its sales from its first-and-second-line approvals in renal cell carcinoma (RCC) and its approval to treat advanced hepatocellular carcinoma. These indications should help Cabometyx top $1 billion in recurring sales either this year or 2022.</p>\n<p>The only reason this company is as inexpensive as it is now -- 21 times forward-year earnings for sustainable mid-teens sales growth -- is the disappointing update from the Cosmic-312 trial. Though the combination of Cabometyx and atezolizumab led to a statistically significant improvement in progression-free survival for previously untreated liver cancer patients, Exelixis notes that it's unlikely to demonstrate a statistically significant improvement in overall survival by trial completion in early 2022.</p>\n<p>While this might sound like a disappointment, it isn't. It's par for the course when developing blockbuster cancer drugs. Cabometyx failed in a late-stage study targeted at prostate cancer patients in 2014 but has since bounced back to gain numerous approvals. With this key drug being examined in close to six dozen clinical trials, label expansion opportunities remain abundant for Exelixis.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e5596b9cd58d43ee65824bd7892b9c5e\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Broadcom</h2>\n<p>Stepping outside the healthcare arena for the moment, semiconductor solutions provider <b>Broadcom</b> (NASDAQ:AVGO) is a perfect stock to put $1,000 to work in for the fourth quarter. I say \"perfect,\" because Broadcom is at the center of two very sustainable growth trends.</p>\n<p>First, it's going to be a multiyear beneficiary of the rollout of 5G wireless infrastructure. A majority of Broadcom's revenue comes from wireless chips and other accessories found in smartphones. Because it's been a decade since consumers and businesses have benefited from an upgrade to wireless download speeds, the expectation is that we'll see a sustainable, multiyear device replacement cycle. This should allow Broadcom to lock in its orders months or years in advance.</p>\n<p>But it's not just smartphones that should have investors excited about Broadcom. The pandemic has also accelerated the shift of enterprise and consumer data into the cloud. This means data center demand should be strong for a long time to come. Broadcom is a provider of connectivity and access chips used by enterprise data centers.</p>\n<p>The icing on the cake here is that the company has grown its quarterly dividend by more than 5,000% in less than 11 years. Investors can collect a nearly 3% yield as they sit back and watch Broadcom's profitability climb.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2fc0013108c05865a77a8fa2e9b54b23\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Vertex Pharmaceuticals</h2>\n<p>Similar to Exelixis, specialty biotech stock <b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) offers the right blend of double-digit sales growth and insane value (a forward-year price-to-earnings ratio of only 14), which makes it a no-brainer buy for the fourth quarter.</p>\n<p>What allows Vertex to stand out is its overwhelming success in developing multiple generations of treatments for patients with cystic fibrosis (CF). CF is a genetic disease characterized by thick mucus production that can obstruct the pancreas and/or lungs. Vertex's latest treatment, combination therapy Trikafta, was approved five months ahead of the U.S. Food and Drug Administration's review date, and is pacing $5 billion in annual run-rate sales despite hitting pharmacy shelves less than two years ago.</p>\n<p>Keeping with the similarities to Exelixis, Vertex was hit hard twice over the past year after two separate experimental treatments targeting alpha-1 antitrypsin deficiency were discontinued in mid-stage trials. Nevertheless, Vertex has more than a half-dozen combined internal and out-licensed treatments in development for a variety of indications. Even though its CF franchise is well-protected from competition, the company is working on an expansive pipeline of products.</p>\n<p>And don't overlook Vertex's cash pile. It ended June with about $6.7 billion in cash and cash equivalents, which is more than enough to fuel internal development, fund novel partnerships, or make acquisitions.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/39a1727edeb0317fbc6386d8981fd8e0\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>Teladoc Health</h2>\n<p>Lastly, buying shares of telemedicine kingpin <b>Teladoc Health</b> (NYSE:TDOC) would be a perfect use of $1,000 for the fourth quarter.</p>\n<p>When the pandemic hit, there's no sugarcoating that Teladoc was in the right place at the right time. With doctors wanting to keep potentially sick and high-risk people out of their offices, they regularly turned to virtual visit platforms, such as those offered by Teladoc. Last year, Teladoc handled almost 10.6 million visits, which was well over double the 4.14 million visits in 2019.</p>\n<p>Some skeptics have cautioned that Teladoc could be a one-hit wonder considering the worst of the pandemic may now be in the rearview mirror. However, this view overlooks the many lasting changes telemedicine brings to the table. It's far more convenient for patients, can allow doctors to keep better tabs on their chronic-care patients, and should result in better patient outcomes and lower total treatment costs for insurers. There's a reason Teladoc's annual sales growth averaged 74% in the six years leading up to the pandemic.</p>\n<p>Teladoc Health also acquired the nation's leading applied health signals company, Livongo Health, in the fourth quarter of 2020. Livongo leans on artificial intelligence to send tips to its chronic-care members to help them lead healthier lives. While most of Livongo' 715,000 chronic-care enrollees are diabetics, it aims to offer its services to those with weight management issues and hypertension, as well. In other words, we're watching the very early innings of a personalized care disruptor.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? 5 Perfect Stocks to Buy for the Fourth Quarter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? 5 Perfect Stocks to Buy for the Fourth Quarter\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 21:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/got-1000-5-perfect-stocks-buy-for-fourth-quarter/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If investors thought the coronavirus crash was historic, the bounce-back rally from the March 2020 bottom has been even more impressive. The benchmark S&P 500 took less than 17 months to double from ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/got-1000-5-perfect-stocks-buy-for-fourth-quarter/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药","AVGO":"博通","TDOC":"Teladoc Health Inc.","NVAX":"诺瓦瓦克斯医药","EXEL":"伊克力西斯"},"source_url":"https://www.fool.com/investing/2021/09/28/got-1000-5-perfect-stocks-buy-for-fourth-quarter/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170672462","content_text":"If investors thought the coronavirus crash was historic, the bounce-back rally from the March 2020 bottom has been even more impressive. The benchmark S&P 500 took less than 17 months to double from its lows, and it's now gone 10 months without so much as a 5% downside correction. Patience is truly paying off for long-term investors.\nBut just because the broader market is a stone's throw from a record high doesn't mean investors can't still find bargains. If you've got $1,000 ready to invest, which won't be needed for bill or emergencies, the following five stocks would make for perfect buys for the fourth quarter.\nImage source: Getty Images.\nNovavax\nWhile I'm generally not a fan of chasing the coronavirus stocks after they've catapulted into the stratosphere, clinical-stage biotech stock Novavax (NASDAQ:NVAX) is the rare exception. It's unlikely to remain a clinical-stage company for much longer and could offer clear advantages that'll help it become a top vaccine player.\nThe company's coronavirus disease 2019 (COVID-19) vaccine, NVX-CoV2373, led to an 89.7% vaccine efficacy (VE) in a large-scale trial in the U.K. earlier this year, and it produced a nearly identical 90.4% VE in a large-scale trial in the U.S. and Mexico in June. This initial efficacy, coupled with the less-than-stellar uptake from AstraZeneca's and Johnson & Johnson's COVID-19 vaccines, should open the door for Novavax to become the No. 3 player in developed markets.\nAlso working in Novavax's favor is the mutability of the SARS-CoV-2 virus that causes COVID-19. Novavax's drug-development platform is capable of quickly bringing variant-specific vaccines to trial, if necessary. The company could also benefit from the need for booster shots, depending on how long vaccine-based immunity lasts.\nNovavax has an opportunity to beat its peers to market with a combination COVID-19/influenza vaccine, as well. This could be a differentiating vaccine that really allows the company to stand out.\nImage source: Getty Images.\nExelixis\nBiotech stocks are a common theme on this list of perfect stocks to buy for the fourth quarter. Cancer drug developer Exelixis (NASDAQ:EXEL) offers the right blend of growth and value to make patient investors richer.\nThe superstar for Exelixis continues to be cancer drug Cabometyx, which derives the bulk of its sales from its first-and-second-line approvals in renal cell carcinoma (RCC) and its approval to treat advanced hepatocellular carcinoma. These indications should help Cabometyx top $1 billion in recurring sales either this year or 2022.\nThe only reason this company is as inexpensive as it is now -- 21 times forward-year earnings for sustainable mid-teens sales growth -- is the disappointing update from the Cosmic-312 trial. Though the combination of Cabometyx and atezolizumab led to a statistically significant improvement in progression-free survival for previously untreated liver cancer patients, Exelixis notes that it's unlikely to demonstrate a statistically significant improvement in overall survival by trial completion in early 2022.\nWhile this might sound like a disappointment, it isn't. It's par for the course when developing blockbuster cancer drugs. Cabometyx failed in a late-stage study targeted at prostate cancer patients in 2014 but has since bounced back to gain numerous approvals. With this key drug being examined in close to six dozen clinical trials, label expansion opportunities remain abundant for Exelixis.\nImage source: Getty Images.\nBroadcom\nStepping outside the healthcare arena for the moment, semiconductor solutions provider Broadcom (NASDAQ:AVGO) is a perfect stock to put $1,000 to work in for the fourth quarter. I say \"perfect,\" because Broadcom is at the center of two very sustainable growth trends.\nFirst, it's going to be a multiyear beneficiary of the rollout of 5G wireless infrastructure. A majority of Broadcom's revenue comes from wireless chips and other accessories found in smartphones. Because it's been a decade since consumers and businesses have benefited from an upgrade to wireless download speeds, the expectation is that we'll see a sustainable, multiyear device replacement cycle. This should allow Broadcom to lock in its orders months or years in advance.\nBut it's not just smartphones that should have investors excited about Broadcom. The pandemic has also accelerated the shift of enterprise and consumer data into the cloud. This means data center demand should be strong for a long time to come. Broadcom is a provider of connectivity and access chips used by enterprise data centers.\nThe icing on the cake here is that the company has grown its quarterly dividend by more than 5,000% in less than 11 years. Investors can collect a nearly 3% yield as they sit back and watch Broadcom's profitability climb.\nImage source: Getty Images.\nVertex Pharmaceuticals\nSimilar to Exelixis, specialty biotech stock Vertex Pharmaceuticals (NASDAQ:VRTX) offers the right blend of double-digit sales growth and insane value (a forward-year price-to-earnings ratio of only 14), which makes it a no-brainer buy for the fourth quarter.\nWhat allows Vertex to stand out is its overwhelming success in developing multiple generations of treatments for patients with cystic fibrosis (CF). CF is a genetic disease characterized by thick mucus production that can obstruct the pancreas and/or lungs. Vertex's latest treatment, combination therapy Trikafta, was approved five months ahead of the U.S. Food and Drug Administration's review date, and is pacing $5 billion in annual run-rate sales despite hitting pharmacy shelves less than two years ago.\nKeeping with the similarities to Exelixis, Vertex was hit hard twice over the past year after two separate experimental treatments targeting alpha-1 antitrypsin deficiency were discontinued in mid-stage trials. Nevertheless, Vertex has more than a half-dozen combined internal and out-licensed treatments in development for a variety of indications. Even though its CF franchise is well-protected from competition, the company is working on an expansive pipeline of products.\nAnd don't overlook Vertex's cash pile. It ended June with about $6.7 billion in cash and cash equivalents, which is more than enough to fuel internal development, fund novel partnerships, or make acquisitions.\nImage source: Getty Images.\nTeladoc Health\nLastly, buying shares of telemedicine kingpin Teladoc Health (NYSE:TDOC) would be a perfect use of $1,000 for the fourth quarter.\nWhen the pandemic hit, there's no sugarcoating that Teladoc was in the right place at the right time. With doctors wanting to keep potentially sick and high-risk people out of their offices, they regularly turned to virtual visit platforms, such as those offered by Teladoc. Last year, Teladoc handled almost 10.6 million visits, which was well over double the 4.14 million visits in 2019.\nSome skeptics have cautioned that Teladoc could be a one-hit wonder considering the worst of the pandemic may now be in the rearview mirror. However, this view overlooks the many lasting changes telemedicine brings to the table. It's far more convenient for patients, can allow doctors to keep better tabs on their chronic-care patients, and should result in better patient outcomes and lower total treatment costs for insurers. There's a reason Teladoc's annual sales growth averaged 74% in the six years leading up to the pandemic.\nTeladoc Health also acquired the nation's leading applied health signals company, Livongo Health, in the fourth quarter of 2020. Livongo leans on artificial intelligence to send tips to its chronic-care members to help them lead healthier lives. While most of Livongo' 715,000 chronic-care enrollees are diabetics, it aims to offer its services to those with weight management issues and hypertension, as well. In other words, we're watching the very early innings of a personalized care disruptor.","news_type":1},"isVote":1,"tweetType":1,"viewCount":14,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699335292,"gmtCreate":1639747930518,"gmtModify":1639747931645,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699335292","repostId":"1138605449","repostType":4,"repost":{"id":"1138605449","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639746084,"share":"https://www.laohu8.com/m/news/1138605449?lang=&edition=full","pubTime":"2021-12-17 21:01","market":"us","language":"en","title":"Toplines Before US Market Open on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1138605449","media":"Tiger Newspress","summary":"U.S. Stock futures headed for a lower open Friday morning after a rout in technology stocks during T","content":"<p>U.S.&nbsp;Stock futures headed for a lower open Friday morning after a rout in technology stocks during Thursday's regular trading day, as investors turned away from growth stocks in anticipation of tighter monetary policy next year.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were down 117 points, or 0.33%, S&amp;P 500 e-minis were down 24 points, or 0.52%, and Nasdaq 100 e-minis were down 153.5 points, or 0.97%.<img src=\"https://static.tigerbbs.com/120d112226a9ec4591babf844729ca58\" tg-width=\"1080\" tg-height=\"376\" width=\"100%\" height=\"auto\">Investors' main focus this week has remained fixed on the Federal Reserve's updated outlook on monetary policy for next year, with the central bank's projections delivered mid-week suggesting the Fed&nbsp;could hike interest rates three times next year.</p>\n<p><b>Stocks making the biggest moves premarket: </b></p>\n<p><b><a href=\"https://laohu8.com/S/DRI\">Darden Restaurants</a></b> – The parent of Olive Garden, Longhorn Steakhouse and other restaurant chains beat estimates by 5 cents with quarterly earnings of $1.48 per share and revenue that also topped forecasts. Same-restaurant sales jumped 34.4%, higher than the 32.6% consensus estimate compiled by StreetAccount, and Darden issued an upbeat forecast. Separately, Darden announced that CEO Eugene Lee will retire in May 2022, to be replaced by current President and Chief Operating Officer Ricardo Cardenas. Darden fell 5% in the premarket.</p>\n<p><b><a href=\"https://laohu8.com/S/WGO\">Winnebago</a></b> – The recreational vehicle maker added 3.4% in premarket trading after a sizable bottom-line beat for its fiscal first quarter. Winnebago earned $3.51 per share, compared with the consensus estimate of $2.26 and revenue that also came in above analyst forecasts.</p>\n<p><b><a href=\"https://laohu8.com/S/FDX\">FedEx</a></b> – The delivery service’s shares rallied 5.9% in the premarket after beating estimates on the top and bottom lines for its latest quarter. FedEx earned an adjusted $4.83 per share, beating the $4.28 consensus estimate, with higher shipping rates helping to make up for increased expenses.</p>\n<p><b><a href=\"https://laohu8.com/S/RIVN\">Rivian Automotive, Inc.</a></b> – The electric vehicle maker lost $1.23 billion for the third quarter stemming from expenses to begin production of its electric pickup truck. It was Rivian’s first quarterly report since going public, and revenue was $1 million from its first deliveries. The stock tumbled 7.9% in premarket trading.</p>\n<p><b><a href=\"https://laohu8.com/S/EPAY\">Bottomline</a></b> – Bottomline shares soared 15.1% in the premarket after the fintech company agreed to be acquired by private equity firm Thoma Bravo for $57 per share in cash, or $2.6 billion.</p>\n<p><b><a href=\"https://laohu8.com/S/CERN\">Cerner</a></b> – The healthcare information-technology company’s stock soared 18.9% in premarket trading after the Wall Street Journal reported that&nbsp;Oracle(ORCL) was in talks to buy Cerner in a potential $30 billion deal. Oracle fell 4.6%.</p>\n<p><b><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a></b> – <b><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a></b> shares fell 2.1% in the premarket after the CDC recommended that adults receive the&nbsp;Pfizer(PFE) or&nbsp;Moderna(MRNA) Covid-19 vaccines rather than the J&amp;J shot. The CDC cited new data showing higher levels of a blood clotting condition than previously thought, although that condition remains rare.</p>\n<p><b><a href=\"https://laohu8.com/S/AFRM\">Affirm Holdings, Inc.</a></b> – The “buy now pay later” company’s stock fell 2.3% in the premarket after the Consumer Financial Protection Bureau said it was launching an inquiry into firms that offer such plans.</p>\n<p><b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> – The drug maker’s stock rose 1.3% in premarket action on a Financial Times report that the European Medicines Agency may approve its Covid-19 vaccine for emergency use as early as next week.</p>\n<p><b><a href=\"https://laohu8.com/S/X\">U.S. Steel</a></b> – The steel maker’s stock slid 4.4% in the premarket after the company issued lower-than-expected current-quarter guidance, with higher expenses and cautious customer buying patterns offsetting improved steel pricing.</p>\n<p><b><a href=\"https://laohu8.com/S/SCS\">Steelcase</a></b> – The office furniture maker reported lower-than-expected profit and revenue for the third quarter, with Steelcase saying its results have been impacted by supply chain issues and higher costs. Steelcase fell 4.4% in premarket trading.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-17 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S.&nbsp;Stock futures headed for a lower open Friday morning after a rout in technology stocks during Thursday's regular trading day, as investors turned away from growth stocks in anticipation of tighter monetary policy next year.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were down 117 points, or 0.33%, S&amp;P 500 e-minis were down 24 points, or 0.52%, and Nasdaq 100 e-minis were down 153.5 points, or 0.97%.<img src=\"https://static.tigerbbs.com/120d112226a9ec4591babf844729ca58\" tg-width=\"1080\" tg-height=\"376\" width=\"100%\" height=\"auto\">Investors' main focus this week has remained fixed on the Federal Reserve's updated outlook on monetary policy for next year, with the central bank's projections delivered mid-week suggesting the Fed&nbsp;could hike interest rates three times next year.</p>\n<p><b>Stocks making the biggest moves premarket: </b></p>\n<p><b><a href=\"https://laohu8.com/S/DRI\">Darden Restaurants</a></b> – The parent of Olive Garden, Longhorn Steakhouse and other restaurant chains beat estimates by 5 cents with quarterly earnings of $1.48 per share and revenue that also topped forecasts. Same-restaurant sales jumped 34.4%, higher than the 32.6% consensus estimate compiled by StreetAccount, and Darden issued an upbeat forecast. Separately, Darden announced that CEO Eugene Lee will retire in May 2022, to be replaced by current President and Chief Operating Officer Ricardo Cardenas. Darden fell 5% in the premarket.</p>\n<p><b><a href=\"https://laohu8.com/S/WGO\">Winnebago</a></b> – The recreational vehicle maker added 3.4% in premarket trading after a sizable bottom-line beat for its fiscal first quarter. Winnebago earned $3.51 per share, compared with the consensus estimate of $2.26 and revenue that also came in above analyst forecasts.</p>\n<p><b><a href=\"https://laohu8.com/S/FDX\">FedEx</a></b> – The delivery service’s shares rallied 5.9% in the premarket after beating estimates on the top and bottom lines for its latest quarter. FedEx earned an adjusted $4.83 per share, beating the $4.28 consensus estimate, with higher shipping rates helping to make up for increased expenses.</p>\n<p><b><a href=\"https://laohu8.com/S/RIVN\">Rivian Automotive, Inc.</a></b> – The electric vehicle maker lost $1.23 billion for the third quarter stemming from expenses to begin production of its electric pickup truck. It was Rivian’s first quarterly report since going public, and revenue was $1 million from its first deliveries. The stock tumbled 7.9% in premarket trading.</p>\n<p><b><a href=\"https://laohu8.com/S/EPAY\">Bottomline</a></b> – Bottomline shares soared 15.1% in the premarket after the fintech company agreed to be acquired by private equity firm Thoma Bravo for $57 per share in cash, or $2.6 billion.</p>\n<p><b><a href=\"https://laohu8.com/S/CERN\">Cerner</a></b> – The healthcare information-technology company’s stock soared 18.9% in premarket trading after the Wall Street Journal reported that&nbsp;Oracle(ORCL) was in talks to buy Cerner in a potential $30 billion deal. Oracle fell 4.6%.</p>\n<p><b><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a></b> – <b><a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a></b> shares fell 2.1% in the premarket after the CDC recommended that adults receive the&nbsp;Pfizer(PFE) or&nbsp;Moderna(MRNA) Covid-19 vaccines rather than the J&amp;J shot. The CDC cited new data showing higher levels of a blood clotting condition than previously thought, although that condition remains rare.</p>\n<p><b><a href=\"https://laohu8.com/S/AFRM\">Affirm Holdings, Inc.</a></b> – The “buy now pay later” company’s stock fell 2.3% in the premarket after the Consumer Financial Protection Bureau said it was launching an inquiry into firms that offer such plans.</p>\n<p><b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> – The drug maker’s stock rose 1.3% in premarket action on a Financial Times report that the European Medicines Agency may approve its Covid-19 vaccine for emergency use as early as next week.</p>\n<p><b><a href=\"https://laohu8.com/S/X\">U.S. Steel</a></b> – The steel maker’s stock slid 4.4% in the premarket after the company issued lower-than-expected current-quarter guidance, with higher expenses and cautious customer buying patterns offsetting improved steel pricing.</p>\n<p><b><a href=\"https://laohu8.com/S/SCS\">Steelcase</a></b> – The office furniture maker reported lower-than-expected profit and revenue for the third quarter, with Steelcase saying its results have been impacted by supply chain issues and higher costs. Steelcase fell 4.4% in premarket trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138605449","content_text":"U.S. Stock futures headed for a lower open Friday morning after a rout in technology stocks during Thursday's regular trading day, as investors turned away from growth stocks in anticipation of tighter monetary policy next year.\nAt 8:00 a.m. ET, Dow e-minis were down 117 points, or 0.33%, S&P 500 e-minis were down 24 points, or 0.52%, and Nasdaq 100 e-minis were down 153.5 points, or 0.97%.Investors' main focus this week has remained fixed on the Federal Reserve's updated outlook on monetary policy for next year, with the central bank's projections delivered mid-week suggesting the Fed could hike interest rates three times next year.\nStocks making the biggest moves premarket: \nDarden Restaurants – The parent of Olive Garden, Longhorn Steakhouse and other restaurant chains beat estimates by 5 cents with quarterly earnings of $1.48 per share and revenue that also topped forecasts. Same-restaurant sales jumped 34.4%, higher than the 32.6% consensus estimate compiled by StreetAccount, and Darden issued an upbeat forecast. Separately, Darden announced that CEO Eugene Lee will retire in May 2022, to be replaced by current President and Chief Operating Officer Ricardo Cardenas. Darden fell 5% in the premarket.\nWinnebago – The recreational vehicle maker added 3.4% in premarket trading after a sizable bottom-line beat for its fiscal first quarter. Winnebago earned $3.51 per share, compared with the consensus estimate of $2.26 and revenue that also came in above analyst forecasts.\nFedEx – The delivery service’s shares rallied 5.9% in the premarket after beating estimates on the top and bottom lines for its latest quarter. FedEx earned an adjusted $4.83 per share, beating the $4.28 consensus estimate, with higher shipping rates helping to make up for increased expenses.\nRivian Automotive, Inc. – The electric vehicle maker lost $1.23 billion for the third quarter stemming from expenses to begin production of its electric pickup truck. It was Rivian’s first quarterly report since going public, and revenue was $1 million from its first deliveries. The stock tumbled 7.9% in premarket trading.\nBottomline – Bottomline shares soared 15.1% in the premarket after the fintech company agreed to be acquired by private equity firm Thoma Bravo for $57 per share in cash, or $2.6 billion.\nCerner – The healthcare information-technology company’s stock soared 18.9% in premarket trading after the Wall Street Journal reported that Oracle(ORCL) was in talks to buy Cerner in a potential $30 billion deal. Oracle fell 4.6%.\nJohnson & Johnson – Johnson & Johnson shares fell 2.1% in the premarket after the CDC recommended that adults receive the Pfizer(PFE) or Moderna(MRNA) Covid-19 vaccines rather than the J&J shot. The CDC cited new data showing higher levels of a blood clotting condition than previously thought, although that condition remains rare.\nAffirm Holdings, Inc. – The “buy now pay later” company’s stock fell 2.3% in the premarket after the Consumer Financial Protection Bureau said it was launching an inquiry into firms that offer such plans.\nNovavax – The drug maker’s stock rose 1.3% in premarket action on a Financial Times report that the European Medicines Agency may approve its Covid-19 vaccine for emergency use as early as next week.\nU.S. Steel – The steel maker’s stock slid 4.4% in the premarket after the company issued lower-than-expected current-quarter guidance, with higher expenses and cautious customer buying patterns offsetting improved steel pricing.\nSteelcase – The office furniture maker reported lower-than-expected profit and revenue for the third quarter, with Steelcase saying its results have been impacted by supply chain issues and higher costs. Steelcase fell 4.4% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":666,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690608287,"gmtCreate":1639660378795,"gmtModify":1639660378795,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Hmmmm","listText":"Hmmmm","text":"Hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690608287","repostId":"1142996286","repostType":4,"repost":{"id":"1142996286","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639659703,"share":"https://www.laohu8.com/m/news/1142996286?lang=&edition=full","pubTime":"2021-12-16 21:01","market":"us","language":"en","title":"Toplines Before US Market Open on Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1142996286","media":"Tiger Newspress","summary":"U.S. stock-index futures advanced Thursday morning after the market staged a U-turn the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.$Delta Air Lines$ – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-","content":"<p>U.S.&nbsp;stock-index futures advanced Thursday morning after&nbsp;the market staged a U-turn&nbsp;the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 204 points, or 0.57%, S&amp;P 500 e-minis were up 31.25 points, or 0.66%, and Nasdaq 100 e-minis were up 115.25 points, or 0.71%.<img src=\"https://static.tigerbbs.com/6e8a71c62338c2a045263d40bb9c86e4\" tg-width=\"1080\" tg-height=\"368\" width=\"100%\" height=\"auto\">With the Fed giving markets a breather Wednesday, traders will turn their Thursday to&nbsp;fresh Labor Department data on initial weekly jobless claims. First-time unemployment filings are expected to reflect a slight increase after&nbsp;last’s 52-week low.</p>\n<p><b>Stocks making the biggest moves premarket: </b></p>\n<p><b><a href=\"https://laohu8.com/S/DAL\">Delta Air Lines</a></b> – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-pandemic profit levels.</p>\n<p><b><a href=\"https://laohu8.com/S/ACN\">Accenture PLC</a></b> – The consulting firm’s shares surged 6.7% in the premarket after it reported better-than-expected profit and revenue for its latest quarter, and raised its earnings guidance for fiscal 2022. Revenue rose by more than 20% across the four biggest industry groups in Accenture’s customer base.</p>\n<p><b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> – The drugmaker’s shares declined 1% in premarket trading after it said its antibody cocktail loses potency against the omicron Covid-19 variant. Regeneron did say that the cocktail is effective against the delta variant.</p>\n<p><b><a href=\"https://laohu8.com/S/LEN\">Lennar</a></b> – Lennar reported quarterly earnings of $3.91 per share, below the $4.15 consensus estimate, and the homebuilder’s revenue also fell short of forecasts. Lennar was hurt by higher lumber costs as well as increased labor costs and shortages of raw materials, resulting in delayed home deliveries. Lennar tumbled 6.3% in premarket action.</p>\n<p><b><a href=\"https://laohu8.com/S/NVS\">Novartis AG</a></b> – Novartis launched a new share buyback program worth up to $15 billion, with the drug maker planning to complete those repurchases by the end of 2023. Shares jumped 4% in premarket trading.</p>\n<p><b><a href=\"https://laohu8.com/S/V\">Visa</a>&nbsp;</b>– <a href=\"https://laohu8.com/S/V\">Visa</a> rose 1.1% in the premarket after announcing that it added $12 billion to its share buyback program, bringing the total amount of its repurchase authority to $13.2 billion.</p>\n<p><b><a href=\"https://laohu8.com/S/SJM\">Smucker's</a> </b>– Smucker struck a deal to sell its natural beverage and grains businesses to private equity firm Nexus Capital Management for $110 million, with the food producer saying it wanted to focus more resources on its core brands.</p>\n<p><b><a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> </b>– <a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> was added to the “conviction buy” list at Goldman Sachs, which points to the company’s pending launch of a new surgical system. Shares added 1.2% in the premarket.</p>\n<p><b><a href=\"https://laohu8.com/S/T\">AT&amp;T Inc</a> </b>– Morgan Stanley upgraded AT&amp;T to “overweight” from “equal-weight,” saying a recent slide by the stock creates an attractive risk-reward profile. The firm said there are several other key factors driving the upgrade, including the pending completion of the WarnerMedia/Discoverymerger. AT&amp;T gained 1.5% in premarket trading.</p>\n<p><b><a href=\"https://laohu8.com/S/WOOF\">Petco Health and Wellness Company, Inc.</a> </b>– The pet products seller’s stock added 1.9% in the premarket after Needham began coverage with a “buy” rating. The firm feels Petco should outperform competitors in the pet category, given its presence in multiple channels including veterinary hospitals.</p>\n<p><b><a href=\"https://laohu8.com/S/SHOP\">Shopify</a> </b>– The e-commerce platform operator rallied 2.9% in premarket trading after Evercore upgraded it to “outperform” from “in line.” Evercore noted that the stock is about 20% below its year highs and that the company represents a high-quality asset in terms of growth opportunities.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-16 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S.&nbsp;stock-index futures advanced Thursday morning after&nbsp;the market staged a U-turn&nbsp;the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 204 points, or 0.57%, S&amp;P 500 e-minis were up 31.25 points, or 0.66%, and Nasdaq 100 e-minis were up 115.25 points, or 0.71%.<img src=\"https://static.tigerbbs.com/6e8a71c62338c2a045263d40bb9c86e4\" tg-width=\"1080\" tg-height=\"368\" width=\"100%\" height=\"auto\">With the Fed giving markets a breather Wednesday, traders will turn their Thursday to&nbsp;fresh Labor Department data on initial weekly jobless claims. First-time unemployment filings are expected to reflect a slight increase after&nbsp;last’s 52-week low.</p>\n<p><b>Stocks making the biggest moves premarket: </b></p>\n<p><b><a href=\"https://laohu8.com/S/DAL\">Delta Air Lines</a></b> – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-pandemic profit levels.</p>\n<p><b><a href=\"https://laohu8.com/S/ACN\">Accenture PLC</a></b> – The consulting firm’s shares surged 6.7% in the premarket after it reported better-than-expected profit and revenue for its latest quarter, and raised its earnings guidance for fiscal 2022. Revenue rose by more than 20% across the four biggest industry groups in Accenture’s customer base.</p>\n<p><b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> – The drugmaker’s shares declined 1% in premarket trading after it said its antibody cocktail loses potency against the omicron Covid-19 variant. Regeneron did say that the cocktail is effective against the delta variant.</p>\n<p><b><a href=\"https://laohu8.com/S/LEN\">Lennar</a></b> – Lennar reported quarterly earnings of $3.91 per share, below the $4.15 consensus estimate, and the homebuilder’s revenue also fell short of forecasts. Lennar was hurt by higher lumber costs as well as increased labor costs and shortages of raw materials, resulting in delayed home deliveries. Lennar tumbled 6.3% in premarket action.</p>\n<p><b><a href=\"https://laohu8.com/S/NVS\">Novartis AG</a></b> – Novartis launched a new share buyback program worth up to $15 billion, with the drug maker planning to complete those repurchases by the end of 2023. Shares jumped 4% in premarket trading.</p>\n<p><b><a href=\"https://laohu8.com/S/V\">Visa</a>&nbsp;</b>– <a href=\"https://laohu8.com/S/V\">Visa</a> rose 1.1% in the premarket after announcing that it added $12 billion to its share buyback program, bringing the total amount of its repurchase authority to $13.2 billion.</p>\n<p><b><a href=\"https://laohu8.com/S/SJM\">Smucker's</a> </b>– Smucker struck a deal to sell its natural beverage and grains businesses to private equity firm Nexus Capital Management for $110 million, with the food producer saying it wanted to focus more resources on its core brands.</p>\n<p><b><a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> </b>– <a href=\"https://laohu8.com/S/ISRG\">Intuitive Surgical</a> was added to the “conviction buy” list at Goldman Sachs, which points to the company’s pending launch of a new surgical system. Shares added 1.2% in the premarket.</p>\n<p><b><a href=\"https://laohu8.com/S/T\">AT&amp;T Inc</a> </b>– Morgan Stanley upgraded AT&amp;T to “overweight” from “equal-weight,” saying a recent slide by the stock creates an attractive risk-reward profile. The firm said there are several other key factors driving the upgrade, including the pending completion of the WarnerMedia/Discoverymerger. AT&amp;T gained 1.5% in premarket trading.</p>\n<p><b><a href=\"https://laohu8.com/S/WOOF\">Petco Health and Wellness Company, Inc.</a> </b>– The pet products seller’s stock added 1.9% in the premarket after Needham began coverage with a “buy” rating. The firm feels Petco should outperform competitors in the pet category, given its presence in multiple channels including veterinary hospitals.</p>\n<p><b><a href=\"https://laohu8.com/S/SHOP\">Shopify</a> </b>– The e-commerce platform operator rallied 2.9% in premarket trading after Evercore upgraded it to “outperform” from “in line.” Evercore noted that the stock is about 20% below its year highs and that the company represents a high-quality asset in terms of growth opportunities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142996286","content_text":"U.S. stock-index futures advanced Thursday morning after the market staged a U-turn the previous trading session, welcoming a Federal Reserve decision to ramp up the pace of its taper and leave interest rates unchanged — for now.\nAt 8:00 a.m. ET, Dow e-minis were up 204 points, or 0.57%, S&P 500 e-minis were up 31.25 points, or 0.66%, and Nasdaq 100 e-minis were up 115.25 points, or 0.71%.With the Fed giving markets a breather Wednesday, traders will turn their Thursday to fresh Labor Department data on initial weekly jobless claims. First-time unemployment filings are expected to reflect a slight increase after last’s 52-week low.\nStocks making the biggest moves premarket: \nDelta Air Lines – Delta rose 2.3% in the premarket after projecting a $200 million fourth-quarter profit. Consensus forecasts were predicting a quarterly loss for Delta, but the carrier said it is seeing strong holiday demand and it is on the path toward exceeding pre-pandemic profit levels.\nAccenture PLC – The consulting firm’s shares surged 6.7% in the premarket after it reported better-than-expected profit and revenue for its latest quarter, and raised its earnings guidance for fiscal 2022. Revenue rose by more than 20% across the four biggest industry groups in Accenture’s customer base.\nRegeneron Pharmaceuticals – The drugmaker’s shares declined 1% in premarket trading after it said its antibody cocktail loses potency against the omicron Covid-19 variant. Regeneron did say that the cocktail is effective against the delta variant.\nLennar – Lennar reported quarterly earnings of $3.91 per share, below the $4.15 consensus estimate, and the homebuilder’s revenue also fell short of forecasts. Lennar was hurt by higher lumber costs as well as increased labor costs and shortages of raw materials, resulting in delayed home deliveries. Lennar tumbled 6.3% in premarket action.\nNovartis AG – Novartis launched a new share buyback program worth up to $15 billion, with the drug maker planning to complete those repurchases by the end of 2023. Shares jumped 4% in premarket trading.\nVisa – Visa rose 1.1% in the premarket after announcing that it added $12 billion to its share buyback program, bringing the total amount of its repurchase authority to $13.2 billion.\nSmucker's – Smucker struck a deal to sell its natural beverage and grains businesses to private equity firm Nexus Capital Management for $110 million, with the food producer saying it wanted to focus more resources on its core brands.\nIntuitive Surgical – Intuitive Surgical was added to the “conviction buy” list at Goldman Sachs, which points to the company’s pending launch of a new surgical system. Shares added 1.2% in the premarket.\nAT&T Inc – Morgan Stanley upgraded AT&T to “overweight” from “equal-weight,” saying a recent slide by the stock creates an attractive risk-reward profile. The firm said there are several other key factors driving the upgrade, including the pending completion of the WarnerMedia/Discoverymerger. AT&T gained 1.5% in premarket trading.\nPetco Health and Wellness Company, Inc. – The pet products seller’s stock added 1.9% in the premarket after Needham began coverage with a “buy” rating. The firm feels Petco should outperform competitors in the pet category, given its presence in multiple channels including veterinary hospitals.\nShopify – The e-commerce platform operator rallied 2.9% in premarket trading after Evercore upgraded it to “outperform” from “in line.” Evercore noted that the stock is about 20% below its year highs and that the company represents a high-quality asset in terms of growth opportunities.","news_type":1},"isVote":1,"tweetType":1,"viewCount":881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603520446,"gmtCreate":1638429891300,"gmtModify":1638429904315,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603520446","repostId":"1197973971","repostType":4,"repost":{"id":"1197973971","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638429281,"share":"https://www.laohu8.com/m/news/1197973971?lang=&edition=full","pubTime":"2021-12-02 15:14","market":"us","language":"en","title":"Glaxo says its vaccine retains activity against key Omicron mutations","url":"https://stock-news.laohu8.com/highlight/detail?id=1197973971","media":"Tiger Newspress","summary":"GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced an update to bioRxiv, a preprint ser","content":"<p>GlaxoSmithKline plc&nbsp;and Vir Biotechnology, Inc.&nbsp;today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations[1]&nbsp;of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.</p>\n<p><b>George Scangos, PhD, Chief Executive Officer of Vir, said:</b>“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”</p>\n<p><b>Dr Hal Barron, Chief Scientific Officer and President R&amp;D, GSK, said:</b>“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though very early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”</p>\n<p><b>About sotrovimab</b></p>\n<p>Sotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.</p>\n<p>Updated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).</p>\n<p><b>About the sotrovimab clinical development programme</b></p>\n<ul>\n <li>COMET-ICE: a Phase III, multi-centre, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalised and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p&lt;0.001) in hospitalisation for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published in<i>The New England Journal of Medicine</i>on 27 October 2021 and final data were pre-published on 8 November 2021 on<i>medRxiv</i>.</li>\n <li>COMET-TAIL: a Phase III, randomised, multi-centre, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised adult and paediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.</li>\n <li>COMET-PEAK: a Phase II, randomised, multi-centre, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.</li>\n <li>GSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis programme will take place in due course.</li>\n</ul>\n<p><b>About global access to sotrovimab</b></p>\n<ul>\n <li>Sotrovimab is authorised for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorisations for sotrovimab have been granted in a dozen countries.</li>\n <li>GSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe</li>\n <li>COVID-19.</li>\n <li>Sotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.</li>\n</ul>\n<p><b>Sotrovimab in the United States</b></p>\n<p>The following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorised use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providers, and fullFact Sheet for Patients, Parents, and Caregivers.</p>\n<p>Sotrovimab has been authorized by the U.S. FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.</p>\n<p>Sotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</p>\n<p><b>Authorized Use</b></p>\n<p>The U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.</p>\n<p><b>Limitations of Authorized Use</b></p>\n<p>Sotrovimab is not authorized for use in patients:</p>\n<ul>\n <li>who are hospitalized due to COVID-19, OR</li>\n <li>who require oxygen therapy due to COVID-19, OR</li>\n <li>who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)</li>\n</ul>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID 19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation.</p>\n<p><b>Important Safety Information</b></p>\n<p><b>CONTRAINDICATIONS</b></p>\n<p>Sotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.</p>\n<p><b>WARNINGS AND PRECAUTIONS</b></p>\n<p>There are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.</p>\n<p><b>Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions</b></p>\n<p>Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.</p>\n<p>Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.</p>\n<p>Signs and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.</p>\n<p>Consider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.</p>\n<p>Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.</p>\n<p><b>Clinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration</b></p>\n<p>Clinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.</p>\n<p><b>Limitations of Benefit and Potential for Risk in Patients with Severe COVID‑19</b></p>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19, OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.</p>\n<p><b>ADVERSE EVENTS</b></p>\n<p>Hypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.</p>\n<p>The most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.</p>\n<p><b>USE IN SPECIFIC POPULATIONS</b></p>\n<p><b>Pregnancy</b></p>\n<p>There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.</p>\n<p><b>Lactation</b></p>\n<p>There are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant, or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.</p>\n<p><b>About the GSK and Vir collaboration</b></p>\n<p>In April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.</p>\n<p><b>GSK commitment to tackling COVID-19</b></p>\n<p>GSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organisations.</p>\n<p>GSK is collaborating with several organisations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi S.A., Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.</p>\n<p>GSK is also working with mRNA specialist, CureVac N.V., to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.</p>\n<p>GSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.</p>\n<p><b>Vir’s commitment to COVID-19</b></p>\n<p>Vir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaxo says its vaccine retains activity against key Omicron mutations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxo says its vaccine retains activity against key Omicron mutations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-02 15:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GlaxoSmithKline plc&nbsp;and Vir Biotechnology, Inc.&nbsp;today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations[1]&nbsp;of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.</p>\n<p><b>George Scangos, PhD, Chief Executive Officer of Vir, said:</b>“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”</p>\n<p><b>Dr Hal Barron, Chief Scientific Officer and President R&amp;D, GSK, said:</b>“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though very early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”</p>\n<p><b>About sotrovimab</b></p>\n<p>Sotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.</p>\n<p>Updated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).</p>\n<p><b>About the sotrovimab clinical development programme</b></p>\n<ul>\n <li>COMET-ICE: a Phase III, multi-centre, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalised and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p&lt;0.001) in hospitalisation for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published in<i>The New England Journal of Medicine</i>on 27 October 2021 and final data were pre-published on 8 November 2021 on<i>medRxiv</i>.</li>\n <li>COMET-TAIL: a Phase III, randomised, multi-centre, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised adult and paediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.</li>\n <li>COMET-PEAK: a Phase II, randomised, multi-centre, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.</li>\n <li>GSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis programme will take place in due course.</li>\n</ul>\n<p><b>About global access to sotrovimab</b></p>\n<ul>\n <li>Sotrovimab is authorised for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorisations for sotrovimab have been granted in a dozen countries.</li>\n <li>GSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe</li>\n <li>COVID-19.</li>\n <li>Sotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.</li>\n</ul>\n<p><b>Sotrovimab in the United States</b></p>\n<p>The following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorised use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providers, and fullFact Sheet for Patients, Parents, and Caregivers.</p>\n<p>Sotrovimab has been authorized by the U.S. FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.</p>\n<p>Sotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</p>\n<p><b>Authorized Use</b></p>\n<p>The U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.</p>\n<p><b>Limitations of Authorized Use</b></p>\n<p>Sotrovimab is not authorized for use in patients:</p>\n<ul>\n <li>who are hospitalized due to COVID-19, OR</li>\n <li>who require oxygen therapy due to COVID-19, OR</li>\n <li>who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)</li>\n</ul>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID 19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation.</p>\n<p><b>Important Safety Information</b></p>\n<p><b>CONTRAINDICATIONS</b></p>\n<p>Sotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.</p>\n<p><b>WARNINGS AND PRECAUTIONS</b></p>\n<p>There are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.</p>\n<p><b>Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions</b></p>\n<p>Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.</p>\n<p>Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.</p>\n<p>Signs and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.</p>\n<p>Consider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.</p>\n<p>Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.</p>\n<p><b>Clinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration</b></p>\n<p>Clinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.</p>\n<p><b>Limitations of Benefit and Potential for Risk in Patients with Severe COVID‑19</b></p>\n<p>Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19, OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.</p>\n<p><b>ADVERSE EVENTS</b></p>\n<p>Hypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.</p>\n<p>The most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.</p>\n<p><b>USE IN SPECIFIC POPULATIONS</b></p>\n<p><b>Pregnancy</b></p>\n<p>There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.</p>\n<p><b>Lactation</b></p>\n<p>There are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant, or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.</p>\n<p><b>About the GSK and Vir collaboration</b></p>\n<p>In April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.</p>\n<p><b>GSK commitment to tackling COVID-19</b></p>\n<p>GSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organisations.</p>\n<p>GSK is collaborating with several organisations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi S.A., Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.</p>\n<p>GSK is also working with mRNA specialist, CureVac N.V., to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.</p>\n<p>GSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.</p>\n<p><b>Vir’s commitment to COVID-19</b></p>\n<p>Vir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197973971","content_text":"GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations[1] of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.\nGeorge Scangos, PhD, Chief Executive Officer of Vir, said:“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by preclinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”\nDr Hal Barron, Chief Scientific Officer and President R&D, GSK, said:“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though very early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”\nAbout sotrovimab\nSotrovimab is an investigational SARS-CoV-2 neutralising monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.\nUpdated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).\nAbout the sotrovimab clinical development programme\n\nCOMET-ICE: a Phase III, multi-centre, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalised and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p<0.001) in hospitalisation for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published inThe New England Journal of Medicineon 27 October 2021 and final data were pre-published on 8 November 2021 onmedRxiv.\nCOMET-TAIL: a Phase III, randomised, multi-centre, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised adult and paediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.\nCOMET-PEAK: a Phase II, randomised, multi-centre, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.\nGSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis programme will take place in due course.\n\nAbout global access to sotrovimab\n\nSotrovimab is authorised for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorisations for sotrovimab have been granted in a dozen countries.\nGSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe\nCOVID-19.\nSotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.\n\nSotrovimab in the United States\nThe following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorised use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providers, and fullFact Sheet for Patients, Parents, and Caregivers.\nSotrovimab has been authorized by the U.S. FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.\nSotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.\nAuthorized Use\nThe U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.\nLimitations of Authorized Use\nSotrovimab is not authorized for use in patients:\n\nwho are hospitalized due to COVID-19, OR\nwho require oxygen therapy due to COVID-19, OR\nwho require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)\n\nBenefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID 19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID 19 requiring high flow oxygen or mechanical ventilation.\nImportant Safety Information\nCONTRAINDICATIONS\nSotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.\nWARNINGS AND PRECAUTIONS\nThere are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.\nHypersensitivity Including Anaphylaxis and Infusion-Related Reactions\nSerious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.\nInfusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.\nSigns and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.\nConsider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.\nHypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.\nClinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration\nClinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.\nLimitations of Benefit and Potential for Risk in Patients with Severe COVID‑19\nBenefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19, OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.\nADVERSE EVENTS\nHypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.\nThe most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.\nUSE IN SPECIFIC POPULATIONS\nPregnancy\nThere are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.\nLactation\nThere are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant, or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.\nAbout the GSK and Vir collaboration\nIn April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.\nGSK commitment to tackling COVID-19\nGSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organisations.\nGSK is collaborating with several organisations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi S.A., Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase III clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.\nGSK is also working with mRNA specialist, CureVac N.V., to jointly develop next-generation, optimised mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.\nGSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.\nVir’s commitment to COVID-19\nVir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.","news_type":1},"isVote":1,"tweetType":1,"viewCount":194,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600119394,"gmtCreate":1638086160817,"gmtModify":1638086161266,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600119394","repostId":"2186432895","repostType":4,"repost":{"id":"2186432895","pubTimestamp":1638069921,"share":"https://www.laohu8.com/m/news/2186432895?lang=&edition=full","pubTime":"2021-11-28 11:25","market":"us","language":"en","title":"$300 a Month in These 3 Stocks Could Make You a Millionaire by Retirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2186432895","media":"Motley Fool","summary":"A little money can go a long way.","content":"<p>Thanks to the wonders of compound interest, it doesn't take a lot of money to grow a million-dollar nest egg. For example, investing $300 a month could grow into more than $1 million in 30 years if it can generate a 12% annual return. That's slightly better than the&nbsp;average stock market return&nbsp;over the last 50 years of nearly 11%.&nbsp;</p>\n<p>Many companies have a long history of beating the market. Three companies that appear likely to continue doing so in the decades ahead are&nbsp;<a href=\"https://laohu8.com/S/BEP\"><b>Brookfield Renewable</b>&nbsp;</a>,&nbsp;<a href=\"https://laohu8.com/S/CCI\"><b>Crown Castle International</b>&nbsp;</a>, and&nbsp;<a href=\"https://laohu8.com/S/NEE\"><b>NextEra Energy</b>&nbsp;</a>. Because of that, $100 invested in each one every month could grow into a $1 million nest egg by retirement.</p>\n<h2>Benefiting from a powerful megatrend</h2>\n<p>Brookfield Renewable has enriched its investors over the years. Since its inception, the&nbsp;renewable energy&nbsp;producer has generated an annualized total return of 19%. The company had done that by investing billions of dollars into expanding its renewable energy portfolio. That has powered more than 10% annual growth in its cash flow per share, supporting 6% annual dividend increases over the last decade. </p>\n<p>However, Brookfield's best days appear to lie ahead. The global economy needs to invest trillions of dollars to decarbonize the energy sector over the next 30 years. That should enable Brookfield to continue to invest in expanding its renewable energy portfolio.</p>\n<p>The company currently has 36 gigawatts (GW) of renewable energy projects in development. That's bigger than the company's current operating portfolio of about 21 GW. Combined with rising power rates, and its growing scale, these projects should support up to 11% annual cash flow per share growth through at least 2026. </p>\n<p>Meanwhile, Brookfield sees up to another 9% yearly boost from future acquisitions. Add that growing renewable-powered cash flow stream to the company's 3%-yielding dividend, and Brookfield appears to have the power to produce double-digit annual returns for decades to come.&nbsp;</p>\n<h2>Connected to the data supercycle</h2>\n<p>Crown Castle has been an exceptional value creator over the years. The infrastructure-focused real estate investment trust (REIT) has delivered a more than 13% annual total return over the two-plus decades since its initial public offering. </p>\n<p>A major driver of those returns has been the billions of dollars the company has poured into expanding its communications infrastructure portfolio. Over the last decade alone, the REIT spent $31 billion on acquisitions and capital expenditures (capex), powering 9% annual dividend growth since 2014.&nbsp; &nbsp;</p>\n<p>The company still sees significant investment opportunities ahead. Crown Castle noted that the telecom industry's rollout of&nbsp;5G networks&nbsp;represents a decade-long investment cycle. Meanwhile, some see a 100-year data infrastructure upgrade investment opportunity to support the digital economy. Because of that, Crown Castle has a lot of growth ahead of it, which should drive continued strong returns. </p>\n<p>Crown Castle expects to grow its 3.2%-yielding dividend at a 7% to 8% annual rate in the near term. That suggests the company could deliver double-digit total returns in the coming years.&nbsp;</p>\n<h2>Plugged into several growth catalysts</h2>\n<p>NextEra Energy has also created an enormous amount of wealth for its investors over the years. The&nbsp;utility&nbsp;has generated a roughly 700% total return over the last decade alone, crushing the 276% total return produced by the S&amp;P 500. Powering the company's robust results has been its ability to deliver above-average earnings and dividend growth. It has increased its earnings per share at an 8.7% compound annual rate since 2005, supporting 9.6% compound annual dividend growth. </p>\n<p>A major catalyst has been the company's leadership in renewable energy. It has grown into one of the world's largest wind and&nbsp;solar energy&nbsp;producers.&nbsp;</p>\n<p>That leadership should continue since it has one of the world's biggest backlogs of wind and solar energy development projects. In addition to tried-and-true technologies like wind and solar, NextEra is a leader in emerging technologies, including battery storage and green hydrogen. Meanwhile, it's&nbsp;tapping into other sources of growth&nbsp;like water infrastructure. Because of that, NextEra should have plenty of power to continue growing its earnings and dividend in the decades ahead.</p>\n<h2>Grow rich slowly</h2>\n<p>Compound interest can do wonders for your retirement. Steadily investing a few hundred dollars each month into high-performing stocks can create an enormous amount of wealth. One of the keys to finding stocks that can deliver decades of strong returns is focusing on those benefiting from megatrends. Few are as big and enduring as renewable energy and data, making Brookfield Renewable, Crown Castle, and NextEra Energy stand out as stocks that could mint their share of millionaires in the decades ahead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>$300 a Month in These 3 Stocks Could Make You a Millionaire by Retirement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n$300 a Month in These 3 Stocks Could Make You a Millionaire by Retirement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-28 11:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/27/300-a-month-in-these-3-stocks-could-make-you-a-mil/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Thanks to the wonders of compound interest, it doesn't take a lot of money to grow a million-dollar nest egg. For example, investing $300 a month could grow into more than $1 million in 30 years if it...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/27/300-a-month-in-these-3-stocks-could-make-you-a-mil/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NEE":"新纪元能源","CCI":"冠城","BEP":"Brookfield Renewable Partners LP"},"source_url":"https://www.fool.com/investing/2021/11/27/300-a-month-in-these-3-stocks-could-make-you-a-mil/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2186432895","content_text":"Thanks to the wonders of compound interest, it doesn't take a lot of money to grow a million-dollar nest egg. For example, investing $300 a month could grow into more than $1 million in 30 years if it can generate a 12% annual return. That's slightly better than the average stock market return over the last 50 years of nearly 11%. \nMany companies have a long history of beating the market. Three companies that appear likely to continue doing so in the decades ahead are Brookfield Renewable , Crown Castle International , and NextEra Energy . Because of that, $100 invested in each one every month could grow into a $1 million nest egg by retirement.\nBenefiting from a powerful megatrend\nBrookfield Renewable has enriched its investors over the years. Since its inception, the renewable energy producer has generated an annualized total return of 19%. The company had done that by investing billions of dollars into expanding its renewable energy portfolio. That has powered more than 10% annual growth in its cash flow per share, supporting 6% annual dividend increases over the last decade. \nHowever, Brookfield's best days appear to lie ahead. The global economy needs to invest trillions of dollars to decarbonize the energy sector over the next 30 years. That should enable Brookfield to continue to invest in expanding its renewable energy portfolio.\nThe company currently has 36 gigawatts (GW) of renewable energy projects in development. That's bigger than the company's current operating portfolio of about 21 GW. Combined with rising power rates, and its growing scale, these projects should support up to 11% annual cash flow per share growth through at least 2026. \nMeanwhile, Brookfield sees up to another 9% yearly boost from future acquisitions. Add that growing renewable-powered cash flow stream to the company's 3%-yielding dividend, and Brookfield appears to have the power to produce double-digit annual returns for decades to come. \nConnected to the data supercycle\nCrown Castle has been an exceptional value creator over the years. The infrastructure-focused real estate investment trust (REIT) has delivered a more than 13% annual total return over the two-plus decades since its initial public offering. \nA major driver of those returns has been the billions of dollars the company has poured into expanding its communications infrastructure portfolio. Over the last decade alone, the REIT spent $31 billion on acquisitions and capital expenditures (capex), powering 9% annual dividend growth since 2014.   \nThe company still sees significant investment opportunities ahead. Crown Castle noted that the telecom industry's rollout of 5G networks represents a decade-long investment cycle. Meanwhile, some see a 100-year data infrastructure upgrade investment opportunity to support the digital economy. Because of that, Crown Castle has a lot of growth ahead of it, which should drive continued strong returns. \nCrown Castle expects to grow its 3.2%-yielding dividend at a 7% to 8% annual rate in the near term. That suggests the company could deliver double-digit total returns in the coming years. \nPlugged into several growth catalysts\nNextEra Energy has also created an enormous amount of wealth for its investors over the years. The utility has generated a roughly 700% total return over the last decade alone, crushing the 276% total return produced by the S&P 500. Powering the company's robust results has been its ability to deliver above-average earnings and dividend growth. It has increased its earnings per share at an 8.7% compound annual rate since 2005, supporting 9.6% compound annual dividend growth. \nA major catalyst has been the company's leadership in renewable energy. It has grown into one of the world's largest wind and solar energy producers. \nThat leadership should continue since it has one of the world's biggest backlogs of wind and solar energy development projects. In addition to tried-and-true technologies like wind and solar, NextEra is a leader in emerging technologies, including battery storage and green hydrogen. Meanwhile, it's tapping into other sources of growth like water infrastructure. Because of that, NextEra should have plenty of power to continue growing its earnings and dividend in the decades ahead.\nGrow rich slowly\nCompound interest can do wonders for your retirement. Steadily investing a few hundred dollars each month into high-performing stocks can create an enormous amount of wealth. One of the keys to finding stocks that can deliver decades of strong returns is focusing on those benefiting from megatrends. Few are as big and enduring as renewable energy and data, making Brookfield Renewable, Crown Castle, and NextEra Energy stand out as stocks that could mint their share of millionaires in the decades ahead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":7,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879870693,"gmtCreate":1636709483679,"gmtModify":1636709578075,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879870693","repostId":"1124567274","repostType":4,"repost":{"id":"1124567274","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636707952,"share":"https://www.laohu8.com/m/news/1124567274?lang=&edition=full","pubTime":"2021-11-12 17:05","market":"us","language":"en","title":"Lordstown Motors shares fell 10.6% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1124567274","media":"Tiger Newspress","summary":"Lordstown Motors shares fell 10.6% in premarket trading.\n\nLordstown Motors Corp on Thursday delayed ","content":"<p>Lordstown&nbsp;Motors&nbsp;shares&nbsp;fell&nbsp;10.6%&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/fc7079e6f893c9c350e0638b20f83d0d\" tg-width=\"875\" tg-height=\"609\" referrerpolicy=\"no-referrer\"></p>\n<p>Lordstown Motors Corp on Thursday delayed next year's launch of its Endurance electric pickup truck by a quarter, citing parts and materials shortages and other supply-chain issues.</p>\n<p>A day after announcing it had finalized a deal for Taiwan's Foxconn Technology Co Ltd to buy Lordstown's plant in northeast Ohio for $230 million and take over production of the Endurance, Lordstown said on Thursday it also signed a memorandum of understanding with Cox Automotive.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lordstown Motors shares fell 10.6% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLordstown Motors shares fell 10.6% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-12 17:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Lordstown&nbsp;Motors&nbsp;shares&nbsp;fell&nbsp;10.6%&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/fc7079e6f893c9c350e0638b20f83d0d\" tg-width=\"875\" tg-height=\"609\" referrerpolicy=\"no-referrer\"></p>\n<p>Lordstown Motors Corp on Thursday delayed next year's launch of its Endurance electric pickup truck by a quarter, citing parts and materials shortages and other supply-chain issues.</p>\n<p>A day after announcing it had finalized a deal for Taiwan's Foxconn Technology Co Ltd to buy Lordstown's plant in northeast Ohio for $230 million and take over production of the Endurance, Lordstown said on Thursday it also signed a memorandum of understanding with Cox Automotive.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124567274","content_text":"Lordstown Motors shares fell 10.6% in premarket trading.\n\nLordstown Motors Corp on Thursday delayed next year's launch of its Endurance electric pickup truck by a quarter, citing parts and materials shortages and other supply-chain issues.\nA day after announcing it had finalized a deal for Taiwan's Foxconn Technology Co Ltd to buy Lordstown's plant in northeast Ohio for $230 million and take over production of the Endurance, Lordstown said on Thursday it also signed a memorandum of understanding with Cox Automotive.","news_type":1},"isVote":1,"tweetType":1,"viewCount":9,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870562134,"gmtCreate":1636635597289,"gmtModify":1636635858505,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/870562134","repostId":"1152179749","repostType":4,"repost":{"id":"1152179749","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636630921,"share":"https://www.laohu8.com/m/news/1152179749?lang=&edition=full","pubTime":"2021-11-11 19:42","market":"us","language":"en","title":"Lordstown Motors shares rose nearly 12% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1152179749","media":"Tiger Newspress","summary":"Lordstown Motors shares rose nearly 12% in premarket trading.Lordstown Motors Corp said on Wednesday","content":"<p>Lordstown&nbsp;Motors&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;12%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/97e386320197b4b678930cb38e14a8a0\" tg-width=\"870\" tg-height=\"582\" referrerpolicy=\"no-referrer\">Lordstown Motors Corp said on Wednesday that&nbsp;Foxconn has bought stock worth $50 million from the U.S. electric vehicle maker, finalizing an equity investment announced in September.</p>\n<p>Foxconn acquired the shares at $6.8983 apiece, Lordstown said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lordstown Motors shares rose nearly 12% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLordstown Motors shares rose nearly 12% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-11 19:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Lordstown&nbsp;Motors&nbsp;shares&nbsp;rose&nbsp;nearly&nbsp;12%&nbsp;in&nbsp;premarket&nbsp;trading.<img src=\"https://static.tigerbbs.com/97e386320197b4b678930cb38e14a8a0\" tg-width=\"870\" tg-height=\"582\" referrerpolicy=\"no-referrer\">Lordstown Motors Corp said on Wednesday that&nbsp;Foxconn has bought stock worth $50 million from the U.S. electric vehicle maker, finalizing an equity investment announced in September.</p>\n<p>Foxconn acquired the shares at $6.8983 apiece, Lordstown said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152179749","content_text":"Lordstown Motors shares rose nearly 12% in premarket trading.Lordstown Motors Corp said on Wednesday that Foxconn has bought stock worth $50 million from the U.S. electric vehicle maker, finalizing an equity investment announced in September.\nFoxconn acquired the shares at $6.8983 apiece, Lordstown said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":77,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":826405056,"gmtCreate":1634045051579,"gmtModify":1634045052853,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/826405056","repostId":"1125833702","repostType":4,"repost":{"id":"1125833702","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634047282,"share":"https://www.laohu8.com/m/news/1125833702?lang=&edition=full","pubTime":"2021-10-12 22:01","market":"us","language":"en","title":"Another Facebook whistleblower says she is willing to testify before Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=1125833702","media":"Tiger Newspress","summary":"Facebook shares fell more than 2% in morning trading after another Facebook whistleblower said she w","content":"<p>Facebook shares fell more than 2% in morning trading&nbsp;after&nbsp;another Facebook whistleblower said she was willing to testify before Congress.</p>\n<p><img src=\"https://static.tigerbbs.com/baa96b3e72abe4a626a9d4bbc0c913bd\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>Sophie Zhang, who said she felt like she had \"blood on her hands\" after working at Facebook, is willing to testify before Congress about her former employer, she told CNN Sunday. She said she had also&nbsp;passed on documentation&nbsp;about the company to a US law enforcement agency.</p>\n<p>Zhang, who worked as a data scientist at the tech giant for almost three years, wrote a lengthy memo when she was fired by Facebook last year detailing how she believed the company was not doing enough to tackle hate and misinformation -- particularly in smaller and developing countries. Zhang said the company told her she was fired because of performance issues.</p>\n<p>The memo was first reported last year by&nbsp;BuzzFeed News&nbsp;and later formed the basis of a series of reports byThe Guardian newspaper.</p>\n<p>Speaking to CNN at her home in the Bay Area on Sunday, Zhang said she was encouraged that there appeared to be bipartisan support for action relating to the protection of children online following Facebook whistleblower Frances Haugen's testimony to a Senate subcommittee last week.</p>\n<p>Zhang said she has brought information about Facebook to authorities. \"I provided detailed documentation regarding potential criminal violations to a U.S. law enforcement agency. My understanding is that the investigation is still ongoing,\"she tweeted&nbsp;Sunday.</p>\n<p>She declined to share when asked by CNN what information she had provided or to which agency. An FBI spokesperson declined to comment Monday adding, \"the FBI does not generally confirm, deny, or otherwise comment on information or tips we may receive from the public.\"</p>\n<p>Central to Zhang's allegations about Facebook is that it doesn't do enough to tackle abuse of its platform in countries outside of the United States. Roughly 90% of Facebook's monthly active users are outside the US and Canada, according to its&nbsp;most recent quarterly filing.</p>\n<p>A Facebook spokesperson pushed back on that charge Monday, saying the company had invested billions in safety and security in recent years.</p>\n<p>\"We have also taken down over 150 networks seeking to manipulate public debate since 2017, and they have originated in over 50 countries, with the majority coming from or focused outside of the US. Our track record shows that we crack down on abuse abroad with the same intensity that we apply in the US,\" the spokesperson added.</p>\n<p>In addition,Facebook&nbsp;Inc's oversight board, a body set up by the social network to give independent verdicts on a small number of thorny content decisions, said on Monday it would meet with former employee and whistleblower Frances Haugen in the coming weeks.</p>\n<p>Haugen revealed last week she was the person who provided documents used in a Wall Street Journal investigation and a Senate hearing on Instagram's harm to teenage girls.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Another Facebook whistleblower says she is willing to testify before Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnother Facebook whistleblower says she is willing to testify before Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-12 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Facebook shares fell more than 2% in morning trading&nbsp;after&nbsp;another Facebook whistleblower said she was willing to testify before Congress.</p>\n<p><img src=\"https://static.tigerbbs.com/baa96b3e72abe4a626a9d4bbc0c913bd\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>Sophie Zhang, who said she felt like she had \"blood on her hands\" after working at Facebook, is willing to testify before Congress about her former employer, she told CNN Sunday. She said she had also&nbsp;passed on documentation&nbsp;about the company to a US law enforcement agency.</p>\n<p>Zhang, who worked as a data scientist at the tech giant for almost three years, wrote a lengthy memo when she was fired by Facebook last year detailing how she believed the company was not doing enough to tackle hate and misinformation -- particularly in smaller and developing countries. Zhang said the company told her she was fired because of performance issues.</p>\n<p>The memo was first reported last year by&nbsp;BuzzFeed News&nbsp;and later formed the basis of a series of reports byThe Guardian newspaper.</p>\n<p>Speaking to CNN at her home in the Bay Area on Sunday, Zhang said she was encouraged that there appeared to be bipartisan support for action relating to the protection of children online following Facebook whistleblower Frances Haugen's testimony to a Senate subcommittee last week.</p>\n<p>Zhang said she has brought information about Facebook to authorities. \"I provided detailed documentation regarding potential criminal violations to a U.S. law enforcement agency. My understanding is that the investigation is still ongoing,\"she tweeted&nbsp;Sunday.</p>\n<p>She declined to share when asked by CNN what information she had provided or to which agency. An FBI spokesperson declined to comment Monday adding, \"the FBI does not generally confirm, deny, or otherwise comment on information or tips we may receive from the public.\"</p>\n<p>Central to Zhang's allegations about Facebook is that it doesn't do enough to tackle abuse of its platform in countries outside of the United States. Roughly 90% of Facebook's monthly active users are outside the US and Canada, according to its&nbsp;most recent quarterly filing.</p>\n<p>A Facebook spokesperson pushed back on that charge Monday, saying the company had invested billions in safety and security in recent years.</p>\n<p>\"We have also taken down over 150 networks seeking to manipulate public debate since 2017, and they have originated in over 50 countries, with the majority coming from or focused outside of the US. Our track record shows that we crack down on abuse abroad with the same intensity that we apply in the US,\" the spokesperson added.</p>\n<p>In addition,Facebook&nbsp;Inc's oversight board, a body set up by the social network to give independent verdicts on a small number of thorny content decisions, said on Monday it would meet with former employee and whistleblower Frances Haugen in the coming weeks.</p>\n<p>Haugen revealed last week she was the person who provided documents used in a Wall Street Journal investigation and a Senate hearing on Instagram's harm to teenage girls.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125833702","content_text":"Facebook shares fell more than 2% in morning trading after another Facebook whistleblower said she was willing to testify before Congress.\n\nSophie Zhang, who said she felt like she had \"blood on her hands\" after working at Facebook, is willing to testify before Congress about her former employer, she told CNN Sunday. She said she had also passed on documentation about the company to a US law enforcement agency.\nZhang, who worked as a data scientist at the tech giant for almost three years, wrote a lengthy memo when she was fired by Facebook last year detailing how she believed the company was not doing enough to tackle hate and misinformation -- particularly in smaller and developing countries. Zhang said the company told her she was fired because of performance issues.\nThe memo was first reported last year by BuzzFeed News and later formed the basis of a series of reports byThe Guardian newspaper.\nSpeaking to CNN at her home in the Bay Area on Sunday, Zhang said she was encouraged that there appeared to be bipartisan support for action relating to the protection of children online following Facebook whistleblower Frances Haugen's testimony to a Senate subcommittee last week.\nZhang said she has brought information about Facebook to authorities. \"I provided detailed documentation regarding potential criminal violations to a U.S. law enforcement agency. My understanding is that the investigation is still ongoing,\"she tweeted Sunday.\nShe declined to share when asked by CNN what information she had provided or to which agency. An FBI spokesperson declined to comment Monday adding, \"the FBI does not generally confirm, deny, or otherwise comment on information or tips we may receive from the public.\"\nCentral to Zhang's allegations about Facebook is that it doesn't do enough to tackle abuse of its platform in countries outside of the United States. Roughly 90% of Facebook's monthly active users are outside the US and Canada, according to its most recent quarterly filing.\nA Facebook spokesperson pushed back on that charge Monday, saying the company had invested billions in safety and security in recent years.\n\"We have also taken down over 150 networks seeking to manipulate public debate since 2017, and they have originated in over 50 countries, with the majority coming from or focused outside of the US. Our track record shows that we crack down on abuse abroad with the same intensity that we apply in the US,\" the spokesperson added.\nIn addition,Facebook Inc's oversight board, a body set up by the social network to give independent verdicts on a small number of thorny content decisions, said on Monday it would meet with former employee and whistleblower Frances Haugen in the coming weeks.\nHaugen revealed last week she was the person who provided documents used in a Wall Street Journal investigation and a Senate hearing on Instagram's harm to teenage girls.","news_type":1},"isVote":1,"tweetType":1,"viewCount":58,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}